Viral hemorrhagic fevers: neurologic complications …

Marylou V Solbrig MD

Infectious Disorders

Updated 07.18.2023
Released 06.12.2007
Expires For CME 07.18.2026

Viral hemorrhagic fevers: neurologic complications

Author: Marylou V Solbrig MD

See Contributor Disclosures

Editor: John E Greenlee MD

Viral hemorrhagic fevers: neurologic complications

In This Article

Quick Link

Introduction

Overview

The viral hemorrhagic fevers are febrile illnesses accompanied by abnormal vascular regulation and vascular damage caused by members of the Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae families of viruses. Found in diverse areas of the world, yet true winners of globalization, hemorrhagic fever viruses are potentially present in anyone who steps off a plane from an endemic area.

Although the high mortality and exceptional epidemics of viral hemorrhagic fevers have been well publicized, neurologic aspects of these diseases are less familiar. Neurologic complications occur in many of the viral hemorrhagic fevers, and the CNS diseases are not simple reflections of what has started in the periphery. Some viral hemorrhagic fevers present as pure neurologic illness.

In this article, the dark history, role in human experimentation, global ecology and epidemiology, overall clinical and neurologic aspects, genetic susceptibility, and treatment/prevention of viral hemorrhagic fevers are presented. Travel-acquired viral hemorrhagic fever cases and the widening geographic home range, including the United States, of important human and veterinary viruses and vectors are updated. For example, prolonged maintenance of dengue infections in A aegypti mosquitoes in Florida in the absence of local index human cases is occurring. Prolonged maintenance of Ebola in human hosts restarted an outbreak in Guinea 5 to 7 years after the epidemic was declared over, and it continues to reignite Ebola outbreaks in Democratic Republic of Congo, where zoonotic spillover events seem not to be needed for starting a filovirus epidemic. The world’s newest viral hemorrhagic fever outbreaks: first ever outbreaks of Marburg virus in Guinea (2021), Ghana (2022), Equatorial Guinea (2023), and Tanzania (2023), when presumed of their usual zoonotic origin, indicate the virus is endemic in bats in wider geographic ranges than previously thought (341; 356; 357; 358).

Lessons learned from members of the viral hemorrhagic fever virus families for diagnosis, treatment, prevention, and design of medical countermeasures, such as updates toward a panfilovirus vaccine for Marburg, are presented.

Key points

	• Viral hemorrhagic fevers represent a taxonomically and geographically diverse group of conditions caused by four families of viruses: Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae. These families contain some of the most dangerous viral agents known to humans.
	• The possibility of viral hemorrhagic fever should be kept in mind when confronted with symptomatically sick patients coming from endemic areas.
	• Most of these viruses are handled in Biosafety Level 4 (BSL4) containment facilities. Awareness and diagnosis of the viral hemorrhagic fevers is increasingly relevant for all countries.
	• Excepting agents requiring mosquito intermediates, all other agents have a degree of aerosol infectivity and a potential for human-to-human transmission. Body fluids should be considered infectious.

Historical note and terminology

Viral hemorrhagic fevers are febrile illnesses with abnormal vascular regulation and vascular damage. The combination of fever and hemorrhage can be caused by a number of human pathogens: viruses, rickettsiae, bacteria, protozoa, and fungi. However, the term hemorrhagic fever usually refers to a group of illnesses that are caused by four different families of viruses: Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae.

All viral hemorrhagic fever viruses are lipid-enveloped RNA viruses that persist in nature in an animal or insect host. Except for some viruses in the Flaviviridae family, humans are not normally the natural reservoirs but become infected after contact with infected vectors or natural hosts, usually arthropods or rodents. For some viruses, accidental infection of humans may be followed by human-to-human transmission. The viruses had been geographically restricted to areas where the natural hosts live, usually rural areas but occasionally urban cities. But viral hemorrhagic fevers are opportunistic to circumstances we have handed them. Landscape fragmentation increases the risk of virus exposure and modern transportation can export viremic individuals, infectious host species, or vectors to any location.

Except for the dengue viruses, yellow fever virus, and Chikungunya (Togaviridae family, genus Alphavirus) that require a mosquito intermediate, all of the other agents have a degree of aerosol infectivity. Because of the manner of infection, high virulence, and associated high mortality, these viruses are handled in biocontainment level 4 laboratories and facilities.

Family	Agent	Geographic site of prevalence	Natural Hosts	Transmission	Human-to-human transmission
Arenaviridae	Lassa fever virus	West Africa	Wild rodents	Direct contact, aerosolization of rodent excreta/body fluids	Yes, nosocomial outbreaks
	Junin virus	Argentina	Wild rodents	Direct contact, aerosolization of rodent excreta/body fluids	Yes, nosocomial outbreaks
	LCMV	Worldwide	Mice	Direct contact, aerosolization of rodent excreta/body fluids	Solid organ transplant
Bunyaviridae
Genus: Hantavirus	Hantavirus	Eurasia	Wild rodents	Direct contact, aerosolization of rodent excreta/body fluids	Only Andes virus (South America)
	Puumala virus	Scandinavia, North Europe, Russia	Rodents	Aerosolization rodent body fluids	Not detected, but can be present in human saliva
Genus: Nairovirus	Crimean Congo HF virus	Africa, Asia, Europe	Hares, birds, ticks, domestic animals	Tick, direct contact with infected animals	Yes, nosocomial outbreaks
Genus: Phlebovirus	Rift Valley Fever virus	Africa	Wild and domestic animals	Mosquitoes, direct contact animal carcasses, aerosol lab exposure
Filoviridae	Ebola virus	Rainforests of Central and West Africa	Spp. fruit + insectivorous bats, great apes, wild + domestic pigs, duikers	Direct contact	Yes, nosocomial outbreaks, sexual contact
	Marburg virus	Central and Southern Africa	Fruit bats, primates (eg, green monkeys)	Direct contact	Yes, nosocomial spread, sexual contact
Flaviviridae	Dengue virus	Tropics worldwide Local outbreaks in Europe and Southern US	Man	Mosquitoes	In utero, intrapartum, transfusion, solid organ transplant
	Zika virus	Africa, Americas, Asia, Pacific Outbreaks: Yap (Micronesia), French Polynesia + Pacific, Brazil	Man	Mosquitoes	In utero, sexual contact, transfusion, solid organ transplant
Other:
Togaviridae Genus Alphavirus	Chikungunya virus	Africa, Asia, Oceania, Pacific Islands, Americas, Caribbean, parts of Europe	Man	Mosquitoes	In utero, intrapartum, nosocomial transmission
Adapted from (332)

Epidemic hemorrhagic fever, a possible manifestation of hantavirus infection, may have existed in China as early as 960 CE (Common Era) (152). In early China, there were also descriptions of a dengue-like disease called “water poison,” because of its linkage with water-associated flying insects and fever, rash, arthralgia, myalgia, and hemorrhage, in Chinese literature from the Chin (CE 265-420), Tang (CE 610), and Northern Sung (CE 992) dynasties (139). Other diseases known before modern understanding of pathogens and transmission were named after appearances of the afflicted or sites of epidemics. For example, “yellow fever” applied to jaundiced individuals. “Dengue” was a Spanish attempt at the Swahili phrase “ki denga pepo,” translated as “cramp-like seizure caused by an evil spirit” during a Caribbean outbreak in 1827 (14). The naming of diseases after the location of first encounter yielded the geographic eponyms of Ebola (Ebola River, Zaire 1976), Marburg (Marburg, Germany 1967), Lassa fever (Lassa, Nigeria 1969), as well as Argentine, Bolivian, Rift Valley, Crimean-Congo, Kyasanur Forest, Omsk, Hantaan, Seoul, or Korean hemorrhagic fever. Many of these eponymous virus discoveries coincided with habitat intrusion or ecological changes, some of human making.

Hantaviruses have an interesting and dark history. Records of outbreaks of fever, hemorrhage, and severe renal disease occurring in spring and early summer and again in fall starting in 1913 were retrieved from the archives of a hospital in Vladivostok (62). The Russian and Japanese medical workers who encountered these sporadic epidemic hemorrhagic fever cases in the early 1900s went on to develop a practical working knowledge of the disease. Russian workers produced the Far Eastern disease in humans by parenteral injection of bacteria-filtered serum and urine from patients with natural disease. Experimental subjects were hospitalized, and psychiatric patients required pyrogenic therapy (121). A Japanese group working in Manchuria between 1938 and 1945 also isolated a filterable agent from field rodents and reproduced the disease. The sudden close of World War II interrupted the group’s work and their transmissible agent was lost at the time of surrender (168). In Scandinavia in the 1930s, an acute renal disease was seen, similar to hemorrhagic fever described in the Far East. Sixty Finnish and 1000 German frontline troops in Lapland had nephropathia epidemica (Puumala virus) in 1942 (214). Over 3000 United Nations soldiers serving in Korea between 1950 and 1953 contracted Korean hemorrhagic fever (223). Today, hantaviruses, agents well adapted in nature to a number of common rodents, are becoming a worldwide problem. Actual human cases or seropositive rodents have been found on every continent except Antarctica, so that the potential for Hantaan human disease exists in any area of the world where rodent-human contact is common (222; 221).

During World War II, many countries on both sides examined various pathogens for their potential as biological weapons. These included anti-crop and anti-animal pathogens such as Rift Valley fever virus, in addition to human pathogens. In the United States, research on Rift Valley fever virus continued during the Cold War, and ended when the U.S. signed the Biological Weapons Convention agreement in 1972 (263).

Viral hemorrhagic fevers can cause neurologic disease. Neurologic complications independent of (ie, not directly linked to) metabolic or hemorrhagic complications have been recognized and reported for members of every viral hemorrhagic fever family. Lassa, Argentine hemorrhagic fever, Marburg, hantavirus, Puumala virus, Rift Valley fever, and dengue virus infections have neurologic manifestations or sequelae (258). Although the neurologic illness may be overshadowed by systemic or hemorrhagic illness, CNS disease is not a simple reflection of what has started in the periphery nor just a sign of increased tissue permeability. Notably, South American hemorrhagic fever and Rift Valley fever may cause encephalitic disease without the hemorrhagic fever (483). Similarly, dengue virus CNS disease may occur without hematologic or hemorrhagic findings (211; 227), or encephalitic disease may occur even without signs of systemic disease (359).

Importantly, the viral hemorrhagic fevers are prime examples of viral emergence in recent history. Work on viral hemorrhagic fevers represents much of the pioneering work identifying factors that shape viral emergence: factors such as human behavior, dimensions of human-animal and human-wildlife interface, demographics, economic development, land use, technology and industry, international trade and travel, microbial adaptation and change, and global warming (219; 277; 150; 25).

Today, some of the most innovative work in structure-based antiviral drug design is in viral hemorrhagic fever laboratories. As with ribavirin, a promising agent against one or more viral hemorrhagic fevers may become a successful broad-spectrum antiviral of the future against multiple classes of viruses. However, a caveat is that fever is one of the critical clinical features in viral hemorrhagic fevers. Thus, antiviral drugs developed for treatment and based on the crystal structure of a protein prepared from normal body temperature may not fit perfectly in the target space of a protein at fever temperature. This may potentially induce a more virulent virus through viral gene mutation.

Work on the viral hemorrhagic fevers has also yielded critical recommendations for medical staff safety when implementing and maintaining viral containment measures (67). Looking back on the outbreaks, we find the effective use of nonpharmaceutical barrier nursing measures mitigated the impact of epidemics. Because epidemics may begin in resource-limited settings, lessons from the early Marburg, Ebola, and Lassa fever outbreaks can be as relevant today as in the 1960s and 1970s.

Currently, an estimated 49% of emerging viruses are characterized by encephalitis or serious neurologic clinical symptoms (308). The world is a small place, with constant reminders of the need for greater international monitoring of new viruses, increased investigating of virus ecology and policing of points of potential spillover to humans, and a broader understanding of basic viral and host factors. The viral hemorrhagic fevers outbreak experience helped crystallize these ideas and initiatives. When the viral hemorrhagic fevers emerged, they were brand new or new to man. What was learned from the viral hemorrhagic fevers can prepare us for future outbreaks, particularly management of the explosive outbreaks with high fatality rates, provided we pay attention. The viral hemorrhagic fevers: Crimean-Congo hemorrhagic fever, Ebola, Marburg, Lassa fever, and Rift Valley fever have been placed on World Health Organization’s 2018 blueprint list of priority diseases.

Clinical manifestations

Presentation and course

	• Viral hemorrhagic fevers begin as a febrile prodrome with myalgia and may be accompanied by gastrointestinal symptoms.
	• Early disease is followed by rash and signs of abnormal vascular regulation and vascular damage.
	• Severe disease is accompanied by bleeding and shock. Encephalopathy due to cerebral edema, anoxia, hemorrhage, microvascular injury, hyponatremia, hepatic failure, renal failure, or encephalitis accompany severe disease.
	• Pure encephalitic syndromes without the hemorrhagic fever are seen in Rift Valley fever, dengue, Argentinian hemorrhagic fever, and Lassa fever.
	• Late-stage neurologic syndromes include encephalitis in second stage Kyasanur Forest disease and Omsk hemorrhagic fever; Ebola meningoencephalitis and radiculitis; Lassa fever deafness, myelitis; Argentinian hemorrhagic fever ataxic syndromes; and immune-mediated peripheral, central, and specific autoantibody syndromes with dengue.
	• Long-term sequelae are: neurologic and psychiatric post-Ebola syndromes, sensorineural hearing loss in Lassa fever, visual disturbances in Rift Valley fever, Ebola and Marburg hemorrhagic fevers, pituitary dysfunction or panhypopituitarism in Korean hemorrhagic fever, and Puumala virus infection.

Viral hemorrhagic fevers begin as a febrile prodrome with myalgia, occasionally accompanied by gastrointestinal symptoms. Sore throats occur in cases of Lassa fever and retroorbital pain associates with dengue fever. By the time medical attention is sought, patients may have a severe acute illness with evidence of abnormal vascular regulation and vascular damage. Endothelial cells can be infected or activated by viral proteins, and they reduce endothelial barrier function. Systemically, the abnormal vascular regulation is shown by mild hypotension in the early stages of the disease and by shock in more severe and advanced infections. Local vascular abnormalities manifest as conjunctival suffusion, flushing over the face and trunk, and various exanthems, including petechiae, maculopapular rash, or ecchymoses. Vascular damage can be seen as capillary leakage in nondependent areas, such as periorbital edema, the development of pulmonary edema after fluid infusions, effusions in serous cavities, or proteinuria (483).

Thrombocytopenia is characteristic and frequently accompanied by hemorrhage, which also signals underlying vascular damage. The hemorrhage is usually petechial and common in skin and mucous membranes. There may be remission of fever before recovery or progression to a more severe stage (483).

Clinically apparent jaundice is not a universal feature. Jaundice is seen in yellow fever and may occur in severe Crimean-Congo hemorrhagic fever, Rift Valley fever, and filovirus hemorrhagic fever. Renal insufficiency, usually proportional to the degree of shock, is dominant in hemorrhagic fever with renal syndrome where it is caused by primary renal lesions (483).

Severe disease is accompanied by bleeding, shock, and CNS disturbances often arising from cerebral edema, anoxia, hemorrhage, microvascular injury, hyponatremia, hepatic failure, renal failure, or soluble toxin release. However, some South American hemorrhagic fevers, mainly Argentine hemorrhagic fever, have been associated with pure neurologic syndromes: ataxia, dysarthria, and intention tremor (483). Lassa causes neurologic syndromes (seizures, movement disorders, tremor, or ataxia) that temporally overlap or follow the hemorrhagic fever (410), frequently causes convalescent stage deafness (90), and can have neuropsychiatric sequelae (410). Lassa fever virus has been associated with a pure neurologic syndrome, aseptic meningitis (305), a delayed (7 week) paraparesis (109), and encephalopathy as bradyphrenia and personality changes, accompanied by focal irregular low frequency EEG abnormalities, subcortical (insula, external capsule, lateral putamen) MRI signal changes on day 11 of a resolving febrile illness, CSF lymphocytic pleocytosis on day 16, and sensorineural hearing loss on day 22 (137).

The lymphocytic choriomeningitis virus and a “lymphocytic choriomeningitis virus-like” arenavirus infection, transmitted through solid organ transplantation, have produced fatal febrile illnesses with hemorrhage and encephalopathy. In 2003 and 2005 in the United States, transplant recipients became ill with fever, thrombocytopenia, elevated transaminases, coagulopathy, encephalopathy, and seizures after receiving organs infected with lymphocytic choriomeningitis virus (118; 27). Corneal transplant recipients from the same donors did not develop disease (429). A transplant-associated arenavirus in Australia, considered a new “lymphocytic choriomeningitis virus-like” arenavirus, produced intraabdominal hematomas (in one patient) and encephalopathy (in all three patients) (319). Presumably, the lack of effective T-cell response permitted uncontrolled virus replication and prevented the development of the characteristic immunopathological, self-limited, “aseptic” meningitis. Collectively, these cases indicate the importance of transplant-transmitted pathogens as an underrecognized cause of encephalitis.

Classic hemorrhagic fever with renal syndrome is a syndrome characterized by sequential periods of fever, hypotension, oliguria, and diuresis. Headache may be associated with aseptic meningitis, volume overload, hypertension, cerebral edema, or CNS hemorrhage (409). Brainstem or posterior fossa subarachnoid hemorrhages were found in autopsy cases (233). Both Korean hemorrhagic fever and the milder Puumala cause pituitary dysfunction with pituitary apoplexy or panhypopituitarism (422; 157; 329). Crimean-Congo hemorrhagic fever has been associated with encephalopathy characterized by decreased consciousness, agitation, and myoclonic movements. Severe fever with Thrombocytopenia syndrome (SFTS) encephalopathy/encephalitis may be accompanied by reversible corpus callosum splenial lesions and/or brainstem or thalamic lesions (189; 452).

Acute nephropathia epidemic (NE) patients frequently have headache, vertigo, insomnia, nausea, vomiting, dizziness, light sensitivity, and blurred vision. Ophthalmic findings are reduced vision, myopic shift, shallowing of anterior chamber, or changes in intraocular pressure (155). Encephalitis is rare. When found, encephalitis may be evidence of genetic susceptibility, such as toll-like receptor 3 (TLR3). TLR3.p.L742F variant appears enriched in Finnish populations (326).

Rift Valley fever causes encephalitis and retinal vasculitis without overlap with the hemorrhagic fever syndrome (06).

Marburg begins with high fever, severe headache, and malaise. A late sequelae uveitis with virus isolated from aspirate from the anterior chamber of the eye two months after the primary illness is described (129).

In the 2013 to 2016 West Africa Ebola virus epidemic, headache (53%), confusion (13.3%), eye pain (7.7%), and coma or unconsciousness (5.9%) were clinical features in summarized cases of the first nine months of the epidemic (473). Case reporting detailed encephalopathy or coma accompanying critical illness, respiratory failure, and gram-negative sepsis (206). Encephalitis or meningitis have been reported in several published case reports and newspaper releases. These are reported as: (1) encephalopathy/encephalitis with positive CSF EBOV PCR in a critically-ill stuporous patient with nuchal rigidity and seizures who expired a day later (382); (2) encephalitis in three patients with headache, frontal behavioral disorders, slowed responses, aggression, frontal release or cerebellar signs during acute Ebola, positive CSF EBOV PCR (day 9 to 12 of hospitalization), and survival and behavioral symptom improvement by discharge in all (93); (3) delayed encephalitis developing on day 16 of illness, characterized by precipitous neurologic decline and eventual recovery with supportive care. CSF EBOV PCR was positive when serum was PCR negative on day 40 of illness. CT scan showed generalized brain atrophy (164); (4) meningoencephalitis in a patient with delirium, myoclonus, eye movement disorders, hyperreflexia, frontal release, and meningeal signs, followed by mania, insomnia, and amnestic periods during recovery with supportive care. MRI findings in this case included multifocal punctate lesions in white matter and peri-fourth ventricular locations interpreted as microvascular occlusion and ischemia (78); (5) meningoencephalitis and radiculitis caused by late Ebola virus relapse, first reported in United Kingdom newspapers. An acute Ebola patient initially treated with oral brincidofovir, convalescent plasma, and ZMAb recovered from Ebola but returned to the hospital nine months later with meningitis, positive CSF EBOV PCR and culture, and MRI evidence of meningeal enhancement of brain, lower spinal cord, and within one cerebellar hemisphere (174). Virus was eradicated from the CSF by Gilead’s GS-5734 (Remdesivir) (174).

In summary, Ebola virus can infect the CNS during acute infection, causing encephalitis, which is shown in one fatal case with positive CSF EBOV PCR, three cases with behavioral changes plus CSF EBOV PCR who recovered, and one case with delirium, myoclonus, eye movement changes, pathological reflexes, and abnormal MRI. Ebola virus can also cause late stage encephalitis (from day 16), with positive CSF PCR but negative serum PCR (on day 40). Finally, Ebola virus can relapse as meningoencephalitis and radiculitis nine months after initial treatment and full recovery. During relapse, Ebola virus RNA was identified by RT-PCR at higher level in CSF than plasma, and infectious virus was recovered from CNS. Sequence comparison of virus and initial illness and relapse showed no changes in coding regions, excluding immune escape mutants as cause of relapse. The authors conclude the CNS was probably infected at the time of original illness and persisted in this immune-privileged site (174). The specific site or cells of virus persistence are not known, nor whether the virus continuously replicates or reactivates to produce relapse. Candidate cells, based on immunohistochemical staining pattern of brain of experimentally-infected nonhuman primates, would be microglia, possibly also astrocytes. At the time of the report, similar CNS relapsing illness had not been seen in thousands of survivors in West Africa, and the authors suggested that aspects of initial viral dynamics, immune response, or particular treatment of this individual increased the risk of CNS relapse (174).

Since then, a proportion of Ebola survivors in Sierra Leone have been shown to have a surge in antibody levels 200 to 300 days after recovery, consistent with de novo antigenic stimulation at immune-privileged sites of the eyes, testes, and/or CNS (02). The antibody surge is common. Previous early flare-ups in West Africa have been thought due to persistence of Ebola virus in sanctuary tissue sites and subclinical infections of survivors, but the possibility of hidden reservoirs of virus persisting a very long time after recovery with the potential for subsequent viral transmission was not fully appreciated. The possibility became reality on February 14, 2021. A new Ebola epidemic started in Guinea triggered by someone who was infected 5 to 7 years prior (212; 341).

Another relapse case in Democratic Republic of Congo led to a transmission chain resulting in 91 cases. The index case had been vaccinated with rVSV-ZEBOV, but still got Ebola. He was treated with monoclonal antibody mAb114 and recovered; however, six months later he relapsed with Ebola (253).

The tick-borne hemorrhagic flaviviruses are usually localized in small areas. Kyasanur Forest disease and Omsk hemorrhagic fever are biphasic diseases with a febrile or hemorrhagic period followed by encephalitic syndromes (483). Alkhurma virus patients have hemorrhage, hepatitis, and encephalitis. The frequency of developing CNS disease was 20%, compared to 55% for hemorrhagic signs, in a study (238).

	• Dengue is the leading cause of fever in returning travelers, and viremic travelers to nonendemic regions are the main source for autochthonous transmission.
	• The 2009 WHO case classification for severe dengue was broadened to include CNS involvement.
	• Dengue has been identified in 4% to 47% of hospitalized patients with encephalitis-like illness in endemic areas
	• Within the next few years, dengue and Chikungunya may become the main causes of encephalitis worldwide due to increasing numbers of infected individuals.
	• Coinfection of dengue with other agents may promote emergence of complicated cases, especially neurologic cases.
	• In areas of dengue and Zika virus co-circulation, a complex relation between dengue and Zika virus antibodies is emerging. Cross-reacting antibodies to dengue can yield false-positive serology for Zika and cross-reactivity has the potential to be either immune-protective or be associated with aggravated forms of the disease.

Half of the world’s population is at risk for dengue. Each year, an estimated 390 to 400 million people are infected by dengue virus, 100 million become ill, and 21,000 die. Aedes aegypti and Aedes albopictus are widely adapted for urban and peri-urban environments, and water disasters can become vast mosquito nurseries. After the record monsoon and worst flooding in Pakistan’s history, dengue cases and fatalities surged, June through September 2022. Data collected in 2022 (Jan through Oct 2022) indicated 34,673 dengue cases (62 confirmed deaths) (351), compared to 3442 reported cases in all of 2020 (316), with three fourths of cases occurring during the flood month of September 2022 alone.

Neurologic complications of dengue, estimated in 4% to 13% of all cases (34), cover all categories of virus-associated disease: direct viral effects, neurologic complications of systemic disease, and immune-mediated neurologic syndromes. Dengue immunoreactivity has been found in neurons, astroglia, microglia, and endothelial cells of fatal cases (368).

Dengue accounts for 4% to 47% of hospital admissions with encephalitis-like illness in endemic areas. Dengue, as pure dengue fever or dengue hemorrhagic fever, causes meningitis, meningoencephalitis, bitemporal encephalitis, thalamic or basal ganglia lesions, parkinsonism, stereotypy, dystonia, rhombencephalitis, hemorrhagic encephalitis, SIADH, postencephalitic hydrocephalus, opsoclonus-myoclonus, cerebellitis, acute disseminated encephalomyelitis, subdural hematoma, ischemic or hemorrhagic stroke, encephalopathy, cerebral edema, cortical laminar necrosis, or reversible splenial lesions, cauda equina syndrome due to spontaneous spinal hematoma, myelitis, acute polyradiculoneuritis, mononeuritis multiplex, brachial plexitis retinochoroiditis, retinal vasculopathy (190; 412; 479; 226; 454; 362; 447; 135; 243; 424; 465; 290; 446; 119; 125; 194; 312; 271; 122; 276; 297). In Asia, neurologic complications have been reported as more frequent with serotypes 2 and 3 (412).

The incidence of encephalopathy and encephalitis has been estimated as 0.5% to 6.2% (437). Encephalopathy includes depressed sensorium; convulsion; and behavioral disorders, such as mood and personality disorders, acute mania, emotional lability, anxiety, psychosis (23; 419). Meningeal involvement, focal evidence of the virus in the central nervous system, and virus isolation from CSF have been recorded in a number of cases (198; 234; 432; 299; 425). Intracranial hemorrhage due to microcapillary bleeds (210), punctate hemorrhages of deep white matter in edematous brains, subarachnoid hemorrhage, and postmortem diencephalic, brainstem, or cerebellar hemorrhages have been found (181). Microhemorrhages are seen as “blooming” on susceptibility weighted images (SWI) (230). An ischemic stroke patient who received TPA died of intracerebral hemorrhage after developing acute dengue and thrombocytopenia (321). Bilateral thalamic lesions with central hemorrhage associated with dengue are named the “double doughnut” sign (209). Selective pontine tract involvement has a brainstem “jack-o’-lantern” pattern on diffusion-weighted imaging and corresponding apparent diffusion coefficient maps (398). Altered signal intensities in bitemporal perisylvian regions, bilateral hippocampi and cingulate gyri, or symmetric gyral edema have been found (437). Additionally, dengue fever may present as encephalopathy with EEG burst suppression, electrographic seizures, epilepsia partialis continua, focal patterns, or as structural brain lesion (187; 272; 226; 227). Headaches can accompany illness or appear later as post-dengue new daily persistent headache (42).

Thrombocytopenia is not the only correlate of intracranial hemorrhage, raising the possibility of multiple contributing factors: vasculopathy, coagulopathy, and platelet dysfunction, in brain bleeds. Similar pathogenic mechanisms may apply to intraretinal dots, blots, or flame-shaped hemorrhages associated with dengue-related maculopathy. Vascular sheathing and vasculitis can also be found with macular hemorrhage (437).

Although autoimmune encephalitis is possibly underdiagnosed in resource-limited settings, links of dengue to peripheral, immune-mediated, and specific antibody syndromes are well documented. Peripheral nervous system complications include: Guillain-Barré, acute motor sensory axonal neuropathy or acute motor axonal neuropathy types, diaphragmatic paralysis, myositis, and hypokalemic quadriparesis or plegia, which may ultimately be shown to be a channelopathy unmasked by virus (176; 394; 448; 145; 370; 399; 140; 437). Immune-mediated syndromes associated with dengue include: Miller-Fisher variant Guillain-Barré syndrome (61; 360), cranial and optic neuritis, limbic encephalitis with NMDA receptor antibodies (34), myoclonus-ataxia with mGluR1 antibodies (76), and NMO-like syndromes. There have been two reports of convalescent or recurrent aquaporin-4 negative neuromyelitis optica spectrum disorders. A steroid-responsive optic-spinal syndrome developed in a child of Japanese ancestry one week after having a benign form of dengue fever (94). In a 17-year-old, an acute brainstem and transverse myelitis syndrome with longitudinally extensive spinal lesions and persistent DENV-1 infection (shown by + RT-PCR in blood) improved with steroids. In this patient’s second myelitis episode, the patient had DENV-1 RNA in blood along with evidence of acute or recent CMV infection (shown by development of CMV IgM antibodies since the first attack). The myelitis improved with steroids (359).

These immunopathologic cases, examples of ongoing immune activation due to previous viral infection or persistent infection, are now joined by two progressive dementia cases related to dengue. Rapidly progressive dementia and seizures in a 64-year-old were reported as post-dengue complications (273) and progressive dementia with extrapyramidal features in a 45-year-old with chronic panencephalitis was discovered to have persistent dengue infection of brain at autopsy (180).

Based on 2012 data, 48.8% of dengue cases with fatal outcomes in Brazil had laboratory evidence of DENV in CSF by viral isolation, PCR, NS1 Ag, or IgM detection (16). From this data point, severe or complicated CNS cases may be increasing due to emergence of other arboviruses associated with neurologic disease, CHIK and Zika, in the same geographic areas (361; 115), potentially through immunologic interactions with co-circulating arboviruses or viral genetic evolution for adaptation (283).

Dengue hemorrhagic fever is not equated to dengue shock syndrome, the most severe of the dengue syndromes due to acute vascular leak and disseminated intravascular coagulation (Srichaikul and Nimmannitya, 2000). Dengue hemorrhagic fever in Asia is generally considered a disease of childhood. The disease in infants is associated with primary infection in the presence of maternal antibody against a different strain. Most cases in older children are due to secondary or a sequence of multiple serotype infections (148; 146). However, evidence suggests that the incidence of severe dengue disease may occur at similar rates between primary and secondary dengue virus infection in the adult population (268). Importantly, although CNS involvement in dengue virus infection was often considered an encephalopathy secondary to a leaky capillary syndrome, reports show increasing prevalence of dengue encephalitis in dengue-prone regions (251). Dengue has been identified in 4% to 47% of admissions with encephalitis-like illness in endemic areas, and patients may have encephalitis without typical signs of systemic or symptomatic dengue (61).

Prognosis and complications

Case fatality rates have been estimated for many of these organisms (483):

Arenaviridae:
	• Lassa fever (15%) • South American hemorrhagic fevers (15% to 30%)
Filoviridae:
	• Marburg (25%) • Ebola (90%, Zaire and Sudan epidemics), (66% to 75%, Gabon 1996), (60%, West Africa)
Bunyaviridae:
	• Rift Valley fever (50%) • Crimean-Congo hemorrhagic fever (15% to 30%) • Hemorrhagic fever with renal syndrome • Hantaan (5% to 15%) • Puumala (less than 1%) • Severe fever with thrombocytopenia syndrome (30%)
Flaviviridae:
	• Yellow fever (20%) • Dengue hemorrhagic fever/dengue shock syndrome (1% to 5%, depending on endemic regions) • Kyasanur Forest disease/Omsk hemorrhagic fever (0.5% to 9%)

Major reported sequelae of infection by these viruses include the following:

Arenaviridae. Thirty percent of recovered Lassa patients have partial or total hearing loss, an incidence that considerably exceeds all other viral causes of postnatal deafness (90). Other sequelae reported in Sierra Leone have been ataxia and cognitive, mood, psychotic, and behavior disorders (410). Similar proportions of acute meningitic, encephalitic, and encephalopathic syndromes were found during hospitalization for Lassa virus in one study in Nigeria (306). Differing from the earlier study and excluding hearing loss patients from this group, they reported survivors had no long-term neurologic sequelae. The different results may reflect advantages of earlier diagnosis (by RT-PCR rather than IgM and IgG detection), early hospitalization and treatment, more advanced care capacity, or strain differences. Twenty-six hundred kilometers separates the Sierra Leone and Nigeria treatment centers.

Filoviridae. Patients who acquire Ebola in the latter stages of an epidemic may have a better chance of recovery.

Patients who recovered from Marburg in 1967 had neuropathy, “restless legs,” psychosis, amnesia, depression, or fatigue (249). Marburg virus was cultured from the anterior chamber of the eye from a uveitis patient two months after recovery (129), and the recent Ebola epidemic has presented examples of viral persistence: in the eye (444), semen, urine, and CSF.

With an estimated 17,000 survivors in West Africa, encounters with "post-Ebola syndrome" spectrum of diseases is increasing in this large survivor cohort. The first reports of signs and symptoms after recovery include eye pain and pressure, vision problems or blindness, eye movement abnormalities, sensorineural hearing loss, headache, musculoskeletal pain, affective and cognitive disorders, memory loss, anxiety attacks, insomnia, tremors, hair loss, abdominal or chest pain, and rash or pruritis (340; 35; 387).

Neurologic, psychiatric, and ophthalmologic evaluations and, in some cases, CT scans have been completed for participants triaged for neurologic care in a survivors’ clinic in Sierra Leone (165). The study confirmed long-term neurologic sequelae and disability and inability to perform activities of daily living (ADLs) in some, and the study confirmed that a substantial portion of patients had ongoing mental health problems. In addition, the study clearly presented the need for services integrated across several specialties for Ebola virus survivors.

Of 35 survivors, 30 had headaches, 13 of which were diagnosed as migraine. Other diagnoses were stroke (2), sensory neuropathy (2), and peripheral nerve or plexus lesions (2). Three CT scans showed cerebral and/or cerebellar atrophy, two were from patients known to have had Ebola virus encephalitis. One recovered with mild cognitive impairment and hippocampal atrophy, another was completely disabled, requiring 24-hour care. Two other CTs showed remote infarcts. Among the 35 patients, anxiety, depression, PTSD, psychosis, confusion, psychosocial issues, insomnia, tinnitus, and altered sensations were recognized, and mental health followup was required in several cases. Eye pain, redness, photophobia, and visual loss were reported; uveitis and unique peripapillary lesions were found (165).

Earlier studies of Ebola virus survivors have estimated uveitis at 13% to 34%, and unilateral white cataracts at 7%, which are frequently accompanied by hypotony (low intraocular pressure) (391; 418). A novel retinal lesion consisting of pale peripapillary lesions and pigmentation of large lesion areas was first reported in 14.6% of the Sierra Leonean Ebola virus survivors with ocular symptoms seen in 2016 (418). The pathologic changes were curvilinear lesions distinct from retinal vasculature and retinal nerve fiber wedge defects on the photoreceptor matrix. Lesions followed the retinal ganglion cell nerve fiber distribution in the absence of major retinal vessels, which was interpreted to represent the potential for neurotrophic spread into the eye from the optic nerve and along the retinal ganglion cell axons (418). In the laboratory, researchers have shown human pigment epithelial cells could be infected and were permissive for Ebola (406).

Uveitis, neuropsychiatric syndromes, arthritis, or other conditions may involve persistent infection, treatment effect, and autoimmune or exaggerated convalescent immune responses. Research was undertaken to characterize the post-Ebola virus syndrome clinical spectrum, establish diagnostic criteria and surrogate markers for early diagnosis, predictors, and biomarkers of organ-specific disease (60; 35; 390), and establish specialized or multidisciplinary services for clinical care. Although there had been reports of similar long-term sequelae in survivors of EBOV-Zaire in Kikwit 1995 and EBOV-Bundibugyo in Uganda in 2007, the large numbers of patients are unprecedented. Whether different Ebola virus species cause different post-Ebola syndromes remains unknown.

To evaluate the possibility of persistence of Ebola virus in CNS after recovery and Ebola Treatment Unit discharge, investigators in Liberia performed neurologic and CSF evaluations. Seven men and women were selected at a survivors clinic. They reported symptoms of paresthesias, headache, memory loss, tinnitus, and confusion. On examination, eye movement abnormalities were noted, as well as frontal release or extrapyramidal signs, tremor, sensory loss, or hearing loss. CSFs were normal and negative for Ebola virus by RT-PCR in all cases (35).

At least eight flare-ups in West Africa have been linked to persistence of Ebola virus in other tissues and subclinical infections of survivors. The virus, detected in semen up to 18 months after recovery and persisting in other body fluid such as breast milk, urine, and aqueous humor, could be found as viral nucleic acid at 40 months, which at the time was the longest time from acute EBOV infection to detection of viral RNA in semen (421; 337). For the first time, investigators found that a woman can harbor virus for more than one year and then infect others (104). The virus re-emerged in fatal form in the woman shortly after giving birth, raising the question of the contribution of immunosuppression or immunotolerance during pregnancy.

Recommendations that survivors’ body fluids be monitored for at least 18 months after recovery or until the fluids test negative at least twice were made in 2018 (421). However, intermittent viral RNA detection in semen and the fact that two negative tests could be followed by a positive test was noted in the NIAID NEI PREVAIL study (PREVAIL III Study Group 2019). Ebola virus persistence in semen, urine, and aqueous humor is associated with ongoing viral replication and, therefore, is not quiescent or latent infection (459). Guinea’s newest Ebola epidemic declared February 14, 2021 started with sexual transmission by someone who was probably infected 5 to 7 years prior (212; 341). Cumulatively, there were 18 cases (14 confirmed; 4 probable), with nine deaths and six recoveries reported (196; 349).

The Partnership for Research on Ebola in Liberia (PREVAIL) III longitudinal study of Ebola sequelae in Liberia involving survivors of EBOV as well as their seronegative close contacts found the incidence of most symptoms and neurologic findings greater among survivors. Headache, muscle pain, memory loss, and joint pain were more frequent in this group, and neurologic abnormalities among survivors and controls were abnormal reflexes (1.4% vs. 0.7% respectively), tremor (0.9% vs. 0.2%), gait or balance difficulty (0.7% vs. 0.9%), speech abnormality (0.7% vs. 0.2%), and cranial nerve findings (0.7% vs. 0.1%). Prevalence of findings declined over time except for uveitis. There was a positive correlation between viral persistence in semen and detection of uveitis on baseline examination, and the incidence of new uveitis was higher among survivors than controls at 12 months (337).

A simultaneous study, the Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) II study in Sierra Leone, reported cataract surgery to be safe and effective in Ebola virus disease survivors, resulting in restoration of vision (392).

In Guinea, an estimated three fourths of survivors of the West Africa epidemic experienced symptoms including migraine-like headaches, visual problems, joint and muscle pain, and fatigue a year after initial infection and sometimes for much longer. Sequelae could decrease over time but after 48 months, neurologic (30%), musculoskeletal (6%), and ocular (4%) conditions remained in survivors in Guinea (98). No association between cardinal post-Ebola symptoms and serologic markers of inflammation and immune activation has been found in the longitudinal Liberian EBOV survivor study that followed participants for up to 3 to 4 years after acute infection (435).

Survivor studies from the world’s second largest Ebola epidemic, August 2018 to June 2020 (North Kivu and Ituri Provinces, Democratic Republic of Congo), which infected 3481 individuals and took 2290 lives, showed PTSD, depression, or anxiety in an estimated 25% to 33% of study participants (191). As in West African studies, psychic trauma and mental health issues were not a side show but a significant, ongoing public health issue. Persistent headache or short-term memory impairment accompanied anxiety and depression.

Bunyaviridae. Hemorrhagic fever with renal syndrome has produced hallucinations, delusions, paranoid reactions and affective disorders, myelopathy, fatigue, endocrine disorders, and convalescent headache associated with hypertension. Two convalescent-phase deaths from CNS complications were recorded between 1961 and 1963 in Korea. One was associated with a meningitic syndrome because of severe nausea, vomiting, and CSF pleocytosis. The other was from pituitary dysfunction (201). A complication of Puumala virus, the agent of nephropathia epidemica, is also hypophyseal hemorrhage and panhypopituitarism (157).

Rift Valley fever is associated with major ocular morbidity. There is a characteristic retinitis with white macular lesions accompanied by extensive vasculitis. Retinal hemorrhages, vitreous reactions, and optic disc edema may be present. Due to involvement of the uvea and posterior chorioretinal area, permanent visual loss resulting from macular and paramacular scarring, vascular occlusion, and optic atrophy occurs (96; 05). Cerebral vasculitis may have been the cause of quadriparesis and other poor neurologic outcomes (06).

Severe fever with thrombocytopenia syndrome (SFTSV) virus, a tickborne phlebovirus, is an emerging zoonotic infection and a recognized cause of encephalitis in China (89; 452; 475), Korea (324), Taiwan (331), Japan (189; 205). Haemaphysalis longicornis ticks, the vector of severe fever with thrombocytopenia syndrome, are indigenous Asian ticks that have been detected in the United States in several eastern and southern states on domestic animals, wildlife, and two humans during 2017 to 2018 (28).

Flaviviridae. Neurologic complications of dengue virus infection include encephalitis, acute disseminated encephalitis, transverse myelitis, Guillain-Barre syndrome, mononeuropathies, encephalopathy without encephalitis, and subdural hematoma. Patients with encephalopathy have more severe illness and worse outcome compared to patients with acute motor weakness (272). CNS invasion by dengue was an important fatal complication in a postmortem study from Brazil (16). After bilateral hippocampal involvement by dengue, recovery of memory to average performance on the Wechsler Adult Intelligence Scale required 70 days (479). Recovered Omsk hemorrhagic fever patients may have hearing loss or neuropsychiatric syndromes. Complications of yellow fever vaccine include encephalitis, acute disseminated encephalomyelitis, and Guillain-Barre syndrome (262).

Togaviridae. Chikungunya virus is a rapidly emerging virus causing febrile rash and arthritis. The name is from the Makonde (East African) language for “that which bends up”. Virus may affect the CNS, with meningitis, encephalitis, or encephalomyeloradiculitis, generally in pediatric groups or individuals with advanced age and underlying diseases (64; 123; 375; 91; 83; 294; 24; 131).

Clinical vignette

A 16-year-old girl with 4 days of fever, headache, body aches, two days of vomiting, and one generalized seizure was admitted to a hospital in rural Sierra Leone, West Africa in February. It was the region’s dry season, which is also Lassa season. The patient had a fever of 38.7°C, subconjunctival hemorrhages, and abdominal tenderness. She was drowsy but arousable with a symmetric motor exam and normal tone and reflexes. She was immediately transferred to the Lassa Ward, a building separate from the general hospital with its own supplies, segregated laboratory, and strict barrier nursing practices. Laboratory investigations showed leucopenia, thrombocytopenia (white blood count 2500/mm3; hematocrit 35, platelets 59,000/mm3), elevated liver function tests (serum glutamic pyruvic transaminase 362 IU) (serum aspartate transaminase) (normal range 3 to 35) and no malaria parasites on several peripheral blood smears. There were eight white blood cells/mm3 in CSF with no gram-stained organisms. Reagents for measuring CSF protein and glucose were not available. Intravenous ribavirin, penicillin, and chloramphenicol were started for possible Lassa fever, bacterial meningitis, or typhoid fever. Involuntary movements, grimacing or stretching of the lower face, and pursing of the lips were noted the next hospital day. She had difficulty maintaining a normal head posture and speech was harsh. Her jaw tightened, her lips retracted, and her head arched back when attempting to drink from a bottle. Diazepam suppressed the lower face movements. The patient’s overall condition improved within days of intravenous ribavirin treatment (2 g loading dose, followed by 1 g every 6 hours for 4 days, then 0.5 g every 8 hours for another 6 days). By hospital day 4, the involuntary movements were gone. She recovered but had no memories of recent events or the circumstances of her illness. She seemed subdued, less fluent, inattentive, and was unable to retrieve some general cognitive information such as the name of her village chief. Antibodies to Lassa virus were detected on day 12 of illness (IgM=4, IgG=64), increasing to IgM greater than 16; IgG was greater than 1024 two days later. The patient was discharged after 10 days of intravenous ribavirin. When the CSF examination was repeated, there were no cells.

Comment. This case demonstrates typical systemic disease plus a clinical encephalitic syndrome with seizure, focal dystonia, and amnesia associated with Lassa fever. This clinical presentation illustrates overlap with malaria, bacterial meningitis, or enteric pathogens. Because February, the dry Hamartan season in West Africa is, also the region’s N meningitides season, the patient received meningitic doses of antibiotics on the first hospital day. The diagnosis of Lassa fever on site relied on demonstration of antibodies to Lassa virus and exclusion of other bacterial and parasitic infections. Criteria for Lassa fever diagnosis are IgM titers greater than 16 and IgG titers greater than 128 or a 4-fold rise in IgG antibodies to Lassa virus by indirect immunofluorescent antibodies. Indirect fluorescent-antibody tests were performed on slides of infected cells prepared at the U.S. Centers for Disease Control and Prevention. Confirmation was by virus isolation at a biosafety level 4 lab at the U.S. Centers for Disease Control and Prevention.

The patient recovered, highlighting what can be accomplished in a resource-limited setting. Published guidelines for the optimal type and duration of intravenous antiviral treatment for Lassa fever were followed (256). The decision to treat was based on clinically compatible syndrome and elevated liver function tests, which signified significant systemic disease. The patient recovered and there were no secondary cases among patient’s contacts or staff, a result of isolation in the Lassa ward and the work of trained staff.

Biological basis

Etiology and pathogenesis

	• Viral hemorrhagic fevers are a group of illnesses that are mainly caused by members of four different families of viruses: Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae.
	• Vascular leakage and immune system dysregulation or immunosuppression are common to all viral hemorrhagic fevers.
	• Viral tropism indicates some pathogenic mechanisms of disease.
	• The liver, spleen, regional lymph nodes, macrophages, and monocytes are early targets of infection and replicate virus. As such, virus can enter the CNS through infected monocytes and movement across the blood-brain barrier is aided by barrier breakdown due to endothelial infection. CNS disease can be direct infection and damage to neurons or glia, bystander inflammatory, or autoimmune injury.
	• Mechanisms of vascular damage include: direct endothelial infection, capillary infiltration by infected cells, localized hypoxia and release of vasoactive neuropeptides, release of cytokines and other soluble inflammatory mediators, and immune-complex injury.
	• Mechanisms of hemorrhage include: impaired hepatic synthesis of coagulation factors, DIC, platelet sequestration, and cytokine-induced megakaryocytosis suppression.
	• Mechanisms of immune suppression include: direct infection of lymphoid tissue, direct attack on bone marrow compartment, and cytokine-induced immune and myeloid suppression. Some viral genomes contain immunosuppressive domains.
	• Encephalopathy in critical illness may be cerebral edema, anoxia, hemorrhage, hyponatremia, hepatic or renal failure, microcapillary hemorrhage, or release of toxic substances.
	• CNS disease or CNS penetration is not clearly related to viral load.

Viral hemorrhagic fevers are a group of illnesses that are mainly caused by members of four different families of viruses: Arenaviridae, Filoviridae, Bunyaviridae, and Flaviviridae.

To date, five Old World arenavirus species and 17 New World arenaviruses have been recognized by the International Committee for Taxonomy of Viruses, but the presence of additional arenaviruses in Africa is suspected.

Arenaviruses causing hemorrhagic syndromes are Lassa fever virus (Lassa fever) in West Africa and Lujo virus in South Africa (45; 327) as well as agents of the South American hemorrhagic fevers including: Junin virus (Argentine hemorrhagic fever), Chapare and Machupo (Bolivian hemorrhagic fever), Guanarito (Venezuelan hemorrhagic fever), Sabia virus in Brazil, Ocozocoautla de Espinosa virus in southern Mexico (Chiapas state) (52), and the White Water Arroyo virus in the states of New Mexico and California in the United States. Lymphocytic choriomeningitis virus transmitted by solid-organ transplantation caused hemorrhagic syndromes in the United States (118), and a new lymphocytic choriomeningitis virus-related arenavirus in Australia, Dandenong virus transmitted by solid-organ transplantation, caused a similar hemorrhagic syndrome (319). There have been several reported clusters of lymphocytic choriomeningitis virus donor-derived infections in the United States and worldwide. In the transplant groups, CNS abnormalities were found, including meningoencephalitis, dural effusions and thickening, intracerebral and subarachnoid hemorrhages, and EEG slowing. Often, the CNS disease was overshadowed by the systemic disease looking like Lassa hemorrhagic fever (118; 250). Where a high prevalence of infected mice and seropositive humans are found, there may be more congenital lymphocytic choriomeningitis virus (LCMV) infection than previously thought (41). The congenital syndrome is microcephaly, periventricular calcifications, hydrocephalus, chorioretinitis, and cataracts (41; 95).

Ebola and Marburg viruses, previously the only members of the Filoviridae family, are both hemorrhagic fevers with high mortality rates. To better reflect high-resolution phylogeny now available, a revised taxonomy of the family Filoviridae with species named Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, Tai Forest ebolavirus, Bundibugyo ebolavirus, Marburg marburgvirus, and Ravn marburgvirus has been proposed along with a new family member, Lloviu cuenavirus, which is found in Schreiber’s long-fingered bats in Spain (208).

Bunyaviruses causing hemorrhagic fevers are Rift Valley fever virus (Rift Valley fever), Crimean-Congo hemorrhagic fever virus, Hantaan, Seoul, Dobrava/Saaremaa (hemorrhagic fever with renal syndrome/HFRS), Puumala (nephropathia epidemica), and Ilesha virus (318). Currently, the Dobrava-Belgrade orthohantavirus species is divided into four distinct European hantavirus genotypes: Dobrava (DOBV), Kurkino (KURV), Saaremaa (SAAV), and Sochi (SOCV). DOBV and SOCV are associated with life-threatening infections, KURV with relatively mild infections, and SAAV with subclinical infections in man (441).

Flaviviruses associated with hemorrhagic fevers are yellow fever virus (yellow fever), dengue virus (dengue hemorrhagic fever/dengue shock syndrome), Kyasanur Forest disease virus, Omsk hemorrhagic fever virus, and Alkhurma virus. Although flaviviral hemorrhagic fevers affect all ages, incidences can be significantly higher in some age groups in certain virus infections, such as dengue virus, for which infection of school-aged children dominates. The reasons thus far are still unclear.

Recent epidemics of Chikungunya virus have focused attention on this member of the Togaviridae family, genus Alphavirus, as a cause of hemorrhagic and encephalitic illness. Neurologic manifestations of Chikungunya fever are influenced by patient age, with greatest frequency in pediatric groups. Clinical signs of meningeal, retinal, or CNS involvement include nuchal rigidity, retinitis, ophthalmoplegia, and slurred speech (291). Neurologic syndromes in children include febrile seizures, aseptic meningitis, seizures, and altered mental status (375). Stimulus-sensitive myoclonus and cerebellar ataxia following chikungunya meningoencephalitis (186) and post chikungunya brain stem encephalitis (127) have been reported. Cases of confirmed meningoencephalitis, though rare, are significant for their association with severe or fatal disease (433; 397). Virus has been recovered from brain and CSF. A steroid-responsive, rapidly progressive flaccid paralysis with cranial nerve sparing was described in the Andaman and Nicobar Island epidemic of 2005-6 (400).

Vascular leakage is common to all the viral hemorrhagic fevers, but no single model for vascular damage or vascular endothelial permeability fully accounts for all syndromes. For example, vascular leak may be due to direct endothelial infection (Ebola/Marburg, hantaviruses), localized hypoxia and release of vasoactive neuropeptides (arenaviruses), complement activation and release of bradykinin (Puumala virus), release of cytokines and other soluble inflammatory mediators (arenaviruses, Ebola/Marburg, dengue), immune-mediated or immune-complex injury (hantaviruses, dengue), elaboration of matrix metalloproteinases, alterations in the antithrombotic and protein C pathways and vascular endothelial growth factor (dengue), or endothelial injury triggering disseminated intravascular coagulation (Rift Valley fever, Crimean-Congo hemorrhagic fever, Ebola). The transient or reversible vascular permeability and coagulopathy, found in dengue hemorrhagic fever, would be consistent with multiple short-lived and soluble immune effectors as mechanisms of effect. When better understood, each step in the process of endothelial or transendothelial injury and progression of vascular leakage represents a potential checkpoint for infection.

A second pathogenic feature common to many viral hemorrhagic fevers is immune system dysregulation or immunosuppression. Although lymphoid tissues are thought to be the primary targets for many viral infections, there is also evidence of direct viral attack of the bone marrow compartment, with this tissue tropism playing a critical role in outcomes (84; 108; 301). The ability to disable the host immune response by attacking and manipulating cells that initiate antiviral responses has been demonstrated, for example, in Ebola and Lassa fever, by downregulation of dendritic cell function (116; 130). Filoviruses encode proteins with regions similar to the immunosuppressive domain of oncogenic retroviruses (450; 49; 476) and arenavirus protein segments can inhibit interferon pathways (457; 46). Dengue is an exception, instead producing significant pathologic changes in the reticuloendothelial system, liver, and the vascular system (32). Bone marrow suppression at early infection and hypercellularity at late infection in conjunction with circulating immune complexes reaching the liver or spleen may induce further organ damage through positive feedback loops that amplify inflammatory responses (480). These secondary insults could account, in part, for why patients rapidly worsen soon after the first clinical symptoms are noted.

The pathophysiology of neurologic symptoms is most often attributed to cerebral edema, anoxia, hemorrhage, hyponatremia, hepatic or renal failure, microcapillary hemorrhage, and release of toxic substances. Yet there have been descriptions of clinical syndromes consistent with encephalitis, raising the possibility that some of the viruses are neurotropic, causing disease by direct infection and damage or bystander inflammatory injury. Due to the remoteness of sites of many of the epidemics, specimens would not have been available for confirmation by virus detection in CSF or brain (by culture, PCR, immunostaining, or electron microscopy ultrastructure). Where CNS data are available, they are presented with mechanisms of the viruses’ hemorrhagic effect. The nervous system complications of viral hemorrhagic fevers are summarized in Table 1.

Table 1. Viral Hemorrhagic Fevers and CNS Disease

Family; virus		Neurologic syndromes	Virus detection in CNS
*Arenaviridae*
	Lassa	Seizures, dystonia, tremor, cerebellar ataxia, hearing loss, encephalopathy, amnesia, psychosis, fatigue, depression, dementia, late-onset paraparesis, subcortical MRI abnormalities	CSF (culture, PCR, virus-specific antibodies)
	Lymphocytic choriomeningitis virus and “lymphocytic choriomeningitis virus-like” organ transplant arenavirus	Encephalopathy, seizures, congenital disease, aseptic meningitis, hydrocephalus
	Argentine hemorrhagic fever	Acute cerebellar ataxia, dysarthria, tremor; or late cerebellar and oculomotor signs after immune plasma treatment
	Lujo	Cerebral edema, coma
*Filoviridae*
	Marburg	Uveitis, neuropathy, restless legs, psychosis, amnesia, Depression, fatigue	Anterior eye chamber (culture)
	Ebola	Meningoencephalitis, delayed encephalitis, eye movement disorders, cerebellar, white matter, or spinal lesions, behavior and cognitive disorders, uveitis, retinitis, post-Ebola syndrome	Anterior eye chamber (culture), CSF (PCR)
*Bunyaviridae*
	Hemorrhagic fever with renal syndrome	Headache, dizziness/vertigo, confusion, aseptic meningitis, hypertensive encephalopathy, CNS parenchymal or subarachnoid hemorrhage, pituitary apoplexy, reversible corpus callosum splenium lesion or PRES on MRI, Guillain Barré	CSF (viral antigen and virus-specific antibodies)
	Puumala (NE)	Encephalitis, ataxia, seizures, Guillain-Barré, bladder dysfunction, cerebral hemorrhage, hypophyseal hemorrhage, panhypopituitarism, MRI-demonstrated white matter lesions, posterior corpus callosum enhancement	Brain (pituitary) (viral antigen in endothelial and chromogranin + cells) (immunohistochemistry) CSF (virus-specific antibodies, PCR)
	Dobrava (HFRS)	Headache, blurred vision, seizures, hemiparesis	CSF (virus-specific antibodies)
	HPS (North America)	Transverse myelitis, ADEM, painful peripheral neuropathy
	Andes HPS (South America)	Headache, confusion, excitement, seizure, cortical and subcortical MRI abnormalities, minor intraventricular hemorrhage
	Rift Valley	Encephalitis, retinal vasculitis, autoimmune retinitis, delayed meningoencephalitis	CSF (virus-specific antibodies)
	Crimean-Congo hemorrhagic fever	Encephalopathy, cerebral edema, intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma
	Severe fever with thrombocytopenia syndrome	Encephalopathy, encephalitis, seizures, MRI-demonstrated lacunar infarcts, ICH, hypoxic white matter changes	CSF (culture, RT-PCR)
*Flaviviridae*
	Dengue virus	Meningoencephalitis, encephalitis, hemorrhagic encephalitis (dengue hemorrhagic encephalopathy), SIADH, postencephalitic hydrocephalus, opsoclonus-myoclonus, autoantibody syndromes, encephalopathy, myelitis, Guillain Barré, NMO spectrum, brachial plexitis, subdural hematoma, ADEM, ischemic stroke, retinochoroiditis, diaphragmatic paralysis, hypokalemic paralysis	CSF (culture, PCR, virus-specific antibodies), brain (immunohistochemistry)
	Kyasanur Forest disease, Omsk hemorrhagic fever, and Alkhurma virus	Late-stage encephalitis, hearing loss, neuropsychiatric sequelae, encephalitis
*Togaviridae*
	Chikungunya virus	Meningoencephalitis, myelitis, encephalitis, acute encephalopathy, febrile seizures, peripheral neuropathies, radiculitis, Guillain Barré-type syndrome, acute flaccid paralysis, ophthalmoplegia, retinitis, slurred speech	CSF (culture, PCR, virus-specific antibodies)

Arenaviruses. Except for the congenital and organ-donor transmitted cases, the virus is transmitted from asymptomatic rodents. Virus enters the human host via mucosal surfaces, abraded skin, or parenteral or inhalation routes. Initial replication at the site of infection in nonreservoir hosts is followed by infection of macrophages. Infection spreads, involving additional cell types in liver, adrenal, spleen, lymphatic tissue, lung, and intestine. Widespread infection of submucosal macrophages causes secretion of cytokines, neuropeptides, and inflammatory mediators, which are thought to play an important role in evolution of shock syndrome and pulmonary edema (48). In the 2005 donor-transmitted cases of lymphocytic choriomeningitis virus, all organs came from a donor who had been exposed to a hamster infected with lymphocytic choriomeningitis virus (08).

Lassa virus was isolated from three of three spinal fluids from patients with signs of meningitis (179) and a Lassa aseptic meningitis, diagnosed by CSF pleocytosis and positive serum PCR, was reported (305). In one patient with fever and a 30-minute generalized seizure followed by two days of disorientation and stupor, Lassa virus was cultured from CSF, not serum, and real-time PCR indicated higher virus load in CSF compared to serum. Lassa virus-specific IgM and IgG antibodies were present in CSF (143). Acute CNS syndromes (seizures, dystonia, tremor, ataxia, encephalitis/encephalopathy) with inflammatory CSF and convalescent syndromes (amnesia, psychosis, fatigue, depression, dementia) have been described (410), and close to one third of Lassa patients develop hearing loss during recovery or convalescence (90).

Nonhuman primates with Lassa also develop hearing loss as a convalescent phenomenon, and studies have linked deafness to a systemic immune-mediated vasculitis. The vasculitis is characterized by inflammatory vascular findings in tissues in the absence of circulating virus or evidence of viral antigen in tissues or vessel walls. The mechanism of hearing loss in surviving nonhuman primates is presumed inflammation and occlusion of anterior inferior cerebellar artery and downstream vessels resulting in cochlear hypoxia, as seen in polyarteritis nodosa in man. Perivascular inflammation around cochlear nerve branches had no viral staining in surviving nonhuman primate study subjects with BSER-demonstrated hearing loss, and serologic markers of autoimmune systemic vasculitis, such as elevated C-reactive protein, circulating immune complexes, elevated proinflammatory cytokines, and positive antineutrophil cytoplasmic antibodies, were present (63).

In a mouse model of sensorineural hearing loss, investigators find LASV particles enter the ear by hematogenous spread or through CSF and cause damage to the inner ear hair cells and auditory nerve by immunopathologic mechanisms (482).

A guinea pig model of Lassa fever, showing persistent smooth muscle infection of arteries and chronic systemic vascular inflammation (arteritis) during convalescence, may link to some of the other long-term sequelae in man: vision distortion, vertigo, back pain, and polyserositis (126).

Thirty percent of Lassa patients cared for at Irrua Specialist Teaching Hospital, Nigeria from 2011 to 2015 were reported to have severe CNS symptoms: coma, seizures, irrational talk or behavior, altered sensorium, tremors, disorientation, and confusion, and they were diagnosed as encephalitis, meningitis, or encephalopathy. Surviving patients in this cohort, followed for 3 to 18 months, had no long-term neurologic sequelae. One patient who had Lassa virus nucleic acid in CSF during acute illness, followed for over 24 months, also had no sequelae. An additional 37 hospitalized Lassa patients were not included in the study; five (14%) had early sensorineural hearing loss, some of whom did not recover and had permanent hearing loss (306). Presumably, most or all patients were treated with intravenous ribavirin.

The authors note that the circulating virus in Nigeria is more diverse and genetically distinct than the virus elsewhere, and they suggest some of their clinical findings, such as CNS disorders or intrinsic kidney disease, may be a result. With up to 32% strain variation, it is comparable in variation to Crimean-Congo hemorrhagic fever (CCHF) (30% sequence variation among isolates), in contrast to Ebola (3% across all sequenced strains) and Rift Valley fever (5%). Lassa virus sequence data were not provided, which would help correlate Lassa virus variants with mortality or CNS disease.

Lassa viruses are classified in five lineages (I-V) with lineages I to III found in Nigeria, IV in West Africa, and V in Mali and Ivory Coast. Molecular clock estimates show that Lassa virus may have evolved from an ancestral stock 500 to 1000 years ago (274).

A late neurologic syndrome of fever, headache, cerebellar ataxia, and cranial nerve palsies was reported after immune plasma treatment in about 10% of treated Argentine hemorrhagic fever patients (240). Presence of the Argentine hemorrhagic fever convalescent syndrome raises the possibility of prior invasion of CNS by virus and persistent infection. Whether this late neurologic syndrome is the result of CNS relapse with viral replication or immune reaction is not known from the 1979 report. One group has suggested neurologic diseases could be a function of pathogenic differences between Old and New World arenaviruses, with Old World arenaviruses such as Lassa causing disease through generalized immunosuppression and New World viruses such as Junin causing disease by cytokine storm (261). An effective T cell-mediated response is required for recovery from Lassa. Antibody response is ineffective in controlling Lassa infection but is important in Argentine hemorrhagic fever (261).

Studies are testing the hypothesis that Lassa fever virus is a driver of natural selection of genes associated with Lassa infectivity and immunity in West African populations where Lassa is endemic (11). Lassa fever virus uses aDG (alpha-dystroglycan—a cell surface molecule for attachment to the extracellular matrix) as a host cellular receptor. Lassa fever virus exposure results in positive selection on genes affecting expression, modification, and proper function of aDG. The International HapMap project has identified positive selection of two genes: LARGE and dystrophin; in a Nigerian population such that allelic variants may alter ability of Lassa fever virus Gp to bind aDG. LARGE (cellular like-acetylglucosaminyltransferase) glycosylates aDG, enabling its interaction with extracellular matrix or Lassa fever virus GP and dystrophin, is a cytosolic adapter protein for aDG (261).

Filoviruses.

Ebola/Marburg viruses. Virus enters the human host via mucosal surfaces, abraded skin, or a parenteral route.

The endosomal protein Neumann-Pick C1 (NPC1) is an intracellular receptor. EBOV-glycoprotein interacts with NPC1 at the endosomal membrane, triggering release of viral material into the host cell (58). T cell immunoglobulin mucin domain-1 (TIM-1) is a phosphatidylserine (PS) receptor mediating filovirus entry into cells through interactions with phosphatidylserine on virions. TIM-1 is widely expressed in epithelial cells of mucosal epithelial surfaces (47).

Macrophages and monocytes are early targets of infection and replicate virus. With dissemination via lymphatic and vascular systems, endothelial cells are infected next. Possibly, virus enters the CNS through infected monocytes, and movement across the blood-brain barrier is aided by barrier breakdown due to endothelial infection. Activation of endothelial and mononuclear phagocytic cells is triggered by direct viral infection and by binding of soluble viral and host cellular factors. Endothelial injury and dysfunction are induced by the cytopathic replication that follows direct endothelial cell infection and by mediator-induced inflammatory responses. Infection of endothelial cells, together with cytokine production, sustains the vascular injury and increases permeability, leading to hemorrhage and circulatory compromise. Liver function is eroded as hepatocytes, endothelial cells, monocytes, and Kupffer cells are overwhelmed by the replicating virus. Virus infection of kidneys, adrenals, intestines, skin, and the reproductive system also occurs. Efficient viral replication over a wide host-cell range, cytotoxic viral and host products, and filovirus immunosuppression through interference with innate immune responses culminate in vascular dysregulation, fluid-distribution problems, coagulopathy, and bleeding (116). Fatal outcome is characterized by impaired humoral responses, failure to generate specific IgG, and intravascular apoptosis of peripheral blood leukocytes (21; 478; 384). Highly elevated d-Dimer levels early in disease (0 to 2 days after onset), which signify disseminated intravascular coagulation, are also associated with fatal outcomes (378).

In cases from the 1967 Marburg outbreak, CSF contained between 0 and 24 white blood count and protein up to 68 mg/dL (420). Virus has been detected in CSF in Ebola patients (382; 164), potentially having gained access to the CNS via infected monocytes or macrophages. Immunostained glial nodules in the brain of Ebola-infected nonhuman primates (216) raise the possibility of CNS cells, perhaps microglia, as virus reservoirs. Marburg has been cultured from the anterior chamber of the eye in a recovered patient (129), and Ebola has been cultured from the aqueous humor of a convalescent individual with anterior uveitis 10 weeks after the onset of Ebola virus (444). Patterns of lesions of retinal ganglion cell nerve fibers seen in Sierra Leone in Ebola survivors raise the possibility of EBOV’s capacity for transneuronal spread (418).

Acute or convalescent neurologic syndrome signs and symptoms have been noted in Marburg patients (248; 409) and postmortem exams from patients surviving several days with Marburg show widely distributed microglial nodules, diffuse glial cell proliferation, perivascular inflammation, and scattered petechial hemorrhages (29; 173).

Bunyaviruses.

Hemorrhagic fever with renal syndrome. Hantaviruses are transmitted from the infected rodent reservoir to humans by inhalation of infectious aerosols produced from rodent excreta. The detection of hantavirus in mites raises the possibility of a role for arthropods in transmission as well (486). Viral RNA is present in blood at early stages of disease. Hantaviruses infect endothelial cells without cytopathic effect and interact with beta integrins present on platelets (298). The more pathogenic hantaviruses may utilize beta-3 cell surface integrins, whereas less pathogenic hantaviruses use beta-1 integrins for cell entry (128). Pathogenic effects could relate to integrin modulation of calcium signaling, but early events in infection are incompletely understood. Because hantavirus-specific antibodies and T cells are detected at onset of symptoms, immune changes, rather than virus-induced cell death, may drive early disease. Later, virus antigen is pervasive, present in endothelial cell layers throughout the body. Antigen predominates in kidney endothelial cells in postmortem cases of hemorrhagic fever with renal syndrome and lung endothelial cells in cases of hantavirus pulmonary syndrome.

Hantavirus (Asian/Korean/Seoul) hemorrhagic fever with renal syndrome complications include encephalopathy, characterized as depressed mental status and abnormal behavior, along with choreiform movements, rigidity, or finger tremors, CSF pleocytosis, radiologic features of reversible corpus callosum, splenial lesion or posterior reversible encephalopathy syndrome, pituitary dysfunction, and Guillain-Barre syndrome (201; 409; 20; 110; 177). MRI findings in hemorrhagic fever with renal syndrome-related encephalopathy patients associate with stage of disease. MRI changes of PRES (posterior reversible encephalopathy syndrome) are found in the oliguric phase, and splenial lesion pattern in the febrile phase (207). Postmortem findings include brain intraparenchymal hemorrhage, petechial hemorrhage, subdural hematoma pituitary necrosis, or cerebral edema (233; 336). Dobrava (HFRS) has caused focal seizures and hemiparesis in a Slovenian patient (69).

Severity of hemorrhagic fever with renal syndrome (HFRS) has been associated with human platelet alloantigen (HPA) alleles. Platelet and platelet-associated proteins are highly polymorphic, and up to 30% of natural variation in platelet reactivity is estimated related to genetic inheritance. There are five common HPA gene variants, with differential susceptibility to cardiovascular disease and stroke found among individuals with different alleles. One of these polymorphisms, the HPA-3b allele, is observed in patients with more severe HFRS (229).

Nephropathia epidemica of Puumala virus, generally the mildest form of hemorrhagic fever with renal syndrome, has encephalitis, ataxia, seizures, Guillain-Barré syndrome, bladder dysfunction, cerebral hemorrhage, hypophyseal hemorrhage and panhypopituitarism, or MRI-demonstrated white matter lesions or signal enhancement of the posterior corpus callosum as complications (30; 154; 155). High CSF neopterin levels have been associated with intrathecal PUUV-IgM production, elevated markers of tissue permeability, and reduced visual acuity (disturbed refractive properties of the eye, lens thickening, acute myopic shift) (156). As in severe hemorrhagic fever with renal syndrome cases, a mechanism of pituitary injury can be hemorrhage or hypovolemic shock. The hypophyseal gland is vulnerable because of its anatomical location and organization of blood supply. The anterior lobe of the pituitary receives 10% to 20% of its blood supply from superior and inferior hypophyseal arteries, with the remaining 80% to 90% provided by hypophyseal venous portal circulation. Both ischemic and hemorrhagic damage of the pituitary have been found in radiologic images (33). Alternatively, accumulation of antigen in critical target tissues could yield inflammatory responses that enhance lesions. In one case, Puumala viral antigen was found in neuroendocrine stromal and vascular endothelial cells (157).

There is increasing experimental evidence that immunogenetic factors such as HLA, complement genes, and cytokine polymorphisms affect susceptibility and course of Puumala infections. Susceptibility HLA haplotypes for severe infection may explain, in part, the wide spectrum and variable intensity of Puumala virus disease.

Severity of Puumala illness has been associated with HLA haplotype. Severe disease is seen in B8 DRB1*0301 patients and mild disease in HLA B27 allele patients (288), the same HLA associations found in rapid and slow progressors, respectively, in HIV patients (288). Deletions within the C4A gene encoding the C4A component of the complement system is invariably linked to HLA-B8-HLA-DRB1*0301 (71). Complement activation and bradykinin release drive the capillary leakage contributing to Puumala disease severity, which is treatable with the bradykinin BK receptor blocker icatibant (404).

Susceptibility to PUUV infection is also related to TNF-a and noncarriage of the interleukin-1 receptor antagonist (IL-1RA) allele 2 and IL1a (-511) allele 2 (287).

A study finds that a genetic defect in innate antiviral immunity, analogous to the toll-like receptor 3 (TLR3) mutations seen in HSV-1 encephalitis vulnerability, severe influenza pneumonia, and VZV ophthalmicus may be related to PUUV hantavirus encephalitis risk. TLR3 recognizes dsRNA and activates antiviral immune responses by producing inflammatory cytokines and type I interferons. Exome sequencing of PUUV encephalitis patients identifies a TLR3p.L742F variant that showed reduced biological activity in functional studies of cellular immune response, potentially a factor in PUUV encephalitis predisposition (326).

Hantavirus pulmonary syndrome has been associated with single cases of ADEM and transverse myelitis (167). However, both patients received extracorporeal membrane oxygenation therapy, which carries a risk of cerebrovascular injury and complicates the interpretation of these cases. North American hantavirus pulmonary syndrome triggered a painful peripheral neuropathy in one patient (10).

Andes viruses, which are agents of HPS circulating in Argentina, Bolivia, Chile, and Uruguay, are now also implicated in encephalitic syndromes. In 2010, an Argentine patient with a febrile syndrome, respiratory distress, and shock developed, on day 13 of illness, an encephalitic syndrome characterized by headache, confusion, excitation, generalized seizure, and bilateral frontal and parieto-occipital T1 and T2 signal abnormalities on MRI, with greater cortical than underlying white matter involvement. The patient received ICU supportive care and empiric antibiotics. On follow-up eight months later, the patient was well and the MRI was normal (427).

Rift Valley fever. Human transmission is mainly by mosquito bite but can occur after contact with infected animals or infected aerosols. After inoculation of virus by Aedes mosquito bite, virus is transported by lymphatic drainage to regional lymph nodes where local replication occurs. Virus spills over into the circulation causing primary viremia and spread of virus to major organs. Reduction of antithrombin function of endothelial cells initiates intravascular coagulation and necrosis of hepatocytes and other infected cells. Release of procoagulants into the circulation, liver damage that impairs synthesis of coagulation factors, and removal of circulating activated coagulation factors contribute to disseminated intravascular coagulation. Biomarkers of overall prognosis include cytokine profiles, soluble adhesion molecules, and coagulopathy. Primary encephalitis and retinitis have been described (237; 373; 200; 06), with one patient who died of meningoencephalitis having brain pathology showing perivascular cuffing and round-cell infiltration (259). Patients with encephalitis or the CNS complications of systemic disease can have altered mental status, seizures, amnesia, abnormal movements, vertigo, ataxia, paresis, meningeal signs, visual loss (239), and MRI changes of cortical and thalamic areas of diffusion restriction (06). Encephalitic complications may be as high as 8% of infections, and retinitis in 10% in recent epidemics (295). Lower percentages, less than 0.5% of human Rift Valley fever cases, develop encephalitis 1 to 4 weeks after recovery from the acute illness (298), but sequelae after delayed encephalitis are more frequent. CSF has normal protein, glucose, and lymphocytic pleocytosis. Both direct viral and immune-mediated cell injury are implicated in this complication (333). The potential for an autoimmune pathogenesis for retinitis is supported by the report of antibodies to retinal tissue in Rift Valley fever virus-exposed individuals with retinitis (295). Active ocular lesions resolve in 10 to 12 weeks, but resulting macular and paramacular scarring, vascular occlusions, and postinfectious optic atrophy cause visual loss (175). Underlying mechanisms leading to different diseases and different outcomes are incompletely understood. Viremic load correlates with severe disease, so that significant exposures with higher inoculation rate probably link to severe disease. Encephalitis is a complication in immunosuppressed patients, and single nucleotide polymorphisms of the host (TLR3, TLR7, TLR8, MyD88, TRIF, MAVS, and RIG-I) also associate with severe symptomatology (175). Confection with HIV or malaria has been associated with severe disease that can include encephalitis. Schistosomal hepatic disease and bacterial or fungal co-infection have been found in fatal cases (175). No serum biomarkers of CNS disease in humans have been found (257).

Crimean-Congo hemorrhagic fever. Crimean-Congo hemorrhagic fever (CCHFV) is spread principally by ixodid ticks of genus Hyalomma. Crimean-Congo hemorrhagic fever is maintained in vertical and horizontal transmission cycles in iodide ticks and a variety of wild and domestic vertebrates (ie, hedgehogs, hares, ground-feeding birds, sheep cattle, and other large mammals). Man is the only species to show clinical disease. On introduction of virus by tick bite, there is local replication followed by blood and lymph-borne spread of virus to endothelium and major organs, including liver. Congestion, edema, focal hemorrhage, and necrosis of infected tissue follow (423). Disseminated intravascular coagulation then plays a role in disease progression and encephalopathy (298). Experiments with Crimean-Congo hemorrhagic fever in humanized mice have shown viral antigen in astroglia, microglia, and meninges, with virus entry to the CNS in turn facilitated by activation of astrocytes and impairment of astrocyte contribution to blood-brain barrier function (414). Cerebral edema with herniation or intracerebral, subdural, and subarachnoid hemorrhages have been reported (04; 86; 203).

One study from Turkey reported reduced susceptibility to Crimean-Congo hemorrhagic fever disease in individuals with the CCR5Δ32 heterozygous genotype, such that protection would link to CCR5 receptor down regulation (380; 111).

Ilesha virus. Ilesha virus, first isolated from a patient in Western Nigeria in 1957 (307), and isolated from Anopheles gambiae mosquitoes in the Central African Republic (100), has been associated with fatal meningoencephalitis in the Central African Republic (81) and hemorrhagic fever in Madagascar (278; 318).

Severe fever with thrombocytopenia syndrome (SFTS). Severe fever with thrombocytopenia syndrome, recognized in central and northeastern China in 2009, is caused by a novel phlebovirus isolated from febrile patients (481). The tick Haemaphysalis longicornis is the vector of severe fever with thrombocytopenia syndrome, and person-to-person spread through direct contact with contaminated blood and other body fluids has also been reported. Infection ranges from asymptomatic or self-limited to life-threatening. Encephalitis complications were reported in 19% of patients (89). Severe fever with thrombocytopenia syndrome cases have been found in China, Japan, and South Korea. Severe fever with thrombocytopenia syndrome’s closest relative is Bhanja virus, a tick borne human pathogenic phlebovirus that causes fever and meningitis. Two cases of febrile illness caused by another closely related tickborne phlebovirus (Heartland virus) were reported in the United States (264). The discovery of the emergence of this virus in China (home to one fourth of the world's population and numerous wild and domestic animals living close to humans) reiterates that country's significant potential for emergence or reemergence of infectious diseases.

Flaviviruses.

Yellow fever. Yellow fever virus is the prototype of the Flavivirus genus, transmitted by Aedes aegypti mosquitoes. After inoculation, the virus replicates in regional lymph nodes then spreads to liver, spleen, bone marrow, and cardiac and skeletal muscle. Bleeding is promoted by decreased synthesis of vitamin K-dependent coagulation factors by injured liver, disseminated intravascular coagulation, and altered platelet function (50). Neurotropic yellow fever infection of mice has been used as a model system for studies of flavivirus encephalitis.

Dengue hemorrhagic fever. Dengue is transmitted predominantly by A aegypti and occasionally by A albopictus mosquitoes. All four dengue virus serotypes cause dengue hemorrhagic fever. Dengue follows three clinical stages: acute febrile phase, critical phase, and recovery/convalescent phase. The immune response promotes dengue fever clearance and disease resolution, but also has a role in pathogenesis. In the context of dengue, “original antigenic sin” hypotheses and mechanisms have been advanced.

There are four DENV serotypes, exhibiting approximately 70% sequence homology. One hypothesis is that severe disease has an immunopathologic basis, it ascribes to antibody-dependent enhancement, and it (ADE) is of heterologous viral replication in cells of the reticuloendothelial system. This occurs in individuals previously sensitized by infection with a heterologous serotype. The first infection provides long-term or life-long immunity to the infecting serotype but only poor short-term immunity to the other three (heterotypic) serotypes. Later, with a next infection with a different serotype, antibodies from the first infection bind but do not inactivate a heterotypic virus (147).

A second hypothesis attributes DHF/DSS to a heterotypic T lymphocyte response during secondary DENV predominantly directed against the first infecting DENV serotype the secondary T cell response is thought to be suboptimal, differing from primary responses in cytokine production and cytotoxicity.

Antibody-dependent enhancement is an explanation generally accepted for dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). One pathogenesis hypothesis is that severe disease has an immunopathologic basis and antibody-dependent enhancement, and it occurs in individuals previously sensitized by infection with a heterologous serotype. The first infection provides long-term or life-long immunity to the infecting serotype but only poor short-term immunity to the other three (heterotypic) serotypes. Later, with a next infection with a different serotype, antibodies from the first infection bind but do not inactivate a heterotypic virus.

Capillary permeability shock syndrome is a multistep process attributed in part to antibody dependent enhancement (cross-reactive antibodies from the first DENV infection bind but fail to neutralize the second DENV serotype). Instead, they form virus-antibody complexes that in turn facilitate the infection of myeloid cells expressing Fc-gamma receptors (339; 117). But this observation has been difficult to fully scientifically confirm in patients because the majority of populations in dengue-endemic regions are serologically positive for all four dengue serotypes before school ages. In addition, the frequent recording of severe primary infections in travelers to endemic regions suggests additional, unidentified factors may account for the severity of re-infection with dengue heterologous serotype (267). For instance, no difference in capillary leak is detected using abdominal sonography between primary dengue (in 32% of cases) and secondary dengue (in 40% of cases) (267). Following up on earlier literature showing that 50% of sera from DHF/DSS patients have detectable endotoxin (439), investigators have suggested that the levels of lipopolysaccharide in plasma of dengue patients have a significant role in disease severity (442). Shock seen in dengue patients may partly be due to the leakage of gastric substances, likely endotoxin or commensal bacteria, into the systematic circulation. Nevertheless, whether the general concept on antibody-dependent enhancement of viral replication may worsen the outcome or not remains to be further investigated. Under the current dogma, the high level of virus replication seen during both secondary infection with a heterotypic virus and during primary DENV infection in late infancy is a direct consequence of antibody-dependent enhancement of replication. Translated to clinical care, this observation means that vaccines will need to provide long-term protection against each of the four DENV serotypes (285), and vaccine strategies for Zika virus would minimize the generation of deleterious cross-reactive antibodies to avoid ZIKV vaccines sensitizing to severe DENV infections (117).

Studies with specimens collected during visible dengue hemorrhagic fever link the hemorrhagic disturbance to microvascular injury, liver injury, platelet dysfunction, thrombocytopenia, neutropenia, and disseminated intravascular coagulation. Hemostatic defects, therefore, are the major finding in dengue hemorrhagic fever. Thrombocytopenia may be due to direct attachment of the dengue virus to platelets, infection of platelets, antiplatelet antibody-mediated platelet lysis, reduced production of platelets from megakaryocytes, and direct infection of megakaryocytes by dengue virus during the acute phase of infection. Procoagulants released from affected platelets, monocytes, or endothelial cells activated by inflammatory cytokines promote disseminated intravascular coagulation, and cross-reactive antibodies have been found between dengue E peptide and plasminogen (50). Increased levels of soluble thrombomodulin in blood (markers of vascular endothelial cell injuries and dysfunction) and levels of cytokines predict dengue hemorrhagic fever and dengue shock syndrome (51). The sources of these measurable parameters and their relation to vascular leakage are incompletely understood. However, a proposal, based on in vitro investigations, is that dengue virus-infected dendritic cells trigger vascular leakage through metalloproteinase production (235). Other work supports platelet dysfunction due to direct infection by dengue virus (302; 300) or increased nitric oxide production (75).

In addition to immune response, viral and host factors have a role in of severe dengue. The NS (non-structural protein)1 protein can interact with multiple host proteins, protects virus from neutralization, and has toxic properties that disrupt the endothelial glycocalyx. In man, genetic polymorphisms in the activating Fc gamma receptor FcyRIIA, cytokines, HLA, MHC class I chain related protein B, phospholipase C epsilon I, and genes in lipid and steroid metabolism pathways, are associated with more severe disease. Polymorphisms in genes that encode proteins linking lipid metabolism pathways with immune response, such as oxysterol binding protein-like 10 and RXRA (retinoid x receptor alpha), may underlie reduced susceptibility of people of African descent to severe dengue (461).

Dengue virus is responsible for a wide spectrum of disease: fever, arthralgia, myositis, rash, neurologic and psychiatric syndromes, hemorrhage, and shock. Neurologic involvement as encephalitis, transverse myelitis, or a lower motor neuron syndrome can occur without hemorrhagic disease, and dengue hemorrhagic fever with encephalopathic symptoms is described (190; 251; 443). Historically, dengue virus was not thought of as a neurotropic pathogen. The incidence of CNS involvement in dengue virus infection was low in past studies, ranging from 0.88% to 5.4% in past studies; however, the fatality rate was high (210).

The newest WHO guidelines for dengue diagnosis include neurologic manifestations in the clinical case classification for severe dengue (469). Wide ranges of neurologic features in clinical manifestation under the term dengue have been noted in 0.5% to 21% of patients admitted to the hospital (61). Furthermore, with the new WHO guidelines, encephalitis-like illness, ranging from 4% to 47% of admissions in dengue endemic regions, has been registered (61).

The evolution of CNS disease is thought to involve direct crossing of the blood-brain barrier by dengue virus infected cells or the virus infected cells riding with immune cells into the CNS. Dengue-infected mice showed a virus-induced, cytokine-mediated breakdown of the blood-brain barrier, providing access to the brain, perhaps by infiltration of virus-containing cells such as macrophages (74) or platelets (300). Dengue IgM antibodies or dengue RNA detected by RT-PCR are found in CSF of dengue patients with or without hemorrhagic disease, and dengue viral antigens can be demonstrated by immunohistochemistry in CNS in postmortem cases (77; 234; 269; 412; 53; 479; 272; 289; 425; 241; 211). Some patients can have virus in the CSF (as dengue viral RNA) and not in serum (105). Currently, neurologic complications in dengue-associated illness are categorized as dengue encephalopathy, encephalitis, neuromuscular complications, immune-mediated syndromes, and neuroophthalmic involvement (61). The main features of dengue maculopathy are: intraretinal hemorrhage, venular sheathing, vascular leakage, yellow subretinal dots, retinal pigment epithelium mottling, macular edema, foveolitis, disc hyperemia, and disc edema. Additional eye complications are exudative retinal detachment and optic neuropathy (369).

Of all the flaviviruses, Zika virus ZIKV is most closely related to the four serotypes of DENV and shares 54% to 59% amino acid identity of the viral E protein, a major immunodominant target for antibody responses (117). DENV-1 through -4 have 60% to 70% genetic homology (149). The similarity presents problems for diagnosis and vaccination, and has implications for disease pathogenesis due to antibody cross-reactivity.

There is experimental evidence that cross-reactivity has the potential to be either immune-protective or be associated with an aggravated form of the disease. Infection by DENV1 can confer transient protection to DENV2 in humans, and in vitro and animal studies suggest the possibility of protection against ZIKV by cross-priming by DENV1 (374). However, most of the Guillain-Barre syndrome cases associated with Zika infection in one region of Colombia had serologic evidence of prior DENV infection by IgM-capture and/or IgG capture ELISA for DENV (325), and all Guillain-Barre syndrome patients in a second area of Colombia had both ZIKV and DENV IgG antibodies (09). These results are consistent with ZIKV infection being a secondary enhancing flavivirus infection, and support the hypothesis that prior or coinfection of dengue with other agents may promote emergence of complicated cases, especially neurologic cases.

Given that the 2015 ZIKV outbreak in the Americas and the Caribbean occurred in dengue-endemic areas, the biological significance of cross-reactivity on protection, virulence, and immunopathology of DENV and ZIKV infections is critical, but there are unanswered questions. Would cross-reactive antibodies produced during prior DENV exposure worsen the severity of Zika through mechanisms like antibody-dependent enhancement, the mechanism that increases the severity of dengue after a second DENV infection? Would this process have a role in Zika congenital syndromes?

In Brazil, preexisting high antibody titers to dengue virus generally were associated with reduced risk of ZIKV infection and symptoms. However, there was one exception. The presence of DENV NS1-reactive molecules of IgG3 subclass, antibodies with a short half-life and indicating recent DENV infection, was inversely correlated with the probability of Zika infection. Therefore, very recent exposure to DENV transiently increased susceptibility to ZIKV infection. Antibodies work together to protect against infection most of the time but sometimes worsen disease (377; 458).

Overall, the literature, with in vitro measures of protection and enhancement, animal models and clinical studies, has indicated that DENV1-4 and ZIKV can reciprocally modify disease outcomes, but the interactions are asymmetric. DENV1-4 followed by ZIKV is mostly associated with cross-protection. ZIKV followed by DENV2 could cause enhanced disease (193).

Kyasanur Forest disease/Omsk hemorrhagic fever. Kyasanur Forest disease virus and Omsk hemorrhagic fever virus are other flaviviruses associated with hemorrhagic fever and neurologic syndromes. They belong to tick-borne encephalitis antigenic complex. Kyasanur Forest disease virus is endemic in several areas of Karnatka and Kerala states of India. Infection is by ixodid tick bite. The virus has been isolated from 16 species of ticks, with Haemaphysalis spingera the major vector. The virus produces systemic illness with fever, headache, myalgia, hypotension, gastrointestinal symptoms, and hemorrhages followed by an asymptomatic period of several days, then fever and signs of meningoencephalitis. In most patients, the illness is biphasic, with the second wave of symptoms at the beginning of the third week. Omsk hemorrhagic fever virus, which occurs in the western Siberian regions of Omsk, Novosibirsk, Kurgan, and Tyume, causes similar systemic and febrile illness, except for frequent sequelae of hearing loss and neuropsychiatric complaints (50). Human infections occur by direct contact with urine, feces, or blood of infected rodents: most commonly muskrat (Ondatra zibethica), water vole (Arvicola terrestris), and narrow-skulled voles (Microtus gregalis). Rodents are the primary host for Omsk hemorrhagic fever, which acquire the virus from the bite of an infected tick. Tick vectors include Dermacentor reticulatus, Dermacentor marginatus, and Ixodes persulcatus.

Alkhurma virus, a subtype of Kyasanur Forest disease, was isolated in 1994 from a patient in Saudi Arabia initially thought to have dengue hemorrhagic fever (483). Hemorrhagic and encephalitic syndromes associated with up to 25% mortality developed in sheep handlers, butchers, and meat and raw camel’s milk consumers. Infection is caused by tick bite, direct contact with infected blood, or by consumption of raw milk (72).

Tick-borne encephalitis. The tick-borne encephalitis complex consists of 17 antigenically related viruses, mainly represented by Russian spring-summer encephalitis virus (the Far Eastern variant of tick-borne encephalitis) or the milder Central European encephalitis virus. They are usually not on the viral hemorrhagic fever list, but sporadic reports of Far Eastern tick-borne encephalitis with encephalitic and hemorrhagic manifestations began appearing in the early 1990s (01). Far Eastern tick-borne encephalitis then “became,” or could be considered hemorrhagic, after further reports of tick-borne encephalitis with hemorrhagic syndrome in the Novosibirsk region Russia in 1999. The genome of hemorrhagic variants differed from all known tick-borne encephalitis and Omsk hemorrhagic fever strains. The hemorrhagic Far Eastern tick-borne encephalitis strain carried mutations in envelope protein E (a protein involved in receptor binding, virus entry, and virulence) and belonged to the Far Eastern genomic subtype. The mutations in protein E were not previously described for tick-borne encephalitis but found among other flaviviruses (yellow fever, dengue type 1,2,3, and 4, Kyasanur, and others) (431), suggesting the representation of certain mutations known previously only in other hemorrhagic flaviviruses predisposes to hemorrhagic phenotype. Ixodes persulcatus and Ixodes ricinus ticks are responsible for transmission in Russia and Europe, respectively. Other tick species, of genera Dermacentor and Haemaphysalis, have also been implicated in transmission in areas without Ixodes species ticks (50).

Togaviruses. Chikungunya, family Togaviridae, genus Alphavirus, is another arbovirus with infrequent hemorrhagic complications on the ICD-9 list of hemorrhagic arboviruses. It is endemic in India, Southeast Asia, the Philippines, and sub-Saharan Africa, where the usual presentation is fever and arthritis. In Africa, the virus is maintained in cycles similar to that of yellow fever virus, between Aedes africanus, A furcifer and wild primates, or Aedes aegypti and humans. Infrequently, a thrombocytopenic hemorrhagic version with shock occurs (138; 330). The extension and explosion of Chikungunya virus cases in Europe (Italy), which started with two cases in Ravenna Province, Italy, in July 2007 (13), is likely the result of the virus extending its host range from A aegypti to A albopictus (Asian tiger) mosquitoes due to a mutation in the viral envelope glycoprotein (E1). The mutation occurred when the virus was in circulation in India and the Indian Ocean nations during the preceding two years, as shown by studies of the outbreak in La Reunion, an island nation in the Indian Ocean, which involved one third of that island’s population. The (A226V) mutation, not present in the original 2005 to 2006 La Reunion epidemic viral isolates, increased infectivity for A albopictus mosquitoes and increased transmission efficiency to vertebrate species (438). By the close of the epidemic in La Reunion, the mutation was detected in more than 90% of viral isolates (386). Unfortunately, A albopictus is a species widely distributed in Europe and North America. The Chikungunya epidemic in the Caribbean that spilled over into the U.S. in returning travelers achieved endemic transmission through mosquitoes in Florida in 2014.

Epidemiology

	• Virus survival is dependent on an animal or insect host, the natural reservoir.
	• Viruses are geographically restricted to areas where the host species live.
	• Arenaviruses cause chronic asymptomatic infections of reservoir rodent hosts. Transmission of infection from rodent to human, an accidental host, occurs via contamination of superficial wounds by rodent urine or excreta, consumption of food contaminated by rats, or inhalation of aerosols or fomites from infected rodents.
	• Lassa fever virus is in West Africa. Junin virus, the agent of Argentine hemorrhagic fever, is in the Argentine pampas region.
	• Filoviruses remain the only causative agents of viral hemorrhagic fever for which a natural maintenance cycle has not been definitely identified. Ebolavirus have been detected in three species of fruit bats in rainforest Africa and in insectivorous bats in West Africa. Marburgvirus has been isolated from Rousettus species of fruit bats in Uganda. Wild and domestic pigs may be a hidden source for Ebola-Zaire, as virus transmission from pigs to cynomolgus macaques without direct contact has been observed.
	• Filovirus infections spread by close contact with another case through body fluid contact or direct contact with infected animals. The geographic range of known Ebola human cases has been most of the African rainforest.
	• Hantaviruses are temperate-zone viruses transmitted to people mainly through inhalation of aerosolized rodent excreta or saliva. The epidemiology of Hantavirus diseases depends on the patterns of infection in the reservoir hosts, factors that bring humans in contact with rodents, and population density.
	• “Old World” hantaviruses found mostly in Europe and Asia cause hemorrhagic fever with renal syndrome (HFRS).
	• Rift Valley fever, acquired by mosquito bite, exposure to aerosols or fomites from infected cattle or sheep, or consumption of raw milk or meat, is found in East Africa and Arabian Peninsula.
	• For Crimean-Congo Hemorrhagic Fever (CCHF), human infections are acquired by bite of infected ticks, contact with ticks during their removal, or contact with blood or tissues of infected livestock (sheep, goats, cattle, or ostriches) in Southern, Eastern Europe, Asia, and Africa.
	• Severe fever with thrombocytopenia syndrome (SFTS) virus is tick-borne virus discovered in China in 2009, causing spring and summer illnesses in several eastern Asian countries. Infection is passed from domestic animals and domesticated deer by tick bite or by person-to-person contact.
	• Dengue, a flavivirus spread through the bite of Aedes species mosquitoes Aedes aegypti and Aedes albopictus, is common in more than 100 tropical and subtropical countries. Forty percent of the world’s population live in areas at risk of dengue.

Arenaviruses. Arenaviruses cause chronic asymptomatic infections of reservoir rodent hosts. The epidemiology of arenavirus diseases depends on the patterns of infection in the reservoir hosts and on factors that bring man in contact with rodents. Lassa virus is enzootic in Mastomys natalensis, peridomestic rats found throughout West Africa. Persistently infected rats excrete virus in urine and feces. Transmission of infection from rodent to man, an accidental host, occurs via contamination of superficial wounds by rodent urine or excreta, consumption of food contaminated by rats, or inhalation of aerosols or fomites from infected rodents. For Lassa fever, human disease occurs maximally during the dry season (winter months) in West Africa through contact with rats, genus Mastomys, and mice, Hylomycus pamfi, principally through agricultural, lumbering, or diamond mining activities or by contamination of food stores. There are an estimated 100,000 to 300,000 Lassa fever cases in West Africa each year, and there are approximately 5000 deaths. Junin virus infection increases in the fall in the Argentine pampas from harvest activities that bring man in contact with the small field rodent, Calomys musculinus. Machupo virus is carried by the field rodent C callosus. Disease activity is in the Beni province of Bolivia. Guanarito is carried by another field rodent, Zygodontomys brevicauda, in Venezuela. Venezuelan hemorrhagic fever was recognized in 1989 following forestry activity and clearing of land for small farms (48). To date, the International Committee for Taxonomy of Viruses recognizes that the family Arenaviridae contains the genus Arenavirus, which includes 24 viral species (73):

• Allpahuayo (Peru)
• Amapari (Brazil)
• Bear Canyon (United States)
• Catarina (United States)
• Chapare (Bolivia)
• Cupixi (Brazil)
• Dandenong (Australia)
• Flexal (Brazil)
• Guanarito (Venezuela)
• Ippy (Central African Republic)
• Junin (Argentina)
• Kodoko (Guinea)
• Lassa (West Africa)
• Latino (Bolivia)
• LCMV (ubiquitous) including Africa (293)
• Machupo (Bolivia)
• Mobala (CAR)
• Mopeia (Mozambique, Zimbabwe)
• Morogoro (Tanzania)
• Oliveros (Argentina)
• Pampa (Argentina)
• Parana (Paraguay)
• Pichinde (Columbia)
• Pinhal (Brazil)
• Pirital (Venezuela)
• Sabia (Brazil)
• Skinner Tank (United States)
• Tonto Creek, Tacaribe (Trinidad)
• Tamiami (United States)
• Whitewater Arroyo (United States)

There are, in addition, about 10 arenaviruses that have been discovered for which taxonomic status is pending. Of these, Merino Walk virus, which was isolated from the rodent Myotomys unisulcatus in South Africa (320), Luna virus, associated with Mastomys natalensis in Zambia (172), and Morogoro with Mastomys natalensis in Tanzania (142) have not yet been associated with disease in man. The rodent host for Lujo virus in southern Africa is not known. Ocozocoautla de espinosa virus in the Tacaribe serocomplex, associated with P mexicanus deer mice, is thought to have been the cause of a hemorrhagic fever epidemic in Chiapas, Mexico, in 1967. Presently, it is the cause of illness clinically identical to dengue hemorrhagic fever and other severe febrile illnesses endemic in Chiapas state (52).

Although the arenavirus family has been thought to infect only mammals, two complete viruses and partial sequence from a related third virus have been isolated from cases of snake inclusion body disease, named for the large eosinophilic inclusions found in cytoplasm of cells, including brain, of infected animals. It is a fatal disease of captive snakes, characterized by behavioral abnormalities (abnormal body posture and movement), wasting, and secondary infections. The viruses share a typical arenavirus-like genome organization but have filovirus-like GP2 domains (417). These viruses show the arenavirus family and its hosts to be much broader than previously recognized. Identification of these highly divergent arenaviruses can be used for development of diagnostics, antivirals, multivalent vaccines, or vaccines based on development of immunity against conserved regions (38).

A conventional vaccine, a live attenuated strain against Argentine hemorrhagic fever, has been the most successful arenavirus vaccine. It is an attenuated vaccine strain Candid#1 (Cd1), derived from the pathogenic XJ strain of JUNV by serial passaging in guinea pigs, mouse brain, and cultured fetal rhesus monkey lung cells, and has an estimated efficacy of 98% (107).

Patients with arenaviral hemorrhagic fevers are thought to pose relatively limited risk of infection in the early stages of disease. As illness progresses, with more extensive infection of target organs and increasing blood virus titers, chances for dissemination increase. Person-to-person spread is uncommon except with Lassa fever virus, although nosocomial outbreaks and infection of multiple contacts, including sexual contacts, have occurred for each of the viruses. For Lassa fever, person-to-person transmission in hospitals and the community occurs by contact of mucous membranes with infected blood or body fluids. The tendency of disease to spread among contacts of acute cases suggests an aerosol mode of transmission as well. After recovery, a patient may continue to excrete virus in urine or semen for weeks. Lassa is the most frequently exported viral hemorrhagic fever. Its incubation period is 7 to 18 days (48).

Filoviruses. Filovirus disease was first recognized in Marburg in 1967 in individuals that had handled monkey blood, tissues, or cell cultures from the African green (vervet) monkeys (Cercopithecus aethiops) that came from Uganda. The first recorded human outbreaks of Ebola were in Democratic Republic of Congo and Sudan in 1976.

Despite multiple internationally-recognized outbreaks, filoviruses remain the only causative agents of viral hemorrhagic fever for which a natural maintenance cycle has not been definitely identified. Bats were suspected because of the association of index Marburg cases with caves (Marburg, Kenya 1980), a bat-infested gold mine (Marburg, Democratic Republic of Congo 1999), and Ebola with a bat-infested factory (Ebola, Sudan 1976).

Outbreaks and sporadic cases of Marburg in Africa have been in Angola, Democratic Republic of Congo, Kenya, South Africa, Uganda. The deadliest was in Angola in 2005 where 227 people died.

Extensive field studies in Uganda, Democratic Republic of Congo, Kenya, South Africa, Gabon, Zambia, and recently in Sierra Leone, have shown that the cave dwelling Egyptian rousette bat (Rousettus aegyptiacus) is a primary natural reservoir, findings consistent with the origins of MARV outbreaks being linked to caves or mines. Arthropod vectors probably do not contribute to the natural enzootic cycle. The Sierra Leone findings extend the known geographic range of the Egyptian rousette bat to West African areas containing fruit trees and caves, and overlap the forest areas in Sierra Leone and neighbors where almost 80% of vegetative cover has been lost (07).

Evidence of asymptomatic infection by Ebola virus was found in three species of fruit bat in Africa (225), and insectivorous bats are thought to have been the source for the West African Ebola epidemic (246). Which species are carriers may vary by region. Duikers and great apes may be intermediate or amplifying hosts. Wild and domestic pigs may be a hidden source for Ebola-Zaire because virus transmission from pigs to cynomolgus macaques without direct contact has been observed (455).

The geographic range of known Ebola human cases has included most of the African rain forest. Prior to the 2013 to 2016 West Africa epidemic, with 28,616 cases and 11,310 deaths recorded, there had been 2317 human clinical infections and 1671 confirmed deaths caused by Ebola-Zaire and Ebola-Sudan documented since filoviruses were first identified more than 40 years ago. One half had occurred in the eight years prior to 2013. A virulent Ebola species, Bundibugyo ebolavirus, caused the hemorrhagic fever outbreak in western Uganda in late 2007 (434). There are five species of Ebolavirus: Zaire Ebolavirus (ZEBOV), Sudan Ebolavirus, Tai Forest Ebolavirus, Bundibugyo ebolavirus, and Reston ebolavirus. Twice, Marburg virus has caused large outbreaks in Africa, including once in Angola, a country where filoviral hemorrhagic fever had never before been seen (44).

Ebola was newsworthy in January 2009 with the report of Ebola-Reston in an important livestock species, pigs, in the Philippines and detection of antibodies to Ebola-Reston in one healthy pig farmer (202). The presence of the virus on pig farms increases the odds of human exposure and infection.

Serologic and virus surveys of bats in Bangladesh completed in 2013 showed a fruit bat species (Rousettus leschenaultii) with a wide geographic range, from China to India, to have antibodies to Ebola Zaire and Reston viruses. The report establishes these bats as a potential reservoir for Ebola or Ebola-like viruses, and extends the range of filoviruses to mainland Asia (310).

In man, spread of filovirus infections is by close contact with another case through body fluid contact or direct contact with infected animals. Transmission by fomites is possible. Aerosol transmission, shown for nonhuman primate infections, may apply for humans. The incubation period is 7 to 9 days. Sexual transmission has been reported for Marburg and Ebola viruses; precautions should be taken during convalescence months (384).

It has been assumed that all known filovirus outbreaks in man have been the result of independent zoonotic transmission events, from reservoir bat species or an intermediate or amplifying host such as duikers and great apes. Now, however, two outbreaks, Guinea 2021 and DRC North Kivu Province 2021, are the result of transmission from humans infected in previous epidemics (196; 472).

West Africa’s first major Ebola outbreak began in December 2013. What was first thought to be a self-limited outbreak in a forested area of Guinea spread rapidly. By March 2014, the largest Ebola outbreak in history was erupting across Guinea, Sierra Leone, and Liberia. The severe Ebola epidemic of West Africa is thought to come from a single zoonotic transmission event to a 2-year-old boy in Meliandou, Guinea, followed by human-to-human transmission. The index case was likely infected when playing in a hollow tree housing a colony of insectivorous free-tailed bats (Mops condylurus). The report expands the range of possible Ebola virus sources (eg, fruit bats and susceptible hosts such as nonhuman primates and duikers) (309) to include insectivorous bats (246).

Ebola virus from Guinea forms a separate clade in relation to the known Ebola virus strains from the Democratic Republic of Congo and Gabon (22) and constitutes a different outbreak from the 69 cases that occurred in the Democratic Republic of Congo over the same time period of July to October 2014 (313).

As of early 2016, the total numbers of cases from the West Africa epidemic were 28,000, and more than 11,300 deaths. Besides Guinea, Liberia, and Sierra Leone, affected countries were Nigeria 20 cases, Senegal 1, Spain 1, United States 4, Mali 8, UK 1. Prior to the 2013 to 2015 Ebola epidemic in West Africa, only seven outbreaks were associated with more than 100 reported cases (313).

The usual Ebola incubation period is 3 to 8 days but can be as long as 3 weeks. Each new confirmed case pushed the end of the outbreak another six weeks into the future, twice the incubation period. The last new cases were found in Guinea and Liberia in March 2016. WHO declared the end of virus transmission in Guinea and Liberia in June 2016. West Africa's epidemic has shown more needs to be done to prioritize research in future outbreaks.

In May 2017, an Ebola outbreak was declared in the Democratic Republic of Congo in the northeast Bas-Uele province, bordering the Central African Republic and was over by July 2017. In May 2018, an Ebola outbreak, also in Democratic Republic of Congo, started in the northwest, Bikoro, Equateur Province and was over by July 2018.

For the first time, two epidemiologically and genetically distinct Ebola outbreaks emerged within weeks of one another. The Congo’s tenth Ebola epidemic since the disease was discovered in 1976 was declared on August 1, 2018 in the troubled north east of the Democratic Republic of Congo, where the affected provinces (Kivu Nord and Ituri) had never had the disease before. Despite deployment of interventions greater than any previous efforts, including vaccination of more than 90,000 people, things have not gone well. The Democratic Republic of Congo is the country with the world’s longest-running humanitarian crisis. The outbreak is occurring in areas of continued conflict among multiple armed groups at the time of troubled elections. People perceived the organized Ebola response as politicized and had little trust or willingness to cooperate in local activities. With dozens of armed civilian or rebel groups active in the northeast, security was a great concern, and health workers and facilities were repeatedly attacked (184).

As of July 2019, there were 2522 cases and 1698 deaths in the Democratic Republic of Congo (347; 348). Against the background lack of community engagement and demilitarization, Ebola spread to the border city of Goma, a city of nearly 2 million. The high-risk for regional spread from this Rwanda-border city and detection of cases in Uganda prompted the World Health Organization to declare the northeast Democratic Republic of Congo the second largest of Ebola epidemics, a “public health emergency of international concern” on July 17, 2019. The declaration brought more international coordination, technical capacity, and funding. All neighboring countries, including Uganda, Rwanda, Burundi, and South Sudan, prepared for potential outbreaks. All together, 297,699 people were vaccinated.

With a total of 3458 Ebola cases and 2266 deaths, the 2017 to 2020 Democratic Republic of Congo epidemic in the northeast was the second largest Ebola outbreak in history. On Feb 17, 2020, once there had been no new cases of Ebola in the Democratic Republic of Congo, the outbreak would be declared over after waiting two full incubation periods (42 days) after the last person tested negative a second time (343). The country had 54 days without a new case and was ready to declare the official end April 13, 2020. However, starting on April 10 there had been four new cases, resetting the counter on this viral hemorrhagic fever epidemic (344). This was the 10th Ebola outbreak in the Democratic Republic of Congo and claimed the lives of 2287.

An 11th DRC outbreak in Equateur Province took 55 lives. The 12th outbreak was declared when new cases of Ebola resurfaced in Northeast Democratic Republic of Congo on February 7, 2021 (349). The 13th outbreak began in October 2021 in North Kivu Province, the same area in which the 2018 outbreak was declared over. The first case in the second North Kivu outbreak represented a new flare-up of the 2018 to 2020 outbreak, due to persistence of virus in the community (472). The Democratic Republic of Congo’s 14th outbreak, and third in Equateur province since 2018, began in April 2022 and was declared over July 4, 2022. The index case was a student vaccinated in 2020, and genetic analysis was consistent with this being a new spillover from an animal reservoir (352). A new Ebola virus case in July 2022 in Beni (North Kivu Province), thought to be linked to human cases in the area, marked the Democratic Republic of Congo’s 15th outbreak. Genetic analysis confirmed the event as a flare up of the previous Ebola outbreaks in 2018 to 2020 in Beni (350; 351).

The Sudan Ebola species, first reported in southern Sudan in 1976, has been responsible for several outbreaks in Sudan and Uganda, the deadliest being in Uganda in 2000 with over 200 deaths. The most recent Ebola-Sudan outbreak began in Uganda in September 2022 and was over in January 2023, after 142 confirmed cases and 55 deaths (358).

In August 2021 in Guinea, for the first time in West Africa, a Marburg outbreak was declared after identifying one case in a man who lived in a remote forest area on the border with Sierra Leone. The outbreak was declared over on September 16 after no further cases were identified by laboratory testing and contact tracing, 42 days (2 incubation periods) after the safe and dignified burial of the only confirmed case (349; 355).

The following year, Marburg virus was detected for the first time in Ghana in July 2022 in a cluster of three cases in the same family with two deaths. There were no additional cases, and the outbreak was declared over on September 16, 2022 (356).

Equatorial Guinea confirmed its first-ever Marburg virus outbreak February 13, 2023, after the deaths of nine people starting in January 2023 (357).

Tanzania confirmed its first-ever outbreak of Marburg virus disease (MVD) on March 21, 2023, after five deaths and seven suspected cases in the northwestern region of the country that borders Uganda. Uganda’s last outbreak of Marburg had been in 2017 (358).

So far, there has been no evidence to indicate the Equatorial Guinea and Tanzanian outbreaks are related. The countries, on opposite sides of the continent, are thought to represent two independent animal-human spillover events.

In summary, the Democratic Republic of Congo has recorded 15 Ebola (Zaire) outbreaks since 1976. Seven of these occurred since 2018 and several have affected urban areas. Ebola-Sudan, since 1976, has been responsible for multiple outbreaks in Uganda and Sudan, most recently in 2022 to 2023 in Uganda. Marburg virus, the founding member of the filovirus family in 1967, was reported for the first time in Guinea in 2021, Ghana in 2022, Equatorial Guinea in 2023, and in Tanzania in 2023. These findings are consistent with Marburg being present in bats over a wider geographic range than previously thought. Marburg should be included in diagnostic tests of hemorrhagic diseases endemic in West Africa.

A novel ebolavirus species discovery was reported in the July 27, 2018 ProMed post (346). The new virus, called Bombali virus, was found in insectivorous bats in Sierra Leone. It is not the virus that caused the 2013 to 2016 West African epidemic, which belongs to the species Ebolavirus Zaire. Whether Bombali virus has infected anyone or is pathogenic for man is not known.

Bunyaviruses. Hantaviruses are temperate-zone viruses transmitted to people mainly through inhalation of aerosolized rodent excreta or saliva. The epidemiology of Hantavirus diseases depends on the patterns of infection in the reservoir hosts, factors that bring man in contact with rodents, and population density. Hemorrhagic fever with renal syndrome is a group of clinically similar rodent-borne infections: Hantaan, Dobrava, Seoul, Saaremaa, and Puumala; characterized by the clinical triad of acute renal failure, fever, and hemorrhage (33).

Hantaan virus is found in parts of eastern China, Korea, and Far Eastern Russia and is present in Apodemus agrarius mantchuricus, a mouse common in agriculture fields. Hemorrhagic fever with renal syndrome cases are more common in fall, reflecting abundance of infected mice in fall, contact with mice during crop harvests, and movements of rodents into houses with winter. Seoul virus is associated with Rattus norvegicus and R rattus and is worldwide in distribution. Dobrava virus is found in Apodemus flavicollis and A agrarius in the Balkans, and the Far East. Puumala virus is associated with the bank vole, Clethrionomys glareolus, in Scandinavia. The incubation period is 7 to 21 days (298). Studies in Hungary show that Puumala, Dobrava, and Saaremaa, all pathogenic hantaviruses, co-circulate in the same geographic area and can be maintained side-by-side in different rodent species (335). Historically, hantaviruses were considered to be associated with specific rodent reservoir hosts due to a long coevolutionary history. However, the discovery of new hantaviruses in nonrodent mammalian hosts, including shrews, moles, and bats (456; 144), now challenges the idea of specific viruses associated with very specific rodent species (372). The addition of viruses of the hantavirus genus to the long list of bat-borne viruses, further supports bats as primordial reservoirs for the majority of viruses pathogenic for man. People infected with the North American strain of hantavirus pulmonary syndrome are not contagious to others. However, some outbreaks in South America have shown evidence of person to person transmission.

Rift Valley fever. The geographic distribution of Rift Valley fever is Africa and the Arabian Peninsula. In endemic areas, there is vertical infection of virus in floodwater by Aedes mosquitoes. In epidemics, there is horizontal transmission by many different mosquito species between domestic animals. Viremic livestock are amplifying hosts. Live cattle movement between East Africa and the Arabian peninsula introduced Rift Valley fever to the Arabian peninsula in 2000. Man acquires infection by mosquito bite, exposure to aerosols or fomites from infected cattle or sheep, or consumption of raw milk or meat. The incubation period is 2 to 6 days. Hemorrhagic fever cases in humans are usually seen 1 to 2 weeks after the appearance of abortions and disease in livestock. Laboratory infections occur because Rift Valley fever is highly infectious by aerosol (298). Rift Valley fever has been isolated or has been shown to infect mosquitoes of mainly Aedes and Culex, but also Anopheles, Coquillitidea, Eretmapoites, Mansonia, and Ochlerotatus genera, as well as sand flies. Wide distribution of the virus is explained by the large number and diversity of potential vectors. Over 40 species of mosquitoes are competent vectors; therefore, mosquitoes in North America and Europe could be competent vectors (263). Outbreaks of RVF in Africa have been linked to human development activities involving water: the flooding of the Aswan dam in Egypt in 1971 and the building of the Diama dam in Senegal and Mauritania in 1987 (Chevalier et 2004).

Crimean-Congo hemorrhagic fever. Crimean-Congo hemorrhagic fever occurs in roughly 30 countries and has the most extensive geographic range among the tick-borne viruses that affect human health. The overall global distribution of Crimean-Congo hemorrhagic fever: Africa, Middle East, the Balkans, southern former Soviet Union, and western China, corresponds most closely with the distribution of Hyalomma ticks, although members of the genera Dermacentor and Rhipicephalus may also become infected, pass the virus through the various stages of the life cycle, from larva to nymph to adult, and transmit. Human infections are acquired by bite from infected ticks, contact with ticks during their removal, or contact with blood or tissues of infected livestock (sheep, goats, cattle, or ostriches). The incubation period length depends on mode of acquisition of virus. Following tick bite infection, the incubation period is 1 to 3 days, with a maximum of nine days. There have been several nosocomial outbreaks (298).

As in Rift Valley fever, human development activities and livestock movements have been implicated in Crimean-Congo hemorrhagic fever outbreaks and introductions to new areas. Regulation of the Volga River to develop new agricultural areas lead to an explosion of the tick population and the first appearance of Crimean-Congo hemorrhagic fever in Astrakhan in 1953 (79).

In Crimean-Congo hemorrhagic fever endemic areas, the Moslem holy feast celebration of Eid-Al-Adha is a particularly vulnerable period for outbreaks due to increased animal movement and exposure. Crimean-Congo hemorrhagic fever is more prevalent in summer. Starting in 2015, and for the next 10 to 15 years, the annual religious festival Eid-Al-Adha, when millions of farm animals (goats, cows, sheep, and camels) are killed, would be celebrated in summer months. The dates in the Islamic Calendar for Eid-Al-Adha drift 10 days earlier each year. Because the summer season potentially increased the risk of more human cases due to increased movements of animals, careless practices of animal slaughter, and inadequate knowledge of the disease beginning in 2015 recommended practices for animal care personnel and abattoir staff were published and training programs were put into action (217; 340).

Erve virus. Erve virus, a European Nairovirus distantly related to other Nairoviruses such as Crimean-Congo hemorrhagic fever virus, has been associated with severe “thunderclap” headaches without evidence of subarachnoid hemorrhage (436) and has been suspected in intracerebral hemorrhage in other cases. Named for the Erve Valley in northwest France, Erve virus is found in France, Germany, the Netherlands, and Czech Republic. Rodents, insectivores, wild boars, red deer, sheep, and seabirds are seropositive, and the mode of transmission to humans, whether ticks, mosquitoes, or sandflies, is unknown (436; 101).

Severe fever with thrombocytopenia syndrome virus. Severe fever with thrombocytopenia syndrome virus is a novel phlebovirus found in China in 2009, and then subsequently in Japan, South Korea, Taiwan, and Vietnam; it causes illness with symptoms of fever, thrombocytopenia, leukopenia, GI, muscle, neurologic symptoms, encephalitis, encephalopathy, coagulopathy, and hemophagocytosis. The virus is found in farm animals and domesticated deer and is spread by long-horned tick Haemaphysalis longicornis. There have been several nosocomial outbreaks. The indigenous Asian tick vector of severe fever with thrombocytopenia syndrome (bunya) virus was found in the United States in 2017 (28).

Flaviviruses.

Dengue. Dengue virus infections are one of the most common mosquito-borne viral diseases of humans worldwide. Initially, dengue infections were primarily recorded when they occurred as epidemics in tropical and subtropical countries. But over time, increasing globalization, rapid human movement, and unplanned urbanization coupled by the increase in the geographic area that Aedes species mosquito vectors Aedes aegypti and Aedes albopictus inhabit have supported the spread of dengue virus infection to nearly every corner of the world. The increase in and disposal of nonbiodegradable containers had an important role. By WHO estimates published in 1997, four of every 10 people in the world are at risk for dengue virus infection (467). Undoubtedly, that number is larger now. Approximately 100 million people contract dengue fever annually, and about 200,000 to 500,000 contract dengue hemorrhagic fever. The mortality rate is about 5%, predominantly in children under 15 years of age (148; 302). Today, dengue is the leading cause of fever in returning travelers, having surpassed malaria for visitors to Southeast Asia. One in six tourists returning from the tropics is estimated to be infected with dengue, and a dengue fever outbreak in the Portuguese archipelago of Madeira spread cases to several other European countries in late 2012.

Since 2001, autochthonous dengue fever outbreaks have occurred in the continental United States and Hawaii: Hawaii (2001, 2005); Brownsville, Texas (2005); South Texas (2013); South Florida (Key West 2009 to 2011, Martin County 2013, Florida Keys 2020) (Centers for Disease Control and Prevention 2020). Twenty-six dengue cases were acquired in Key West, Florida in 2009 and 63 cases in 2010. Transmission was confirmed by detection of DENV-1 in local mosquitoes and Aedes aegypti mosquito pools (136; 03; 367). According to the statistics for the year 2012, there had been 3937 locally acquired dengue fever cases in the United States (4 in Florida and 3933 in Puerto Rico). Finding DENV-4 circulation in Aedes aegypti mosquitoes collected in Manatee County, Florida in 2016 and 2017 was significant for showing not only prolonged maintenance within a local mosquito population in the continental United States, but also that continued vector infection was occurring in the absence of a human index case in the region (43). Silent circulation is attributed to low but persistent vertical transmission in mosquito populations (85).

Blood donors with asymptomatic DENV infections are a potential source of virus spread by transfusion (Thomashek and Margolis 2011; 99).

A surprising outbreak of dengue in Tokyo in 2014 raised concerns for a potential outbreak during the 2020 summer Olympics and Paralympics in Tokyo, and led to development of a preparedness plan for dengue detection. Key features were the national infectious disease control system to detect dengue, training or certification program for physicians on tropical disease management, strengthening multilanguage communications methods, consideration for a tropical disease training program for accommodation staff, along with a contingency plan for infectious disease-suspected travelers (477).

Yellow fever. This is a zoonotic disease maintained by mosquito-monkey-mosquito transmission with occasional human infection when unvaccinated humans enter the forest. Alternatively, in urban epidemics, there is interhuman transmission by the domestic mosquito, A aegypti. Yellow fever occurs throughout much of tropical South America and sub-Saharan Africa. There are about 200,000 cases per year (50).

Kyasanur Forest disease. First described in 1957 in the state of Mysore, India, (renamed Karnataka in 1973), Kyasanur Forest disease is now also found in China (266; 453). The virus cycles between ixodid ticks and wild vertebrates, mainly rodents and insectivores. Monkey deaths may signal increased virus activity. Most human infections occur from tick bites (50).

Omsk hemorrhagic fever. This hemorrhagic fever occurs in western Siberia. Its poorly understood cycle involves ticks, water voles, muskrats, and possibly water-borne transmission. Muskrats are epizootic hosts and human infections occur by direct contact with urine, feces, or blood (50).

Alkhurma virus. Alkhurma virus, endemic in the Arabian Peninsula, may have arisen from the introduction of Kyasanur Forest disease virus from India to Saudi Arabia (103). Sheep, goats, and camels are epizootic hosts. Like other tick-borne flaviviruses, it also infects humans via direct contact with infected blood or by consumption of raw milk. Alkhurma hemorrhagic fever virus (AHFV) infections in man, including syndromes of rhabdomyolysis and muscle weakness in European patients returning from Egypt, confirms the presence of AHFV in Egypt and supports the position that the current endemic area is extending in Africa via the animal trade (59; 371).

Chikungunya virus (Alphavirus, family Togaviridae). Chikungunya fever was first recognized in East African epidemics in 1952 and 1953. Since 2006, the disease has shown explosive emergence in nations of the Indian Ocean area, which then spread to India, China, and Europe.

Since 2012, Chikungunya virus also has been spreading to Pacific Island nations. Epidemics are sustained by human-mosquito-human transmission, with mosquitoes of Aedes species. In 2014, there were more than 600,000 cases in the Caribbean and 1471 cases in the United States. Not all were related to travel, signifying that mosquito transmission is taking place in Florida, where, like dengue, Chikungunya is likely to become endemic (451). Chikungunya virus’s outbreak history has illustrated long-distance movement of this virus by viremic individuals, with introductions of virus into areas where vector mosquitoes are abundant enough to allow continued transmission.

Aedes aegypti and Aedes albopictus are the main vectors of CHIK, Zika, and dengue.

Satellite imagery and weather map predictions, confirmed by entomological and epidemiologic field investigations, is the multidisciplinary way forward to disease prediction and design of risk reduction strategies for all viral hemorrhagic fevers. Already, analysis of eco-epidemiology data sets from remote sensing-derived land cover maps has been shown to reliably connect land management practices and landscape fragmentation with mosquito-borne illnesses (416), zoonotic disease exposure for Ebola (311), and Lassa fever (232).

Prevention

	• Prevention is to minimize exposure to the virus and use vaccines.
	• Prevent nosocomial outbreaks with barrier precautions, sterile instruments, and needles.
	• Prevention of rodent-borne arenaviruses and hantaviruses is preventing contact with rodents and their excreta.
	• Prevention of filoviruses is avoidance of contact with suspect species of fruit and insectivorous bats, or sick or dead monkeys.
	• Prevention of tick-borne viruses CCHF and SFTS is barrier clothing and treatment of clothing with pyrethroid preparations that repel or kill ticks.
	• Immunization of livestock prevents Rift Valley fever epizootics and human cases.
	• Prevention of dengue depends on reducing A aegypti mosquito contact, eradicating breeding sites, and spraying.
	• Vaccines for dengue, Ebola, and AHF support public health preparedness and response. Dengvaxia is FDA-approved, and QDENGA has European Commission Marketing Authorization. Ervebo Ebola vaccine rVSV-ZEBOV (Merck) is FDA-approved. Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo) Ebola vaccine (Janssen Pharmaceuticals of Johnson and Johnson) has European Commission Marketing Authorization. Ad5-EBOV (CanSinoBIO) is licensed in China. Candid #1 for Argentine hemorrhagic fever, with activity against Machupo virus (Bolivian hemorrhagic fever), is a live attenuated vaccine manufactured, registered and available in Argentina since 1991.
	• Formalin Inactivated bunyavirus vaccines for Hantavirus (Hantavax), Crimean-Congo hemorrhagic fever, and Rift Valley fever are used in at-risk groups and laboratory and field workers.

The best prevention is to minimize exposure to the virus. Prevention of rodent-borne arenaviruses and hantaviruses consists of preventing contact with rodents and their excreta. Effective measures include rodent proofing of homes, correct storage of food, disinfection, and removal of trapped rodents and rodent droppings. For filoviruses, contact with suspect species of fruit and insectivorous bats or with sick or dead monkeys should be avoided. Treatment of clothing with pyrethroid preparations that repel or kill ticks and tucking in pant legs are recommended for those likely to come in contact with Crimean-Congo hemorrhagic fever-infected ticks, including individuals with occupational exposure to livestock. Immunization of livestock is the most effective way to prevent Rift Valley fever epizootics and human cases. Yellow fever is prevented by yellow fever 17D, a live viral vaccine that confers immunity within 10 days. Areas containing the domestic form of A aegypti, at risk for introduction and urbanization of yellow fever, are water-treated and sprayed. Prevention of dengue epidemics depends on reduction or eradication of A aegypti by breeding site elimination, use of larvicides, and spraying of insecticides. However, resistance to widely used insecticides (pyrethroids, organophosphates, organochlorines) are developing in mosquito populations. When insecticide-treated bed nets are less effective, application of antiviral drugs to bed nets to inhibit viral infection of the vector may help (106). The next-generation tools to vector-control of mosquito-borne viral diseases include gene-drive-based mosquito population control and release of mosquitoes infected by the symbiotic bacterium Wolbachia to make mosquito populations refractory to viral infection (57).

Dengue vaccines or antiviral drugs are under development. There have been six vaccines for dengue at various clinical trial and approval stages (401). The first to be licensed was Sanofi’s ChimeriVax, a tetravalent vaccine composed of four recombinant, live attenuated viruses (yellow fever 17D/DEN chimeric viruses). It completed phase III trials in highly endemic Latin American (449) and Asian countries (56), including roughly 30,000 children aged 2 to 16 years, and the vaccine was licensed in several endemic countries for those aged 9 years and above in 2015. Specific issues with the Sanofi vaccine were serotype-dependent efficacy in early clinical trials (159; 381), but the vaccine had higher efficacy in individuals with prior dengue infections and higher efficacy with increased age (463). Sanofi Pasteur’s licensing request was for CYD-TDV (Dengvaxia) in the nine years and older age group (463). WHO originally recommended that countries consider vaccination against dengue with CYT-TDV in geographic locations where prior infection with any serotype was greater than 70% in the target age group, and it was not recommended where seroprevalence was less than 50% (171). CYD-TDV was licensed first in Mexico for individuals 9 to 45 years of age living in endemic areas to be given as a 3-dose series six months apart. Given the benefit of CYD-TDV to dengue-primed individuals, ie, vaccination against all four serotypes, now Dengvaxia is licensed in 20 dengue-endemic countries of Asia, Latin America, and Australia in persons aged 9 to 45 years.

Long-term safety follow-up has shown that the vaccine performs differently in seropositive versus seronegative individuals, with lower efficacy in seronegative individuals and increased risk to this group of hospitalization and severe dengue starting 30 months after the first vaccine dose. Dengvaxia presumably mimics an initial natural exposure in dengue-naive recipients, such that subsequent natural infection could cause severe disease by antibody-dependent enhancement. Therefore, SAGE (Strategic Advisory Group of Experts on Immunization) for WHO has stated a preference for “pre-vaccination screening strategy,” resulting in only dengue-seropositive persons being vaccinated. Currently, consideration of this strategy would be at the country level, taking into account sensitivity and specificity of available tests, local dengue epidemiology, and cost (471).

The development of dengue vaccines was delayed by the possible or theoretical risk of vaccine-related adverse events, such as immune enhancement of infection and the requirement to induce long-term protective immunity against all four dengue serotypes simultaneously. The overall efficacy of the tetravalent dengue vaccine in clinical trial did not quite live up to expectation (381), suggesting that alternative approaches toward dengue vaccine development would be needed.

The Sanofi Pasteur (CYD-TDV) (Dengvaxia) vaccine has not presented a straightforward solution and failed to meet the needs of a dengue-naive population. Estimations of vaccine efficacy varied by previous seropositivity to dengue, infecting serotype, clinical severity, and age. There was higher efficacy in trial participants aged 9 to 16 years than in those aged 2 to 8 years. A 3-dose schedule is required, but good neutralizing antibody concentrations alone may not be protective. Therefore, the results of the performance of second-generation dengue vaccines, based on live attenuated vaccines with nonstructural proteins of the dengue virus backbone partially present, or DNA, subunit, virus-like particles, and viral vector technologies, have been eagerly anticipated (462).

The European Commission approved marketing authorization of dengue vaccine QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals 4 years of age and older in the European Union in December 2022. QDENGA also received approval in Indonesia in the fall of 2022 and in Brazil in early 2023. Data from a three-year safety and efficacy study showed the vaccine could induce immune responses to a varied degree against all four dengue serotypes. Compared to Dengvaxia, Takeda’s vaccine had wider protection for young children and people over 45 across eight endemic dengue countries (376).

TAK-003 is Takeda’s live attenuated chimeric tetravalent dengue vaccine and differs from CYD-TDV in type of backbone and extent of chimerization. Designed to induce both humoral and cellular immunity, it differs from CYD-TDV in being based entirely on DENV genome, using an attenuated DENV-2 strain plus three chimeric viruses (containing premembrane and E genes of DENV-1,3, and 4) cloned into an attenuated DENV-2 backbone, rather than yellow fever. The DENV-2 backbone would generate T-cell mediated responses to dengue infection, in addition to humoral responses to the premembrane and DENV proteins.

DENV-4 had shown serodominance in the Sanofi-Pasteur trials, so there was concern for serotype-dependent efficacy in TK-003 (460). NS1 proteins from different serotypes differ in their amino acid sequences such that serotype immune dominance of DENV-2 might hinder the immune response to other serotypes. That problem seems to have been overcome, based on the clinical trials.

A remaining problem is that the leading DENV vaccines were developed before the wide-spread introduction of Zika virus in dengue areas. The performance of DENV vaccines in the context of Zika immunity needs further evaluation.

TV003/TV005 (developed at NIH NIAID) has three full length dengue viruses: DENV 1,3, and 4, attenuated by deletions in the 3’ untranslated region, and DENV-2/DENV-4 chimera containing DENV 2 PM and E coding regions. TV005, a formulation of the same components as TV003 but having a higher dose of DENV-2/DENV-4 chimera, generated a balanced, robust response to all four serotypes. TV003/TV005 has been licensed to Instituto Butantan (Brazil), Indian, and Vietnamese groups, for ongoing efficacy evaluation (188; 462).

Vaccines eliciting immune response have been proven to be one of the most successful medical interventions against viral infections. However, as shown above, dengue has presented difficulties. The morphology of the dengue virus obtained in tissue culture significantly differs from that of in vivo virus. Serum or plasma from patients during secondary infection show high levels of antibody-dependent enhancement (ADE), but no neutralizing activity, with culture-adapted virus strains; however, serum or plasma from the same patient have high levels of neutralization activity but are without ADE with autologous virus directly from patient plasma. Thus, antibody-dependent enhancement effect is with virus derived from culture-adapted virus strains (70). In addition, neutralizing antibody titers obtained with culture-adapted virus do not correlate with the protective effects in vivo (403).

This evidence clearly demonstrates the uniqueness of viral morphology in vivo. As such, considering the multiple serotypes of dengue virus, one of the strategies to develop vaccines that can minimize the potential adverse effects is to have an antibody with broad-spectrum neutralizing capacity. However, understanding the molecular bases of immune recognition is one of the big challenges in vaccine development. The observation that whole protein antigens are not necessarily essential for inducing immunity has led to the emergence of a new branch of vaccine design termed structural vaccinology. One of the goals of structural vaccinology is to enable the design and engineering of improved antigens, suggesting that elucidation of the three-dimensional (3D) structure of antigens and antigen-antibody complexes is central to structural vaccinology. If the 3D structure of the antigen alone is available, it is possible to use its atomic coordinates for the prediction of immunogenic regions, which can then be used for generating optimizing antigens in the form of synthetic peptide epitopes. As a result, resolving the 3D viral morphology of in vivo dengue viral morphology is urgently needed in order to obtain a viral epitope that can have properties responsible for the ability of antigens to elicit functional or protective antibodies, which can have broad neutralizing ability and would be an ideal dengue vaccine candidate. Whether other dengue vaccine candidates in the pipeline (inactivated, live attenuated, chimeric recombinant, subunit DNA) will have higher efficacy than CYD-TDV remains to be seen. So far, CYD-TDV is the only dengue vaccine with WHO license and approval available internationally. Its moderate efficacy supports the strategy of integrating vaccination with improved vector control, which would have added value in helping contain other Aedes-transmitted diseases: CHIK, Zika, yellow fever (463).

In summary, Dengvaxia has been endorsed by the European Medicine Agency and the US Food and Drug Administration. Because of excessive risk of severe dengue in seronegative vaccinees, use is restricted to seropositive individuals. The FDA has approved use in people 9 to 16 years of age who have laboratory-confirmed previous dengue infection and live in endemic areas; youth are at greatest risk for severe symptoms from a second infection of another serotype. Endemic areas include United State territories of American Samoa, Guam, Puerto Rico, and United States Virgin Islands. Dengvaxia is not an ideal travel vaccine due to the absence of a validated rapid diagnostic test to screen dengue serostatus and the 3-dose regimen required for protection (461). Correlates of risk or protective immunity, or neutralizing antibodies or cell-mediated immune responses, have not been established, but the Dengvaxia trials offer possibilities for retrospective analysis to determine correlates of protection. The newly approved two dose QDENGA, which is beneficial regardless of dengue serostatus and can be administered without prevaccination screening, will be advantageous to a broader population (376).

For Ebola, rVSV-ZEBOV vaccine has been licensed and used in emergency situations. Ad26.ZEBOV, MVA-BN-Filo (Modified Vaccinia Ankara), first available under investigational protocols, has EU marketing approval. Both are discussed in the Management section.

To prevent nosocomial outbreaks, patients should be nursed in a hospital with barrier precautions where sterile instruments and equipment for injections are provided.

For high-risk exposure to an agent sensitive to ribavirin, ribavirin has been recommended prophylactically or as expectant treatment at the first sign of fever. Close personal contacts should be monitored for fever for a period of three weeks.

South American arenaviruses, in contrast to Lassa fever virus, produce high-titer neutralizing antibodies and passive serum therapy has been effective. Candid #1, a live attenuated vaccine against Junin virus licensed in Argentina for adults greater than 15 years of age, also protects nonhuman primates against Machupo virus (Bolivian hemorrhagic fever) (197).

Several different inactivated virus vaccines for Hantaan and Seoul viruses have been used in Asia. A Crimean-Congo hemorrhagic fever formalin-inactivated vaccine has been developed in Eastern Europe. Formalin-inactivated Rift Valley fever vaccines have been used for immunization of laboratory and field workers at risk for exposure. The formalin inactivated vaccine, the Salk Institute-Government Services Division (TSI-GSD) 200, developed by the US Army, has been used to vaccinate lab workers through its Special Immunization Program (263). Currently, there is no commercially available FDA-approved RVFV human vaccine. The formalin-inactivated (TSI-GSD) 200 vaccine, live attenuated vaccines MP-12, rMP-12 variants, DDvax, RVFV-4s, and adenovirus vector ChAdOx1-GnGc are under investigation (170). Environmental safety profiles, such as the relative safety of vaccine candidates in the context of mosquito transmissibility, are considered for new vaccines (54). For now, preventing RVFV infection of livestock by vaccination is a key to breaking the links to human epidemics. No specific Omsk hemorrhagic fever vaccine has been made, but tick-borne encephalitis vaccines can provide cross-protective immunity and have been used in high-risk population groups. Knowledge of the geographic range of the diseases, identification of high-risk groups, and proof that candidate vaccines are protective in animal models will all be important should large-scale immunization programs be developed in the future. Integrated approaches to the prevention of zoonotic diseases with products developed for use in animals and humans will also be important in the future.

The multiagency Coalition for Epidemic Preparedness Innovations (CEPI) reviewed the vaccine-development response to the 2014 Ebola epidemic in West Africa and produced a list of agents to be made priorities for their funding of vaccine development. The list of diseases that should be urgently addressed under the WHO Research and Development blueprint included several viral hemorrhagic fevers: filoviruses (Ebola and Marburg), CCHF virus, Lassa fever virus, and Rift Valley fever virus. The category of serious diseases necessitating further action as soon as possible included severe fever with thrombocytopenia syndrome, Chikungunya, and congenital abnormalities and other neurologic conditions associated with Zika virus (379). This action raised hopes that safer vaccines for more agents might be expedited and become available soon.

For Lassa fever, there are currently no licensed vaccines. Candidates most likely to progress to clinical trials and licensure are MOPV/LASV (Mopeia V/Lassa V) reassortment clone 29 and five vaccines endorsed by the Coalition for Epidemic Preparedness Innovations (CEPI) for accelerated development. The portfolio contains:

	• VesiculoVax vectored LASV- VSV platform expressing LASV GPC (Emergent Biosolutions and PATH)
	• INO-4500: a DNA vaccine encoding LASV Josiah strain GPC gene (pLASV-GPC) (Inovio Pharmaceuticals)
	• Recombinant Vesicular Stomatitis Virus rVSV platform expressing LASV GPC (Josiah strain) (International AIDS Vaccine Initiative [IAVI])
	• Live-attenuated Schwarz strain measles virus vector expressing LASV GPC and NP (Themis Bioscience and Institute Pasteur)
	• Chimpanzee adenovirus vector ChAdOx1 expressing Josiah strain LASV GPC (ChAdOx1-Lassa-GP) (Janssen Vaccines, University of Oxford, and CureVac)
Adapted from (363).

Concern for transfusion transmission of flaviviruses and alphaviruses, particularly Chikungunya virus, has been raised because of high population incidence of infection during outbreaks and high-titer viremia lasting about six days. Estimated transfusion risks may be as high as 150 per 10,000 donations during outbreaks, leading to recommendations to defer symptomatic carriers, discontinue donations in impacted areas, and screen blood for Chikungunya virus (334).

Inactivated vaccines are generally thought safe for multiple sclerosis patients, but live attenuated vaccines such as YF17D were reported to provoke multiple sclerosis relapses (114; 231).

Differential diagnosis

Associated or underlying disorders

Early disease. Early signs of disease, such as high fever, prostration, flushing, conjunctival injection, postural hypotension, myalgias, abdominal discomfort, and axillary petechiae, are shared by a wide spectrum of infectious, inflammatory, or autoimmune diseases. At this juncture, major treatable diseases such as malaria, rickettsial diseases, leptospirosis, shigellosis, typhoid, and N meningitides meningitis or meningococcemia should be excluded by specific serologic, microbiology, and CSF studies, and diseases with significant public health consequences, such as reemergent measles, considered. Lab chemistries and hematologic studies would not specify the diagnosis. Rickettsial diseases cause thrombocytopenia and leukopenia. Leptospirosis causes meningitis, myalgia, hepatic or renal disease, thrombocytopenia, and leukopenia.

Next, the differential diagnosis is expanded to include diseases prevalent in the region, such as measles, hepatitis, systemic lupus erythematosus, hemolytic-uremic syndrome, or trypanosomiasis. Both African and American trypanosomiasis are associated with thrombocytopenia and mechanisms of disease may be immune-mediated or associated with splenic sequestration (92; 244). The presentation of encephalitis in Asia can be dengue fever, dengue hemorrhagic fever, Japanese encephalitis, or Nipah encephalitis. A positive tourniquet test has been one of several clinical parameters considered by the World Health Organization to be important in the diagnosis of dengue hemorrhagic fever, but is now less frequently used. It may be useful in diagnosing dengue infection in busy rural health stations in dengue-endemic areas. A positive test should prompt close observation or early hospital referral (55). Encephalitic agents of the California serogroup (Orthobunyavirus, Bunyaviridae) are in the differential diagnosis of early febrile illness in regions of overlap with viral hemorrhagic fevers. For example, Inkoo and Chatanga viruses and mosquito-borne California serogroup viruses are in the differential diagnosis of Puumala virus infections in Finland (364). Acute febrile illness and encephalitis may be Zika, Chikungunya, or dengue in central and South America, with low platelets a feature of dengue. Rash and pruritis are more common in Zika, arthralgias, and joint edema in CHIK.

Advanced disease. The development of a severe multisystem syndrome in which the overall vascular system is damaged, autoregulatory mechanisms are damaged, and there is bleeding signifies advanced disease. Signs and symptoms of advanced viral hemorrhagic fevers may be respiratory (chest pain, shortness of breath), vascular (hypotension, edema), gastrointestinal (vomiting, diarrhea), or neurologic (headache, confusion, coma), and there is frank bleeding (rash, ecchymoses, uncontrolled oozing from venipuncture sites, mucosal hemorrhages). Hematuria can signify malaria (as blackwater fever), yellow fever, Ebola, CCHF, Rift Valley fever virus, leptospirosis, or septicemia with disseminated intravascular coagulation.

Late disease is multiorgan failure and coagulopathy, indicated by shock, convulsions, severe metabolic disturbances, renal failure, and coagulation dysfunction. There is generally laboratory evidence of abnormal platelet function and there may be abnormal liver function tests.

The differential diagnosis of advanced disease includes hematologic disorders associated with fever, infectious, and parainfectious syndromes. Thrombotic thrombocytopenic purpura is precipitated by endothelial injury and is characterized by hemolytic anemia with fragmentation of erythrocytes and signs of intravascular hemolysis, thrombocytopenia, diffuse and nonfocal neurologic findings, decreased renal function, and fever. In thrombotic thrombocytopenic purpura there are hyaline thrombi in arterioles, capillaries, and venules without inflammatory changes in the vessel wall and minimal activation of the coagulation system. Pregnancy, certain drugs, and HIV infection are causes of thrombotic thrombocytopenic purpura.

Immunologic thrombocytopenia occurs when platelets coated with antibody, immune complexes, or complements are rapidly cleared from the circulation. The most common causes are viral or bacterial infections, drugs, or an autoimmune disorder (idiopathic thrombocytopenia purpura). Transient immunologic thrombocytopenia complicates some cases of infectious mononucleosis, acute toxoplasmosis, cytomegalovirus, viral hepatitis, viral exanthems, and initial infection with HIV.

Acute febrile illness with thrombocytopenia and leukopenia has been reported in tick-borne encephalitis, human granulocytic anaplasmosis, rickettsiosis, leptospirosis, and primary HHV-6 infection in infants. In HHV-6, thrombocytopenia is the result of bone marrow suppression rather than immune-mediated peripheral consumption (18).

Disseminated intravascular coagulation occurs in critically ill patients when blood starts to coagulate throughout the body, depleting platelets and coagulation factors. Laboratory markers for disseminated intravascular coagulation are low-platelet counts, prolonged prothrombin time, decreased fibrinogen level, and increased fibrin markers (D-dimers: cross-linked fibrin degradation product and fibrin split products), with fibrin(ogen) derivatives generally correlating with degree of blood coagulation disturbance (65). Laboratory evidence of disseminated intravascular coagulation can accompany Korean, Rift Valley, and dengue hemorrhagic fevers, but apparently not Argentine hemorrhagic fever. Microscopic evidence of disseminated intravascular coagulation or vasculitis is absent from the arenaviruses. In Korean hemorrhagic fever, Rift Valley fever, and dengue hemorrhagic fever, release of tissue factor from cells in which viruses replicate and increased levels of TNF alpha have been suggested as mechanisms for initiation of the tissue factor pathway (389).

Common viral infections, such as influenza, varicella, rubella, and rubeola, have rarely been associated with disseminated intravascular coagulation. Purpura fulminans associated with disseminated intravascular coagulation has been reported in patients with infections and either hereditary thrombophilias or acquired antibodies to protein S. Other extreme examples of sepsis-related disseminated intravascular coagulation are streptococcus A toxic shock syndrome, meningococcemia, Staphylococcus aureus, and Streptococcus pneumoniae infection. Shock not correlated with significant adrenal hemorrhage or necrosis distinguishes the shock-like state of hemorrhagic fever with renal syndrome from the Waterhouse-Friderichsen syndrome (adrenal apoplexy and hemorrhage) (389). A hemorrhagic shock and encephalopathy syndrome has been associated with severe influenza infections in Japan (426) and Europe (134).

Hemophagocytotic lymphohistiocytosis (HLH) is a systemic hyperinflammatory syndrome with high fever, hepatosplenomegaly, cytopenia, hemoferritinemia, increased hemophagocytic macrophage proliferation, and activation in the reticuloendothelial system, mostly seen in infants and children. There is a primary (heritable) form and a secondary hemophagocytotic lymphohistiocytosis associated with cancers, infections, and autoimmune diseases. Children can develop severe Crimean-Congo hemorrhagic fever, which may manifest as hemophagocytotic lymphohistiocytosis. During the Covid pandemic, these Crimean-Congo hemorrhagic fever cases were misdiagnosed as MIS-C (multisystem inflammatory syndrome in children) (317).

Also in the differential diagnosis of viral hemorrhagic fever is acute hemorrhagic leukoencephalitis, a rapidly evolving focal or multifocal cerebral disorder with fever and obtundation. Acute hemorrhagic leukoencephalitis is the more severe and destructive form of para- or postviral acute disseminated encephalomyelitis. The CNS white matter of acute hemorrhagic leukoencephalitis shows necrotizing vasculitis involving venules and capillaries with perivascular accumulations of polymorphonuclear cells and red blood cells. The perivascular demyelinating lesions frequently coalesce to form large lesions. MRI shows extensive white matter abnormalities and hemorrhage distinct from a thrombotic thrombocytopenic purpura case, in which there is symmetric deep gray involvement as may be seen in metabolic abnormalities.

Acute hemorrhagic leukoencephalitis

MRIs obtained from a comatose patient. Axial fluid-attenuated inversion recovery (FLAIR) images (top panels) show extensive white matter abnormal signal intensities in both hemispheres and in white matter adjacent to the insular c...
Thrombotic thrombocytopenic purpura

Axial T2-weighted sequence at the level of lateral ventricles (A), shows bilateral, near-symmetric signal abnormalities in globi pallidi. Axial diffusion b-1000 diffusion-weighted imaging shows symmetric diffusion signal abnormali...

Hemorrhagic forms of smallpox (purpura variolosa) and hemorrhagic chickenpox are also in the differential diagnosis. Finally, there is snake bite. Several species of snakes belonging to the Viperidae family produce venoms that have a wide range of pharmacologic activities affecting hemostasis.

Biphasic disease. Dengue hemorrhagic fever, Kyasanur Forest disease, and Omsk hemorrhagic fever are biphasic diseases with a febrile or hemorrhagic period followed by CNS symptoms. The biphasic course is similar to tick-borne encephalitis and other members of the tick-borne encephalitis antigenic complex, except systemic hemorrhagic manifestations are not characteristic of the first phase of tick-borne encephalitis. Determinants of the biphasic clinical disease are incompletely understood, but may associate with the cycles of virus proliferation or physiological attempts to achieve homeostasis.

Transplant recipients. Lymphocytic choriomeningitis virus is the most commonly recognized arenavirus among solid organ transplant recipients and should be considered in the transplant patient with fever, hepatitis, meningitis/encephalitis, and/or multiorgan failure (12). In the United States from 2002 to 2013, clusters of encephalitis from infectious agents in transplant patients included lymphocytic choriomeningitis virus, West Nile virus, rabies virus, and Balamuthia mandrillaris (405). All reported cases of lymphocytic choriomeningitis virus in solid organ transplant patients had been acquired from an infected donor, with one exception. The transplant patient was infected with lymphocytic choriomeningitis virus after cleaning a basement contaminated with mouse excreta and developed a meningitic syndrome and communicating hydrocephalus (429).

Dengue, if transmitted through solid organ transplantation, most commonly presents with hepatitis. DENV RNA can be detected in cadaver corneoscleral tissue but has not yet been linked to donor-derived infections (280).

Congenital disease. Congenital lymphocytic choriomeningitis virus is characterized by microcephaly, periventricular calcifications, and hydrocephalus, for which the differential diagnosis is TORCH pathogens and Zika virus (95).

Peripheral nervous system. Dengue, as well as other flaviviruses Zika and West Nile, is associated with Guillain-Barre type syndromes. Acute hypokalemic paralysis, similar to other acute flaccid paralysis syndromes, is a rare complication of dengue.

Diagnostic workup

	• The diagnosis of viral hemorrhagic fever should be considered in any febrile patient returning from an endemic area. Travel history is important.
	• Knowing the best approach to collecting samples and choosing the best identification technique for each virus increases the likelihood of positive results for a specific virus.
	• If laboratory capacity exists, RT-PCR assays are used in early or acute disease.
	• If molecular diagnostics are not available, serologic testing by IgM ELISA or rapid antibody or antigen tests are used.
	• Nucleic acid tests will fail if the virus has already been cleared or if the virus is low abundance or not normally present in the fluid tested. Antiviral antibody tests can identify ongoing or cleared infections.
	• Interpretation of serologic tests for flaviviruses is complicated by serologic cross-reactivity between flaviviruses and whether the illness is primary or secondary flavivirus infection.
	• Plaque reduction neutralization test is the gold standard for antiflavivirus antibody differentiation.
	• Laboratory safety practices should follow guidelines from virus’ classification as BSL 3 or 4 and specimens processed with appropriate precautions.

The diagnosis of viral hemorrhagic fever should be suspected in any febrile patient returning from an endemic area, particularly if there had been travel to rural areas during the times of seasonal epidemics. There may be a history of exposure to the animal vector or exposure to ticks or mosquitoes. Evidence for systemic or disseminated infection would be found in abnormal liver function tests, complete blood count, or CSF. Because the combination of fever and hemorrhage can be caused by a number of human pathogens, among them hepatitis viruses, malaria, rickettsia, shigella, typhoid, and leptospiral bacteria, diagnostic workup includes testing to exclude treatable causes. In puzzling cases, cutaneous biopsy of a rash may support an alternative diagnosis and demonstrate pathogens such as rickettsiae.

The majority of diagnostic kits today are not simple and fast enough to get rapid results. Therefore, blood and other bodily fluids should be considered infectious, and great care must be taken when handling any potentially infectious materials. Specimens should be processed with appropriate precautions in biosafety labs. Consultation and guidelines for submitting specimens are available through State Health Departments in the United States and the Centers For Disease Control and Prevention (404-639-1510). Instructions are available at the National Center for Infectious Diseases, Specimen Submission Information and Forms website.

At specialized labs, diagnosis is by seroconversion, antigen detection, or PCR of serum (283). Most of the viral hemorrhagic fevers can be diagnosed from blood by a combination of detecting antigen by ELISA and IgM ELISA. The combination of tests yields a diagnosis within 24 to 48 hours of presentation in most patients. One of the potential pitfalls in the rapid ELISA diagnostic kits is the effect of fever or elevated temperatures on the expression of antigens. All diagnostic ELISA kits are developed under laboratory conditions, in other words, at normal temperature. Thus, although the specificity and sensitivity for antigens prepared at normal temperature appear to be great, the specificity and sensitivity are frequently different from expected in field site investigations. The reason may be due to an alteration of antigen expression at febrile temperature. Thus, if a diagnostic ELISA kit could include a test with antigens prepared at a higher temperature, the accuracy of diagnosis of virus infection might increase.

For greater sensitivity in mild cases or early infection when the patient is viremic, RT-PCR may be used. RT-PCR tests complement immunodiagnostic assays and allow genotyping of the virus. Acute serum RT-PCR has been successfully applied for Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae families. Both antigen detection and amplification of virus RNA can be done on materials that have been rendered noninfectious, utilizing gamma irradiation from a cobalt-60 source, for example. Lassa virus and the South American hemorrhagic fever viruses can be isolated from blood or serum during illness from onset up to 12 to 14 days of illness. Virus can be isolated from blood or serum of Ebola and Marburg patients. Virus isolation from acute clinical specimens from hantavirus infections are generally negative, which may be related to the presence of a strong immune response during early illness that includes serum neutralizing antibodies. On the other hand, virologic diagnosis for Rift Valley fever and Crimean-Congo hemorrhagic fever can be made due to high viremias during acute disease. Yellow fever virus is most easily isolated from serum during the first 4 days of illness, but it may be recovered from serum up to the 14th day and occasionally from liver tissue at death. Kyasanur Forest disease and Omsk hemorrhagic fever viruses can be isolated during the acute hemorrhagic phase.

For dengue fever, virus can be isolated from blood in the early febrile phase of illness. Originally, inoculation into Toxorhynchites species mosquitoes or larva was used for primary virus isolation and the hemagglutination-inhibition test to classify dengue infections. Secondary infections were characterized by the presence of hemagglutination-inhibition antibodies in acute sera and high titers in convalescent sera (50). Nowadays, PCR or nonstructural protein NS1 testing is used for diagnosis during the first week of illness. It takes 4 to 7 days for IgM antibody to be produced. Similarly, PCR and NS1 testing would detect early secondary infection, as would elevated IgG to IgM ratios.

When dengue is suspected, serologic tests are carefully interpreted in populations where dengue and other flaviviruses are endemic. The plaque reduction neutralization test (PRNT) is used when there is high likelihood of cross reactivity between viral antibodies. Also, serologic results are interpreted with regard to the individual patient; whether an adult with probable prior flavivirus infection, an immigrant from a nonendemic area, a tourist, or child (286).

Detection of dengue IgM antibodies or NS1 antigen in CSF, as individual tests, has variable sensitivity and high specificity. The combined use of two markers (NS1Ag and dengue-specific IgM) in CSF increases the sensitivity of dengue diagnosis to an estimated 92% (360) and NS1 antigen detection is not believed to cross-react with Zika (286). The case definition for dengue encephalitis (408) has been fever, acute signs of cerebral involvement, positive IgM dengue antibody or dengue PCR in serum and/or CSF, and exclusion of other causes of encephalitis/encephalopathy, a distinction increasingly difficult because of reports of positive serum IgM for dengue and Japanese encephalitis (399), and high levels of Zika and dengue virus antibody cross-reactivity (339). The plaque reduction neutralization test (PRNT) is used when there is high likelihood of cross reactivity between viral antibodies; it is more specific, measuring virus-specific neutralizing antibodies, and is considered the gold standard for DENV by the World Health Organization when performed by industry standard validated labs. Substitution of chimeric dengue for wild-type virus in diagnostic plaque reduction neutralization tests has the potential to reduce lab requirements from BSL3 to BSL2 conditions (178). Evidence from current publications has been insufficient to draw definite conclusions on time course or kinetics of dengue virus in CSF, viral load in patients with probable/confirmed dengue encephalitis, and appearance of dengue-specific antibodies in CSF (296).

Serologic tests for SARS-CoV-2 need to be evaluated with care when assessing coronavirus disease spread and immunity in the tropics. There have been several reports of serologic cross-reactivity between SARS-CoV-2 and dengue virus (349). Nonspecific or cross-reactive antibody reactions have led to false positive Covid serology among dengue patients and false positive dengue serology among Covid patients. For example, in one nonendemic dengue area, 22% of Covid infections could be falsely identified as dengue, with cross reactivity attributed to structural similarities between dengue envelope protein and SARS-CoV-2 epitopes in HR2-domain of the spike protein (236). If point of care rapid test kits have low specificity, advanced diagnostic assays and serological analyzers would be solutions (396).

For Chikungunya, diagnosis is by acute and convalescent sera testing, and CNS disease by detection of anti-Chikungunya virus IgM in CSF (375). RT-PCR in serum is positive during the viremic phase lasting for one week after onset of symptoms. Alphaviruses such as CHIK are not believed to have IgM ELISA antibody cross-reactive with flaviviruses.

In an outbreak, qualitative rapid diagnostic tests that are easily transported without a cold chain, performed in minutes, visually interpreted by the end user, and requiring no instrumentation are critically needed for rapid on-site testing in areas where diagnostic facilities are limited.

Important examples of early diagnosis/point-of-care applications are the rapid diagnostic tests (RDT) for dengue. These are immunochromatographic tests for detecting dengue virus nonstructural protein 1 (NS1) antigen, and IgM, IgG, and IgA, presented in the form of a lateral flow cassette with strips for antigen and immunoglobulin detection. NS1 and IgA indicate acute infection, IgM antibody is detected during recent not necessarily acute infection, and IgG in primary or secondary infection. The RDTs have been validated in laboratory and clinical stations by comparison to dengue reference ELISAs (NS1Ag, IgA, IgM, and IgG capture ELISAs). However, NS1 antigen test is only sensitive in the early stage of infection and IgM based RDTs are not sufficiently sensitive for acute dengue diagnosis alone. To test across the full temporal spectrum of patient presentation, dengue NS1 antigen and IgM antibody RDTs should be combined (37).

Lateral flow assays, often immunoassays, are the technology behind low-cost, simple, rapid, and portable point-of-care detection devices for viral hemorrhagic fevers. They can be used for detection of proteins, haptens, nucleic acids, and amplicons. Although the concept behind the latera flow assays is straightforward, the device has a complex architecture, with critical elements of the assay, the antibodies, and membrane. Results are most often qualitative (on/off) or semiquantitative (204).

The first lateral flow immunoassay for LASV antigen detection, ReLASV Rapid Diagnostic Test (RDT), was a dipstick style LFI using paired LASV NP mouse monoclonal antibodies derived from recombinant NP immunized mice, and designed to detect Josiah strain LASV of Sierra Leone (39). ReLASV Pan-Lassa Antigen Rapid Test using a mixture of polyclonal antibodies against recombinant nucleoproteins of representative strains, including Nigerian strains, from the three most prevalent LASV lineages, followed the first generation ReLASV RDT (40).

For Ebola, figuring out who has disease, isolating them, and practicing barrier nursing techniques, contains outbreaks. In 2014 to 2016, rapid diagnostic testing using Trombley assay, Real-time TaqManTM PCR, Real Star Filovirius Screen RT-PCR (Altona Hamburg Germany), and other nucleic acid amplification tests were deployed through portable labs and to health centers in the affected West African countries (97; 395). Because current molecular lab diagnostic methods such as PCR require trained personnel and lab infrastructure, development of rapid, accurate, point of care testing continues. Three RDTs field tested during the 2018 to 2020 outbreak in eastern Democratic Republic of Congo did not achieve the desired sensitivity and specificity of the WHO target product profile when compared to detection of viral RNA by Cepheid GeneExpert Ebola assay, a quantitative RT-PCR for Ebola virus that targets NP and GP genes (281). Although the RDTs cannot rule out Ebola, they can triage suspected Ebola virus infection into high and low risk groups, while waiting for GeneXpert Ebola reference testing.

The rapid tests have not been well suited for differentiating among multiple febrile diseases with similar symptoms: Ebola, Lassa, and malaria, for example. Other technologies for multiplex assays are in development (388). Inactivated virus preps coupled to magnetic beads and reacted with samples to detect IgG antibodies to Lassa, Ebola, Marburg, CCHF, Rift Valley, pan-alphavirus, pan-flavivirus have been investigated (304). Conceivably, any ELISA assay can be transitioned to the MAXPIX system, based on xMAP bead technology (magnetic bead-based assays with magnetic microspheres and fluorescent labels) (151).

Next-generation sequencing, available in specialized laboratories, is becoming important both for detection of pathogens when standard lab methods fail (as in a suspected hemorrhagic fever outbreak in Uganda) (265), and for pathogen discovery. Next-generation metagenomic approaches follow an unbiased approach to disease analysis. The method does not require primers to amplify specific sequences or probes. Instead, with deep sequencing machines, large numbers of reads with high coverage of genomes contained in the clinical sample are produced. From established DNA or RNA databases and application of computational biology methods, viral genomes are reconstructed (218; 383; 283).

CRISP sequence together with Cas nucleases are the basis of CRISPR/Cas technology used for genome editing. A newer application of the CRISPR-Cas system is virus detection, when viral disease is diagnosed by nucleic acid based methods. CRISPR-based diagnostic methods identify a certain target sequence associated with a disease, then cleave it to produce a readable signal (182). CRISPR diagnostic tests, which can be performed with simple reagents and paper-based lateral flow assays, are providing rapid point of care diagnostics and decreasing healthcare and lab worker exposure. For example, CRISPR-Cas13a diagnostic tools to detect Ebola and Lassa virus cases have been developed and tested (26).

It is important to keep in mind that nucleic acid tests may fail if the virus has already been cleared or if the virus is low abundance or not normally present in the fluid tested. However, tests detecting antiviral antibodies can identify ongoing or cleared infections. Analysis of antiviral antibodies to cover the entire human virome is now available (474)

VirScan is another specialized research tool, a programmable high throughput method to comprehensively analyze antiviral antibodies that covers the complete human virome. A phage-display assay for viral immune responses enables human virome-wide exploration at the epitope level of immune responses (474). In one case, chronic dengue virus panencephalitis was diagnosed in a patient with progressive dementia based on VirScan identification of elevated dengue antibodies in CSF compared to serum when no virus was detected in serum or CSF (180).

Next steps in testing may be toward development of systems that detect markers of disease severity and be informative enough to provide direction for patient management.

ICD codes for various viral hemorrhagic fevers can be found in Table 2.

Table 2. ICD Codes for Viral Hemorrhagic Fevers

Disease		ICD-9	ICD-10
Arenaviral hemorrhagic fever		078.7	A96
	- Junin hemorrhagic fever		A96.0
	- Machupo hemorrhagic fever		A96.1
	- Lassa fever	78.8	A96.2
	- Other arenaviral hemorrhagic fevers		A96.8
	- Arenaviral hemorrhagic fever, unspecified		A96.9
Arthropod-borne hemorrhagic fever		065	A98
	- Crimean Congo hemorrhagic fever	065.0	A98.0
	- Omsk hemorrhagic fever	065.1	A98.1
	- Kyasanur Forest disease	065.2	A98.2
	- Marburg virus disease	078.89	A98.3
	- Chikungunya hemorrhagic fever	065.4, 66.3	A92.0
	- Dengue hemorrhagic fever	065.4	A91
	- Ebola virus disease	065.8	A98.4
	- Other specified arthropod-borne hemorrhagic fever	065.8	A98.8
	- Arthropod-borne hemorrhagic fever-unspecified	065.9	A99
Dengue		061	A90
Encephalitis in viral diseases classified elsewhere		323.0	G05.1
Hemorrhagic nephrosonephritis (Hemorrhagic fever: epidemic, Korean, Russian with renal syndrome)		078.6	A98.5
Rift Valley fever		066.3	A92.4
Tick-borne viral encephalitis		063	A84
	- Far Eastern tick-borne encephalitis (Russian spring-summer (taiga) encephalitis)	063.0	A84.0
	- Central European encephalitis	063.2	A84.1
	- Other specified tick-borne viral encephalitis	063.8	A84.8
	- Tick-borne viral encephalitis, unspecified	063.9	A84.9
Yellow fever		060	A95
	- Sylvatic yellow fever	060.0	A95.0
	- Urban yellow fever	060.1	A95.1
	- Yellow fever, unspecified	060.9	A95.9

Management

	• Early management is symptomatic and supportive, along with empiric antiviral and/or antibiotic treatment until a diagnosis is made.
	• Fluid status tracking and management are critical in all patients. Supportive therapy is based on fluid resuscitation, electrolyte correction, and preventing shock and its complications.
	• There is no cure or established drug treatment for many of the viral hemorrhagic fevers. The exceptions are ribavirin for Lassa fever, Crimean-Congo hemorrhagic fever, Argentinian hemorrhagic fever, severe fever with thrombocytopenia syndrome, hyperimmune globulin for Argentinian hemorrhagic fever, and monoclonal antibody infusions for Ebola.
	• The following are published protocols: ribavirin for Lassa fever, Argentine hemorrhagic fever, Crimean-Congo hemorrhagic fever, severe fever with thrombocytopenia; ribavirin plus favipiravir for Argentine hemorrhagic fever; ribavirin prophylaxis for primary contacts of patient with a ribavirin-sensitive viral hemorrhagic fever; hyperimmune globulin for Argentine hemorrhagic fever.
	• The following are successful individual or small case series treatments: favipiravir in Ebola; remdesivir in Ebola; hyperimmune globulin for Ebola; monoclonal antibody infusion for Ebola; ZMapp (3 humanized monoclonal antibodies to the Ebola glycoprotein, manufactured in plants); MAb114 (a single human MAb derived from a 1995 Ebola survivor in Kikwit, Democratic Republic of Congo) (now Ebanga); and triple monoclonal antibody REGN-EB3 (a co-formulated mixture of three human IgG1 monoclonal antibodies) (now Inmazeb).
	• Categories of investigational drugs include: nucleoside and nucleotide analogues, nucleic acid-based drugs, and immunotherapeutics. Several investigational drugs (ZMapp, Brincidofovir, TKM-Ebola, Favipiravir, AVI-7537, BCX4430, GS-5734) and blood transfusion of convalescent plasma from recovered patients were used to treat Ebola patients during the 2013 to 2016 West African outbreak. In the Democratic Republic of Congo in 2019, antibody-based therapies MAb114 or REGN-EB3 were shown superior to ZMapp or remdesivir (the nucleotide analogue GS-5734) in reducing Ebola virus mortality.
	• Post-dengue syndromes judged to be immune-mediated are treated with IVIG, plasma exchange, or steroids.
	• Vaccines for dengue, Ebola, and Argentine hemorrhagic fever support public health preparedness and outbreak management. Formalin inactivated bunyavirus vaccines for Hantavirus (Hantavax), Crimean-Congo hemorrhagic fever, and Rift Valley fever, are used in risk groups.

Management is symptomatic, along with empiric antiviral and/or antibiotic treatment until a diagnosis is made. In all viral hemorrhagic fevers, treatment is to preserve function of vital organs by providing supportive care for bleeding, fluid and electrolyte imbalance, shock, and hypoxia. Cardiotonic pressor drugs are used for shock, along with cautious fluid administration because of the tendency to precipitate pulmonary edema. Estimates of central volume status and tracking of fluid resuscitation status is especially important in children with dengue shock syndrome and dengue hemorrhagic fever (279). Fluid management in dengue (169; 428) and use of a hydration tent during epidemics when there is a shortage of hospital beds are reviewed (247). Future studies in filoviruses may test pediatric ICU protocols in primates. Activated protein C, although U.S. FDA-approved for treatment of septic shock (31), has not been systematically tested for efficacy in viral hemorrhagic fevers. Usual precautions for patients with bleeding diatheses, such as avoiding intramuscular injections and aspirin, are practiced and hepatotoxic drugs are avoided. Strict isolation and barrier nursing procedures are followed. Disseminated intravascular coagulation is managed with platelet transfusions and fresh frozen plasma. Platelets are replaced if counts fall below 20,000/µL. Hepatic-induced coagulopathies are treated with vitamin K. Medication selection may be influenced by noting drug-induced immune thrombocytopenia that can be caused by quinine, sulfonamides, penicillins, vancomycin, cephalosporins, or thiazide diuretics. In hemorrhagic fever with renal syndrome (HFRS), acute kidney failure is managed with dialysis. Diuresis can be renal or central due to pituitary dysfunction. The endocrine status of every patient who survives hemorrhagic fever with renal syndrome is checked.

Ribavirin is a broad spectrum antiviral that has been used in the treatment of hemorrhagic fevers for more than 30 years. Ribavirin is the therapeutic agent of choice in Lassa fever. It is efficacious when administered to patients within the first seven days of illness but is contraindicated in pregnant women. It has been used principally in Lassa fever patients with a poor prognosis who have serum aspartate transaminase values above 150. The intravenous dose is a 2 g loading dose, followed by 1 g every 6 hours for 4 days, then 0.5 g every 8 hours for another 6 days (256). Its penetration into the CNS is limited and its main side effects are anemia and serum amylase elevations. Ribavirin plus oral favipiravir, a small molecule purine analogue, (2000 mg loading dose followed by 1200 mg twice a day) successfully treated two Lassa cases in Germany (366).

Results with intravenous ribavirin have also been positive in hemorrhagic fever with renal syndrome (166), Crimean-Congo hemorrhagic fever (66) and Argentine hemorrhagic fever (113). Convalescent serum (usually two to three units with high neutralizing titer) within the first eight days of illness, was the original treatment of choice for Argentine hemorrhagic fever (112). When therapy of Junin virus infections with ribavirin was recognized effective for the visceral phase of the infection, ribavirin was then added to hyperimmune globulin (130). If time to diagnosis is over eight days, considered too long to administer immune plasma, ribavirin plus oral favipiravir (2000 mg loading dose followed by 1200 mg twice a day, to a maximum of 1800 mg twice a day for 14 days) is used (445). Ribavirin, used in China for severe fever with thrombocytopenia syndrome, is reported effective for early-stage disease (120). Ribavirin is not effective in hanta pulmonary syndrome.

Monoclonal antibody therapy, based on anti-JUNV GP neutralizing mouse-human chimeric mAbs, has shown prevention of CNS infection and superiority to all other evaluated drugs in a guinea pig model, and therefore may be an alternative to immune plasma (485). Ways of increasing blood-brain barrier permeability to mAbs and other protein therapeutics are important issues for these classes of compounds. Currently, ribavirin is approved for use in treating viral hemorrhagic fevers caused by arenaviruses and bunyaviruses but not filoviruses under the compassionate use provisions for investigational new drugs (130). Originally treated with intravenous ribavirin, Crimean-Congo hemorrhagic fever has been found to respond well to oral ribavirin. The oral dosage recommended by the World Health Organization for Crimean-Congo hemorrhagic fever is 2000 mg as an initial loading dose, then 1000 mg every 6 hours for 4 days and then 500 mg every 6 hours for 6 days (or 30 mg/kg as an initial loading dose, then 15 mg/kg every 6 hours for 4 days, and then 7.5 mg/kg every 8 hours for 6 days) (source 200 mg tablets made in the United Kingdom for Durbin PLC). Patients with nausea and vomiting receive the drug via nasogastric tube and/or with antiemetic drugs (468; 245; 315). Survival is improved if treatment begins within 4 days of onset of illness (430). Safety and pharmacokinetic data on intravenous ribavirin in a pediatric population, including CSF levels, are provided in a study on La Crosse encephalitis in children (260).

Opinions vary for the use of oral ribavirin for prophylaxis for primary contacts in the event of exposure to one of the viral hemorrhagic fevers susceptible to ribavirin (88). Some experts recommend immediate prophylaxis whereas others suggest observing contacts and treating if an individual becomes febrile (202). Intravenous ribavirin, used during the Rift Valley fever virus outbreak in Saudi Arabia in 2000, was quickly stopped when suspected to increase the chance of neurologic disease (153). Newer broad-spectrum antivirals such as favipiravir have shown promise in rodent models (153), including hamsters that have shown the same augmentation of neurologic disease with ribavirin (385).

Favipiravir (T-705), an investigational antiviral drug that inhibits the RNA-dependent RNA polymerase of influenza virus, also blocks the replication of many other RNA viruses. It has broad-spectrum antiviral activity against arenaviruses (Junin, Machupo, Pichinde), phleboviruses (Rift Valley fever, sandfly virus), nairovirus (Crimean-Congo hemorrhagic fever), and flaviviruses (yellow fever) in vitro and in rodent models, making favipiravir a promising candidate drug for RNA viral diseases with no approved therapies (120). Successful treatment of advanced Ebola virus infection in a small animal model with favipiravir has also been reported. Initiation of T-705 treatment at day 6 postinfection induced rapid virus clearance, reduced biochemical parameters of disease severity, and prevented a lethal outcome in 100% of mice (lacking the type 1 interferon receptor) (303).

Both ribavirin and favipiravir act as purine pseudobases. Ribavirin’s main antiviral activity, through catastrophic mutagenesis, has required early treatment for good outcomes in clinical and animal model studies of Crimean-Congo hemorrhagic fever, for example. On the other hand, favipiravir, an inhibitor of viral polymerase, still provides protective effects in animal models in later stages, when showing signs of advanced disease (158).

Crimean-Congo hemorrhagic fever with hemophagocytotic lymphohistiocytosis (hemophagocytic lymphohistiocytosis) in children has been treated with combined therapeutic plasma exchange, ribavirin, and IVIG (19), or with the combination of ribavirin, IVIG (2 gm/kg body weight as a 48 hr infusion or 400 to 500 mg/kg/day over 4 to 5 days), dexamethasone (10 mg/square meter body surface area) or 2 mg/kg/day methylprednisolone over 3 to 10 days, fresh frozen plasma, vitamin K, and platelets to those who required transfusions (317).

Investigational treatments of Ebola virus disease have included the use of monoclonal antibodies, plasma transfusions from convalescent patients, nucleoside and nucleotide analogues, nucleic acid-based drugs, small molecule antiviral agents, and vaccines.

West Africa, United States, Europe 2014-2017. Monoclonal antibody treatment combined with adenovirus-vectored interferon-alpha has rescued Ebola-infected experimental nonhuman primates after detection of viremia and symptoms (365). Before 2014, monoclonal antibody-based treatments were identified by several BSL4 labs as the preferred clinical option in response to accidental Ebola virus exposure (365). ZMapp is a cocktail of three humanized monoclonal antibodies manufactured in tobacco plants, which targets the Ebola virus glycoprotein. It was used to treat seven patients, with five surviving (255), but available supplies were soon consumed. ZMapp targets only one strain of Ebola, the Zaire strain. A new set of broadly neutralizing monoclonal antibodies has been found in the blood of Ebola survivors, which proved effective against disease caused by several strains, Zaire, Bundibugyo, and Sudan Ebola viruses (133).

Randomized controlled trials of new drugs in people with Ebola continued until the end of the West Africa epidemic. Use of passive immune therapy (blood or plasma transfusions from convalescent patients to treat Ebola-infected patients) had World Health Organization approval in 2014 (141). Transfusion therapy has been successfully used on at least three patients in the United States but could not be used for the fatal Ebola case in the United States because of blood type mismatch (36). Although screening donated blood for pathogens is an issue in resource-limited settings, chemicals can be added and mixed with donated blood that, when exposed to UV light, irreversibly crosslink DNA and RNA of pathogens, thus preventing their replication.

Favipiravir (T-705), the oral nucleoside analogue, successfully treated one French nurse (36). Supplies are available because it had already advanced to late-phase clinical studies. It showed modest efficacy in a phase II trial that did not have a control group. Brincidofovir (CMX-001), an orally available lipid conjugate of cidofovir in clinical trials for double-stranded DNA viruses, was found to have activity against Ebola virus and has been used as a treatment on five patients infected in the U.S. (36). The clinical trial in Liberia begun in early 2015 was terminated because of the drop in numbers of new cases. TKM-Ebola is a small interfering RNA that affects three of Ebola's seven proteins; it received FDA approval for emergency use during the West African epidemic.

Gilead’s GS-5734 (remdesivir), a prodrug nucleoside inhibitor with efficacy in infected primates, moved to phase I studies in healthy human volunteers. It was used to treat relapse in the Scottish nurse in late 2015, in whom it was reported to have eradicated virus from the CNS causing her meningoencephalitis. A survivor cohort study in Africa was planned to study eradicating virus from persistent sites by treatment for 1 or 2 weeks and checks of viral load in immune-privileged sites but timing is important, as the natural history of Ebola is a drop in viral RNA over time. Other investigational agents include: JK-05 (approved in China); AVI-7537 (a phosphorodiaminidate morpholino oligomer that blocks translation), inhibits VP24 protein and potentially improves host innate immunity; BCX-4430, an adenosine analogue; and the antiretroviral lamivudine (36; 199). Sequence-based candidate therapeutics may be strain-specific.

Other treatments have included fibrin-derived peptide for vascular leak syndrome and extracorporeal virus elimination by lectin affinity plasmapheresis; each used in Germany. A summary of treatments in West Africa and what patients have been given outside West Africa appeared in a newspaper article in late 2014 (215).

Doctors needing information on availability and use of experimental therapies should contact the U.S. Food and Drug Administration and drug manufacturers. On a case by case basis, emergency investigational new drug applications are awarded.

The West Africa outbreak ended as numerous Ebola medical countermeasures were being explored or developed. These studies were carried forward into the Democratic Republic of Congo outbreak.

Democratic Republic of Congo 2018-2020. A trial of four investigational therapies was conducted in the Democratic Republic of Congo outbreak, starting in 2018. Patients were randomly assigned in a 1:1:1:1 ratio to intravenous administration of the triple monoclonal antibody ZMapp (the control), the antiviral agent remdesivir (the nucleotide analogue RNA polymerase inhibitor GS-5734, a), the single monoclonal antibody MAb114 (a single human MAb derived from an Ebola survivor), or the triple monoclonal antibody REGN-EB3 (a coformulated mixture of three human IgG1 monoclonal antibodies). Both MAb114 and REGN-EB3 were superior to ZMapp in reducing Ebola virus mortality. Remdesivir had been dropped from the study after an interim analysis showed the superiority of MAb114 and REGN-EB3 to ZMapp and remdesivir. The superior agents had each reduced deaths to 33% to 35% compared to roughly 50% in the ZMapp group. Mortality in all groups highlights the need for further improvements in supportive care and a possible role for combination strategies that use agents with complementary mechanisms of action (282).

A compassionate use protocol, Monitored Emergency Use of Unregistered and Investigational Interventions, offered to all patients in the Democratic Republic of Congo with laboratory-confirmed Ebola virus infection covered these therapies and represented the first time several investigational treatments were available in the midst of an outbreak (184).

Relapses after MAbs appear to be rare but create questions as to whether passive immunotherapy could have a role in viral persistence and relapse (253). There have been three patients with documented cases of relapse: all had received antibody-based therapy as part of their initial infection treatment. A Scottish nurse treated with convalescent plasma and ZMapp relapsed nine months later with meningoencephalitis (174). A man treated with mAb114 relapsed after six months with systemic disease (253).

A nonhuman primate Ebola study demonstrated similar recurrence of disease. Rhesus macaques with acute infection treated with monoclonal antibodies recovered, but went on to develop fatal CNS disease characterized by ventriculitis, choroid plexitis, and meningoencephalitis. At autopsy, infection and inflammation were limited to the brain: to the ventricular system and adjacent neuropil. Macrophages were the cellular reservoir of persistent infection, and EBOV persistence in brain ventricles originated from choroid plexus vasculature (228).

The natural and experimental cases of relapse after antibody treatment mean that antibody treatments may need to be monitored for evolving viral resistance, and future treatments may require a cocktail of mAbs targeting nonoverlapping epitopes of Ebola virus (254).

Vaccines. rVSV-ZEBOV vaccine has been licensed and Ad26.ZEBOV, MVA-BN-Filo is available under investigational protocols. As the only viral surface protein and mediator of virus attachment and cell entry, the Ebola glycoprotein had been of interest as a target for vaccines as well as antibody-based therapies noted above. rVSV-ZEBO (Newlink Genetics/Public Health Agency Canada, subsequently licensed to Merck) stimulates immune response to Ebola glycoprotein using recombinant vesicular stomatitis virus as a delivery vector. A phase III clinical trial in Guinea assessed its efficacy in preventing Ebola virus disease using a ring vaccination method inspired by the strategy used in smallpox eradication. Clusters of individuals at high risk of infection based on their connection to an index case were vaccinated. After confirmation of a new infection, clusters of contacts and contacts of contacts were assigned to immediate or delayed vaccination. Early results showed no cases of Ebola at 10 days after randomization in the immediate vaccination group, but 16 cases from seven clusters in the delayed vaccination group (161). This trial discontinued randomization and continued with immediate vaccination of new clusters of patients. Data on the duration of humoral immunity induced by VSV-EBOV are not yet available. cAd3-EBO (GSK/USNIAID) stimulates antibody and T cell immune response to Ebola glycoprotein using chimpanzee adenovirus vectored ebolavirus vaccine encoding the glycoprotein from Zaire and Sudan species. Reactogenicity and immune response were dose-dependent (220). The vaccine is also under investigation as a primer in the two vaccine (prime-boost) study. Ebola vaccine trials are planned or underway in Liberia, Guinea, and Sierra Leone. Both vaccines appear safe in early reports of the phase II Liberian clinical trial. Johnson & Johnson (through its division Crucell NV, together with Bavarian Nordic and USNIAID) has also accelerated development of a vaccine program based on a prime-boost regimen with sequential use of two Ebola vaccines. The Ad26.ZEBOV uses an adenovirus vector to deliver genetic material from EBOV-Zaire (responsible for the West Africa outbreak) and MVA-BN-Filo uses a modified vaccinia virus Ankara vector (MVA) to deliver the Ebola genetic material, plus inserts for Sudan Ebolavirus, Tai Forest ebolavirus, and the related Marburg virus. All participants in the phase I trial who received the Ad26.ZEBOV vaccine first (the prime) followed by MVA-BN-Filo as a booster developed and maintained antibodies to Ebola eight months after immunization and most of the group maintained vaccine-induced T cells (270). Vaccine updates and commentary can be found on Wellcome Trust-CIDRAP (Center for Infectious Disease Research and Policy) website (cidrap.umn.edu).

In 2015, Merck’s rVSV-ZEBOV vaccine (now Ervebo) stopped the spread of Ebola in Guinea (160). This vaccine was offered to international responders, local health workers, and contacts of people with Ebola in the Democratic Republic of Congo’s 2018 Ebola epidemic. Since the start of vaccination on August 8, 2018, 297,699 people (high risk contacts, contacts of contacts, and front-line providers) had been vaccinated (342). The main vaccination strategy was “ring vaccination”. “Targeted geographic vaccination” was also used and provided for “pop-up” vaccination sites in unsafe areas. The earliest studies have shown a 97.5% vaccine efficacy. Ebola patients in the Democratic Republic of Congo who had received rVSV-ZEBOV vaccination prior to infections had lower viral loads, better outcomes, and were less likely to have kidney injury (192). Vaccinating people already infected increased their chances of survival (470). The vaccine is estimated to have a 1-year efficacy. As of 2022, approximately 10% of patients admitted to Ebola Treatment Units in DRC were fully vaccinated. The vaccine is licensed by WHO in Democratic Republic of Congo, Burundi, Ghana, and Zambia (470), has European Commission marketing authorization, and is approved for medical use in Europe and by FDA in the United States.

The June 2019 revised World Health Organization vaccine strategy proposed the Johnson and Johnson vaccine (Ad26.ZEBOV/MVA-BN) to complement ring vaccination in the Democratic Republic of Congo. The vaccine is a 2-dose heterologous vaccination regimen (Zabdeno [Ad26.ZEBOV] and Mvabea [MVA-BN-Filo]), with a replication-deficient adenovirus type 26 vector-based vaccine expressing Zaire Ebola virus glycoprotein and a nonreplicating modified vaccinia Ankara (MVA) vector-based vaccine, encoding glycoproteins from Zaire Ebola virus, Sudan virus, and Marburg virus, and nucleoprotein from the Tai Forest Ebola virus. The vaccine has marketing authority by the European Medicines Agency.

Originally, the Johnson and Johnson vaccine, which requires two doses separated by 60 days, would be used outside of outbreak zones and would be a preventive vaccine in lower-risk not-yet-exposed groups. The Merck vaccine would continue as vaccination of high-risk individuals already exposed to the virus. The combined efforts would continue ring vaccination protocols around cases while increasing immunity in the general community with the Johnson and Johnson vaccine.

Merck’s rVSV-ZEBOV vaccine (now Ervebo) protects only against Zaire Ebolavirus species of Ebola virus, and Janssen’s Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea) is a heterologous prime-boost Ebola vaccine that contains coding regions of several filoviruses in the MVA-BN-Filo vaccine. Both have regulatory approvals.

Altogether, at least eight vaccines entered clinical trials between 2014 and 2016. However, the immunologic correlates of protection remain unclear. More research is needed. For all the candidate vaccines, long-term persistence of the vaccination response is unknown, along with whether an immune correlate of protection identified for one vaccine applies equally to immunity by another vaccine (407). More vaccine candidates also likely will be needed to provide protection against multiple Ebola species and to extend the length of protection.

The need for additional filovirus vaccines arrived with the Ebola-Sudan outbreak in Uganda (September 2022 to January 2023). WHO and the government of Uganda planned to test three experimental vaccines: the first one was created by IAVI (International AIDS Vaccine Initiative) and was based on the same vaccine platform as Merck’s Ebola Zaire vaccine Ervebo, using VSV to carry Ebola Sudan glycoprotein, rVSVdeltaG-SUDV-GP; the second was created by Sabin Vaccine Initiative and used ChAd3 (chimpanzee adenovirus)-SUDV; the third, by University of Oxford’s Jenner Institute, used the same platform ChAdOx1 designed for AstraZeneca’s COVID-19 vaccine. The single-vector multi-pathogen filovirus vaccine ChAdOx1-TriFilo expresses three filovirus glycoproteins (EBOV, SUDV, MARV) and targets both Sudan and Zaire strains and Marburg virus (353; 354). Uganda received the three vaccines from WHO in Dec 2022. But, with no new cases, the vaccines had come too late.

In 2023, WHO aims to accelerate trials of candidate vaccines for Marburg disease in Equatorial Guinea and Tanzania. Sabin Vaccine Institute ChAd3-MARV and Janssen Ad26nFILO + MVA-BN-FILO* are currently in phase 1 trials, and IAVI rVSVdeltaG-MARV, PHV (Public Health Vaccine) rVSVdeltaG-MARV, and Auro/Emergent rVSV-N4CT1-MARV are in preclinical development (195).

(*Ad26nFILO encodes the glycoprotein of EBOV, SUDV, MARV; and MVA-BN-FILO encodes the gp of EBOV, SUDV, MARV and the nucleoprotein of Tai Forest virus)

There is no consensus for antiviral treatment in dengue. An uncontrolled trial of interferon was performed during an outbreak in Cuba in 1981 with some indication that fatalities were averted (50). General guidelines are in a World Health Organization publication (466). During a 2002 dengue hemorrhagic fever outbreak in Brazil, patients were treated for five days with 500 mg/kg per day intravenously administered IVIG (that had tested negative for any dengue antibody). Platelet counts recovered in five days, compared to nine days in untreated patients in other series (314). The mechanism of IVIG effect was hypothesized to be limiting immune-mediated destruction of platelets and vasculitis caused by immune complexes. However, a different group reported that IVIG has no effect in hastening the recovery of platelet counts in patients with secondary dengue infections (102). The reason for the lack of IVIG efficacy is attributed to enhance platelets phagocytosis by macrophages through Fc gamma receptors (162). Desmopressin, a treatment for refractory bleeding in hemophilia and von Willebrand disease Type 1, was used in a dengue hemorrhagic fever/dengue shock syndrome case (328). DENV-associated hypokalemic paralysis is rapidly reversed with potassium supplements.

Post-dengue syndromes judged to be immune-mediated are treated with IVIG, plasma exchange, or steroids. In one study, hematocrit value, mean body temperature, and alanine aminotransferase (ALT or SGPT) levels during infection were predictors of immune-mediated syndromes (34).

Experimental therapies for critically ill severe fever with thrombocytopenia syndrome patients with encephalopathy have been designed with goals to mitigate early cytokine storm with steroid pulse therapy or plasma exchange and to decrease viral burden with convalescent plasma therapy or ribavirin (323; 322; 82; 292). Ribavirin is used as 30 mg/kg as an initial loading oral dose, then 15 mg/kg every 6 hours for 4 days, and then 7.5 mg/kg every 6 hours for 6 days. A comatose patient recovered after plasma exchange reduced IFN-a and IP-10 levels, and convalescent plasma therapy reduced viral load (82).

In a comparative study of patients with confirmed Crimean-Congo hemorrhagic fever and severe thrombocytopenia (less than 50,000/ml), high dose methylprednisolone was used to suppress host hyperinflammatory response. Methylprednisolone 10 mg/kg for three days in the morning and then 5 mg/kg for 2 or more days with oral ribavirin improved outcomes compared to ribavirin alone. Fewer in the treatment group required transfusions of blood products. Methylprednisolone increased platelet counts within 36 hours and white blood cell counts within 48 hours (393).

Two severe Puumala virus patients with circulation evidence of complement activation and extensive capillary leakage leading to hypotensive shock were successfully treated with a 30 mg sc dose of the bradykinin receptor blocker icatibant (15; 440). Icatibant is a bradykinin B2 receptor antagonist approved for use in episodes of hereditary angioedema. In a proof-of-concept study, icatibant added to standard care improved both COVID-19 pneumonia and mortality (242).

For hantaviruses, reinfections do not exist, so hantavirus vaccines would have a role in public health. Hantavax is available in several Asian countries. Ribavirin is used in hemorrhagic fever with renal syndrome caused by Hantaan virus, and a five-day course of ribavirin has provided successful prophylaxis in Andes virus HPS (252). Strategies to counteract key pathophysiology events are studied.

Reduction in immunosuppression and supportive care are fundamental management of transplant-associated lymphocytic choriomeningitis virus. One survivor had received ribavirin and reduction of immunosuppressive therapy.

Outcomes

Arenaviridae. Eight to 10% of Argentine hemorrhagic fever patients treated with Junin immune plasma developed nystagmus, ataxia, cerebellar tremor, and abnormal brainstem-evoked responses 2 to 3 weeks after discharge from the hospital (240; 87). Lassa fever is associated with a high incidence of hearing disability in West Africa. Thirty percent of those who survive Lassa fever develop sensorineural hearing loss during the recovery or convalescence phase. Hearing loss was an outcome unrelated to whether the patient had received antiviral treatment and was thought to be a consequence of the immune response that promotes clearance and disease resolution (90).

Filoviridae. Seven survivors of the Kikwit 1995 Ebola epidemic received hyperimmune serum (284). Early in the West African epidemic, transfusion therapy with hyperimmune serum was used successfully for three patients in the United States during the West African epidemic. ZMapp is a cocktail of three humanized monoclonal antibodies manufactured in tobacco plants, which targets the Ebola virus glycoprotein. It was used to treat seven patients, with five surviving. Favipiravir (T-705), an oral nucleoside analogue, successfully treated one French nurse (36), and Brincidofovir (CMX-001), an orally available lipid conjugate of cidofovir in clinical trials for double-stranded DNA viruses, was used as a treatment on five patients infected in the United States (36). Gilead’s GS-5734 was used to treat (remdesivir) the meningoencephalitic relapse in the Scottish nurse in late 2015, in whom it was reported to have eradicated the virus from the CNS that caused her meningoencephalitis. A clinical study in Democratic Republic of the Congo in 2018 to 2020 showed both MAb114 and REGN-EB3 to be superior to ZMapp in reducing Ebola virus mortality. Each of the superior agents reduced deaths to 33% to 35% compared to roughly 50% in the ZMapp group. Relapses after MAbs have been rare but create questions as to whether passive immunotherapy could have a role in viral persistence and relapse. A portion of Ebola survivors of the West African 2013 to 2017 epidemic had post-Ebola (neurologic, musculoskeletal, or ocular) symptoms and syndromes were examined 48 months after recovery in a portion of survivors (98).

Flaviviridae. One patient, 60 days after dengue encephalitis diagnosed by inflammatory CSF and positive serology, developed a behavior disorder treated with risperidone (23).

Long-term sequelae have been neurologic, psychiatric, and chronic fatigue-like syndromes. Chronic infection was the cause of progressive dementia in one case (180). Another patient developed a behavior disorder treated with risperidone, 60 days after dengue encephalitis diagnosed by inflammatory CSF and positive serology (23). Three months after acute dengue in Singapore, 18% of patients had persistent fatigue or CNS related symptoms (somnolence, headache, concentration or memory impairment) (185). In the two years following the 2006 Cuban epidemic, long-term persistence of muscle pain, asthenia, hand weakness, general malaise, irritability, lost memories, dizziness, or headache were reported. Clinical symptoms, in turn, were associated with autoimmune blood markers and FcyRIIa gene polymorphisms (124).

Togaviridae. Rarely, Chikungunya virus affects the CNS, with severe encephalitis in neonates, individuals with advanced age and underlying diseases (64). The genotypes of CHIK associated with encephalitis are the Asian and ECSA (East, Central South African) lineages, and not the West African subtype (163).

Special considerations

Pregnancy

Generally, viral hemorrhagic fevers cause more severe disease with higher mortality in pregnant than nonpregnant women due to pregnancy-induced immunotolerance/immunosuppression and complications of severe hemorrhage, vertical transmission, and intrauterine demise. For example, mortality among pregnant women with Ebola hemorrhagic fever (95.5%) was higher than overall mortality (77%) observed during the Ebola epidemic in Kikwit in 1995 (213).

Lassa fever carries a high risk to the fetus throughout pregnancy and to the mother, especially in the third trimester, with 30% or greater fatalities. Evacuation of the uterus significantly improved the mother’s chance of survival and patients seem to improve quickly after delivery or abortion (338). Active obstetric management with induction of labor, caesarian section, and evacuation of retained products of conception has been encouraged, and ribavirin is recommended after delivery. Lassa virus is present in breast milk of infected mothers.

Vertical transmission in humans is reported for Rift Valley fever (17); dengue, presenting as newborn or perinatal encephalitis (402; 183); hemorrhagic fever with renal syndrome (223; 413); and Lassa (275). Early-life Lassa infection causes “swollen baby syndrome,” with generalized edema, abdominal distension, and bleeding (275).

Infants born to dengue-immune mothers and first exposed to dengue when transplacentally-acquired maternal dengue antibodies are waning and risk symptomatic or severe disease (461). Viral hemorrhagic fevers are considered in the differential diagnosis of HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in gravid patients in endemic areas. General anesthesia may be a safer option than subarachnoid block in patients with bleeding diathesis (80).

Anesthesia

Upper airway edema may be severe enough to result in difficult intubation, in which case preparation of equipment for difficult airway management, such as endotracheal tubes of various small sizes and fiberoptic laryngoscopes, is required.

References

01: Abczynska M, Terminska K. Psychopathological symptoms in atypical viral hemorrhagic tick-borne encephalitis. Psychiatr Pol 1995;29:547-51. PMID 7568527
02: Adaken C, Scott JT, Sharma R, et al. Ebola virus antibody decay-stimulation in a high proportion of survivors. Nature 2021;590(7846):468-72. PMID 33505020
03: Adalja AA, Sell TK, Bouri N, Franco C. Lessons learned during dengue outbreaks in the United States, 2001-2011. Emerg Infect Dis 2012;18(4):608-14. PMID 22469195
04: Alavni-Naini R, Moghtaderi A, Metanat M. An unusual intracerebral hemorrhage. Can J Infect Dis Med Microbiol 2004;15(3):175-7. PMID 18159490
05: Al-Hazmi A, Al-Rahji AA, Abboud EB, et al. Ocular complications of Rift Valley fever outbreak in Saudi Arabia. 2005;112:313-8. PMID 15691569
06: Alrajhi AA, Al-Semari A, Al-Watban J. Rift Valley fever encephalitis. Emerg Infect Dis 2004;10:554-5. PMID 15116716
07: Amman BR, Bird BH, Bakarr IA, et al. Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa. Nat Communications 2020;11(1):510. PMID 31980636
08: Amman BR, Pavlin BI, Albarino CG, et al. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. Emerg Infect Dis 2007;13(5):719-25. PMID 17553250
09: Anaya JM, Rodriguez Y, Monsalve DM, et al. A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cucuta, Columbia. J Autoimmun 2017;77:123-38. PMID 28062188
10: Anderson D, Beecher G, Power C, et al. A neuropathic pain syndrome associated with hantavirus infection. J Neurovirol 2017;23(6):919-21. PMID 28895058
11: Andersen KG, Shylakhter I, Tabrizi S, et al. Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever. Philos Trans R Soc Lond B Biol Sci 2012;367(1590):868-77. PMID 22312054
12: Anesi JA, Silveira FP, AST Infectious Disease Community of Practice. Arenaviruses and West Nile Virus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019;33(9):e13576. PMID 31022306
13: Angelini R, Finarelli AC, Angelini P, et al. An outbreak of chikungunya fever in the province of Ravenna, Italy. Euro Surveill 2007;12(9):E070906.1. PMID 17900424
14: Anonymous. “Etomologia: dengue.” Emerg Infect Dis 2006;12:893.
15: Antonen J, Leppanen I, Tenhunen J, et al. A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Scand J Infect Dis 2013;45(6):494-6. PMID 23294035
16: Araujo FM, Araujo MS, Nogueira RM, et al. Central nervous system involvement in dengue: a study in fatal cases from a dengue endemic area. Neurology 2012;78(10):736-42. PMID 22357720
17: Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever in a newborn. Ann Trop Paediatr 2006;26:251-3. PMID 16925964
18: Arnez M, Avsic-Zupanc T, Ursic T, Petrovec M. Human herpesvirus 6 infection presenting as an acute febrile illness associated with thrombocytopenia and leukopenia. Case Rep Med 2016;2016:2483183. PMID 27980872
19: Aydin ZGG, Yesilbas O, Reis GP, Guven B. The first pediatric case of hemophagocytic lymphohistiocytosis secondary to Crimean-Congo haemorrhagic fever successfully treated with therapeutic plasma exchange accompanying ribavirin and intravenous immunoglobulin. J Clin Apheresis 2021;36(5):780-4. PMID 34061376
20: Baek SH, Shin D-I, Lee H-S, et al. Reversible splenium lesion of the corpus callosum in hemorrhagic fever with renal failure syndrome. J Korean Med Sci 2010;25:1244-6. PMID 20676343
21: Baize S, Leroy EM, George-Courbot MD, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med 1999;5:423-6. PMID 10202932
22: Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola Virus Disease in Guinea-Preliminary Report. N Engl J Med 2014;371(15):1418-25. PMID 24738640
23: Baldacara L, Ferreira JR, Seixas Filho LC, et al. Behavior disorder after encephalitis caused by dengue. J Neuropsychiatry Clin Neurosci 2013;25:E44. PMID 23487229
24: Bank AM, Batra A, Colorado RA, Lyons JL. Myeloradiculopathy associated with chikungunya virus infection. J Neurovirol 2016;22(1):125-8. PMID 26306687
25: Barclay E. Is climate change affecting dengue in the Americas. Lancet 2008;371:973-4. PMID 18363202
26: Barnes KG, Lachenauer AE, Nitido A, et al. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. Nature Commun 2020;11(1):4131. PMID 32807807
27: Basavaraju SV, Kuehnert MJ, Zaki SR, Sejvar JJ. Encephalitis caused by pathogens transmitted through organ transplants, United States, 2002-2013. Emerg Infect Dis 2014;20(9):1443-51. PMID 25148201
28: Beard CB, Occi J, Bonilla DL, et al. Multistate infestation with the exotic disease-vector tick Haemaphysalis longicorns- United States, August 2017-September 2018. MMWR Morb Mortal Wkly Rep 2018;67(43):1310-3. PMID 30496158
29: Bechtelsheimer H, Jacob H, Solcher H. The neuropathology of an infectious disease transmitted by African green monkeys (Cercopithecus aethiops). Ger Med Mon 1969;14:10-2. PMID 5389368
30: Bergmann F, Krone B, Bleich S, Prange H, Paulus W. Encephalitis due to a hantavirus infection. J Infect 2002;45(1):58-9. PMID 12217734
31: Bernard GR, Vincent JL, Laterre PE, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. PMID 11236773
32: Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev Infect Dis 1989;11 Suppl 4:S826-9. PMID 2665014
33: Bhoelan S, Langerak T, Noack D, et al. Hypopituitarism after Orthohantavirus infection: What is commonly known? Viruses 2019;11(4),340. PMID 30974852
34: Bhushan B, Sardana V, Maheshwari D, et al. Immune-mediated neurological manifestations of dengue virus- a study of clinics-investigational variability, predictors of neuraxial involvement, and outcome with the role of immunomodulation. Neurol India 2018;66(6):1634-43. PMID 30504556
35: Billioux BJ, Smith B, Nath A. Neurological complications of Ebola virus infection. Neurotherapeutics 2016;13(3):461-70. PMID 27412684
36: Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacotherapy 2015;49(2):196-206. PMID 25414384
37: Blacksell SD. Commercial dengue rapid diagnostic tests for point-of-care application: recent evaluations and future needs. J Biomed Biotech 2012;2012:151967. PMID 22654479
38: Bodewes R, Kik MJ, Raj VS, et al. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. J Gen Virol 2013;94(Pt 6):1206-10. PMID 23468423
39: Boisen ML, Hartnett JN, Shaffer JG, et al. Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. Sci Rep 2018;8(1):5939. PMID 29651117
40: Boisen ML, Uyigue E, Aiyepada J, et al. Field evaluation of a Pan-Lassa rapid diagnostic test. During the 2018 Nigeria Lassa outbreak. Sci Rep 2020;10(1):8724. PMID 32457420
41: Bonthius DJ. Lymphocytic choriomeningitis virus: an underrecognized cause of neurologic disease in the fetus, child, and adult. Semin Pediatr Neurol 2012;19(3):89-95. PMID 22889536
42: Bordini CA, Valenca MM. Post-dengue new daily persistent headache. Headache 2017;57(9):1449-50. PMID 28796302
43: Boyles SM, Mavian CN, Finol E, et al. Under-the-radar dengue virus infections in natural populations of Aedes aegypti mosquitoes. mSphere 2020;3(2):e00316-20. PMID 32350095
44: Bray M, Murphy FA. Filovirus research: knowledge expands to meet a growing threat. J Infect Dis 2007;196:S438-43. PMID 17940981
45: Briese T, Paweska JT, McMullan LK, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus from southern Africa. PLoS Pathog 2009;5(5):e1000455. PMID 19478873
46: Brisse ME, Ly H. Hemorrhagic fever-causing arenaviruses: lethal pathogens and potent immune suppressors. Front Immunol 2019;10:372. PMID 30918506
47: Brunton B, Rogers K, Phillips E, et al. TIM-1 serves as a receptor for Ebola virus in vivo, enhancing viremia and pathogenesis. PLoS Negl Trop Dis 2019;13(6):e0006983. PMID 31242184
48: Buchmeier MJ, Bowen MD, Peters CJ. Arenaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:1635-68.
49: Bukreyev A, Volchov VE, Blinov VM, Netesov SV. The GP-protein of Marburg virus contains the region similar to the ‘immunosuppressive domain’ of oncogenic retrovirus P15E proteins. FEBS Lett 1993;323(1-2):183-7. PMID 8495737
50: Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:1043-125.
51: Butthep P, Chunhakan S, Tangnararatchakit K, Yoksan S, Pattanapanyasat K, Chuansumrit A. Elevated soluble thrombomodulin in the febrile stage related to patients at risk for Dengue Shock Syndrome. Ped Infect Dis J 2006;25:894-7. PMID 17006283
52: Cajimat MN, Milazzo ML, Bradley RD, Fulhorst CF. Ocozocoautla de espinosa virus and hemorrhagic fever, Mexico. Emerg Infect Dis 2012;18(3):401-5. PMID 22377271
53: Cam BV, Fonsmark L, Hue NB, Phuong NT, Poulsen A, Heegaard ED. Prospective case-control study of encephalopathy in children with dengue hemorrhagic fever. Am J Trop Med Hyg 2001;65:848-51. PMID 11791985
54: Campbell CL, Snell TK, Bennett S, et al. Safety study of Rift Valley Fever human vaccine candidate (DDVax) in mosquitoes. Transboundary Emerg Dis 2022;69(5):2621-33. PMID 34890118
55: Cao XT, Ngo TN, Wills B, et al. Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Viet Nam. Trop Med Int Health 2002;7:125-32. PMID 11841702
56: Capeding MR, Tran NH, Hadinegoro SR, et al. Clinial efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014;384:1358-65. PMID 25018116
57: Caragata EP, Dong S, Dong Y, et al. Prospects and pitfalls: next-generation tools to control mosquito-transmitted disease. Annu Rev Microbiol 2020;74:455-75. PMID 32905752
58: Carette JE, Raaben M, Wong AC, et al. Ebola virus entry requires cholesterol transporter Niemann-Pick C1. Nature 2011;477(7364):340-3. PMID 21866103
59: Carletti F, Castilletti C, Di Caro A, et al. Alkhurma hemorrhagic fever in travelers returning from Egypt, 2010. Emerg Infect Dis 2010;16(12):1979-82. PMID 21122237
60: Carod-Artal F. Post-Ebolavirus disease syndrome: what do we know? Expert Rev Anti Infect Ther 2015;13(10):1185-7. PMID 26293407
61: Carod-Artal FJ, Wichmann O, Farrar J, Gascon J. Neurological complications of dengue virus infection. Lancet Neurol 2013;12(9):906-19. PMID 23948177
62: Casals J, Henderson BE, Hoogstraal H, Johnson KM, Shelokov A. A review of Soviet viral hemorrhagic fevers, 1969. J Infect Dis 1970;122:437-53. PMID 4920325
63: Cashman KA, Wilkinson ER, Zeng X, et al. Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa virus exposure in Cynomolgus Macaques. MBio 2018;9(5). PMID 30377282
64: Casolari S, Briganti E, Zanotti M, et al. A fatal case of encephalitis associated with Chikungunya virus infection. Scand J Infect Dis 2008;40:995-6. PMID 18819040
65: Cauchie P, Cauchie CH, Boudjeltia KZ, et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital- meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006;81:414-9. PMID 16680742
66: Centers for Disease Control. Management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep 1988;37(Suppl 3):S1-16. PMID 3126390
67: Centers for Disease Control and Prevention. World Health Organization. Infection control for viral haemorrhagic fevers in the African health care setting. Atlanta: CDC 1998.
68: Centers for Disease Control and Prevention. Dengue 2020. Available at: (cdc.gov). Accessed March 2021.
69: Cerar D, Avsic-Zupanc T, Jereb M, Strle F. Case report: severe neurological manifestation of Dobrava Hantavirus infection. J Med Virol 2007;79:1841-3. PMID 17935168
70: Chaichana P, Okabayashi T, Puiprom O, et al. Low levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients. PLoS One 2014;9(3):e92173. PMID 24642752
71: Charbonnel N, Pages M, Sironen T, et al. Immunogenetic factors affecting susceptibility of humans and rodents to Hantaviruses and the clinical course of Hantaviral disease in humans. Viruses 2014;6(5):2214-41. PMID 24859344
72: Charrel RN, de Lamballerie X. Alkhurma virus (family Flaviviridae, genus Flavivirus): an emerging pathogen causing hemorrhage fever in the Middle East. Med Trop (Mars) 2003;63(3):296-9. PMID 14579470
73: Charrel RN, de Lamballerie X. Zoonotic aspects of arenavirus infections. Vet Microbiol 2010;140(3-4):213-20. PMID 19748747
74: Chaturvedi UC, Dhawan R, Khanna M, Mathur A. Breakdown of the blood-brain barrier during dengue virus infection of mice. J Gen Virol 1991;72(Pt 4):859-66. PMID 1707947
75: Chaturvedi UC, Nagar R. Nitric oxide in dengue and dengue haemorrhagic fever: necessity or nuisance. FEMS Immunol Med Microbiol 2009;56:9-24. PMID 19239490
76: Chaumont H, Petit A, Mameri T, et al. Successful management of anti-mGluR1 encephalitis with immunosuppressive treatment: dengue virus as a trigger? Mov Dis Clin Pract 2019;6(8):727-8. PMID 31745489
77: Chen WJ, Hwang KP, Fang AH. Detection of IgM antibodies from cerebrospinal fluid and sera of dengue fever patients. Southeast Asian J Trop Med Pub Health 1991;22:659-63. PMID 1820657
78: Chertow DS, Nath A, Suffredini AF, et al. Severe meningoencephalitis in a case of Ebola virus disease: a case report. Ann Int Med 2016;165(4):301-4. PMID 27043004
79: Chevalier V, de la Rocque S, Baldet T, Vial L, Roger F. Epidemiological processes involved in the emergence of vector-borne diseases: West Nile fever, Rift Valley fever, Japanese encephalitis and Crimean-Congo haemorrhagic fever. Rev Sci Tech 2004;23(2):535-55. PMID 15702718
80: Chhabra A, Malhotra N. Anesthetic management of a pregnant patient with dengue hemorrhagic fever for emergency cesarian section. Int J Obstet Anesth 2006;15:306-10. PMID 16950613
81: Chippaux A, Chippaux-Hyppolite C, Clergeaud P, Bres P. Isolation of 2 human strains of Ilesha virus in the central African republic [Article in French]. Bull Soc Med Afr Noire Lang Fr 1969;14(1):88-92. PMID 5399299
82: Choi S, Kim MC, Kwon JS, Kim JY, Lee KH, Kim SH. Case report: use of plasma exchange followed by convalescent plasma therapy in a critically ill patient with severe fever and thrombocytopenia syndrome-associated encephalopathy: cytokine/chemokine concentrations, viral loads, and antibody responses. Am J Trop Med Hyg 2018;99(6):1466-8. PMID 30277197
83: Chusri S, Siripaitoon P, Hirunpat S, Silpapojakul K. Case reports of neuro-Chikungunya in southern Thailand. Am J Trop Med Hyg 2011;85(2):386-9. PMID 21813863
84: Clark KB, Noisakran S, Onlamoon N, et al. Multiploid CD61+ cells are the pre-dominant cell lineage infected during acute dengue virus infection in bone marrow. PLoS One 2012;7(12):e52902. PMID 23300812
85: Coatsworth H, Lippi CA, Vasquez C, et al. A molecular surveillance-guided vector control response to concurrent dengue and West Nile virus outbreaks in a COVID-19 hotspot of Florida. Lancet Regional Health-Americas 2022;11:100231.
86: Conger NG, Paolino KM, Osborn EC, et al. Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerging Infect Dis 2015;21(1):23-31. PMID 25529825
87: Cristiano F, Huerta M, D’Avino P, Enria D, Briggiler A, Maiztegui J. Potenciales evocados auditivos de tronco cerebral en periodos alejados de la fiebre hemoragica Argentina (FHA). Medicina (Buenos Aires) 1985;45:409.
88: Crowcroft NS. Management of Lassa fever in European countries. Euro Surveill 2002;7(3):50-2. PMID 12631947
89: Cui N, Liu R, Lu QB, et al. Severe fever with thrombocytopenia syndrome bunyavirus-related human encephalitis. J Infect 2015;70(1):52-9. PMID 25135231
90: Cummins D, McCormick JB, Bennett D, et al. Acute sensorineural deafness in Lassa fever. JAMA 1990;264:2093-6. PMID 2214077
91: Das T, Jaffar-Bandjee MC, Hoarau JJ, et al. Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog Neurobiol 2010;91(2):121-9. PMID 20026374
92: Davis CE. Thrombocytopenia: a uniform complication of African trypanosomiasis. Acta Trop 1982;39:123-33. PMID 6126094
93: de Greslan T, Billhot M, Rousseau C, et al. Ebola virus-related encephalitis. Clin Infect Dis 2016;63(8):1076-8. PMID 27418576
94: de Souza AM, Puccioni-Soher M, Borges AD, Fernandes Adorno L, Papais Alvarenga M, Papais Alvarenga RM. Post-dengue neuromyelitis optic: case report of a Japanese-descendent Brazilian child. J Infect Chemotherapy 2006;12(6):396-8. PMID 17235647
95: Delaine M, Weingärtner AS, Nougairede A, et al. Microcephaly caused by lymphocytic choriomeningitis virus. Emerg Infect Dis 2017;23(9):1548-50. PMID 28820372
96: Deutman AF, Klomp HJ. Rift Valley fever retinitis. Am J Ophthalmol 1981;92:38-42. PMID 7196157
97: de Wit E, Rosenke K, Fischer RJ, et al. Ebola laboratory response at the Eternal Love Winning Africa Campus, Monrovia, Liberia, 2014-2016. J Infect Dis 2016;214(suppl 3):S169-76. PMID 27333914
98: Diallo MSK, Toure A, Sow MS, et al. Understanding the long-term evolution and predictors of sequelae of Ebola virus disease survivors in Guinea: a 48-monty prospective, longitudinal cohort study (PostEboGui). Clin Infect Dis 2021;73(12):2166-74. PMID 33621316
99: Dias LL, Amarilla AA, Poloni TR, et al. Detection of dengue virus in sera of Brazilian blood donors. Transfusion 2012;52(8):1667-71. PMID 22670858
100: Digoutte JP, Salaun JJ, Robin Y, Bres P, Cagnard VJ. Minor arboviral diseases in Central and West Africa. [Article in French]. Med Trop (Mars) 1980;40(5):523-33. PMID 7442511
101: Dilcher M, Koch A, Hasib L, Dobler G, Hufert FT, Weldmann M. Genetic characterization of Erve virus, a European Nairovirus distantly related to Crimean-Congo hemorrhagic fever virus. Virus Genes 2012;45(3):426-32. PMID 22864548
102: Dimaano EM, Saito M, Honda S, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007;77:1135-8. PMID 18165536
103: Dodd KA, Bird BH, Khristova ML, et al. Ancient ancestry of KFDV and AHFV revealed by complete genome analyses of viruses isolated from ticks and mammalian hosts. PLoS Negl Trop Dis 2011;5(10):e1352. PMID 21991403
104: Dokubo EK, Wendland A, Mate SE, et al. Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report. Lancet 2018;18(9):1015-24. PMID 30049622
105: Domingues RB, Kuster GW, Onuki-Castro FL, Souza VA, Levi JE, Pannuti CS. Involvement of the central nervous system in patients with dengue virus infection. J Neurol Sci 2008;267:36-40. PMID 17959198
106: Dong S, Dimopoulos G. Antiviral compounds for blocking arboviral transmission in mosquitoes. Viruses 2021;13(1):108. PMID 33466915
107: Droniou-Bonzom M, Reignier T, Oldenburg JE, et al. Substitutions in the glycoprotein (GP) of the Candid#1 vaccine strain of Junin virus increase dependence on human transferrin receptor 1 for entry and destabilize the metastable conformation of GP. J Virol 2011;85(24):13457-62. PMID 21976641
108: Duffy D, Perrin H, Abadie V, et al. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. Immunity 2012;37(5):917-29. PMID 23142782
109: Duvignaud A, Doutci M, Abejegah C, et al. Delayed-onset paraparesis in Lassa fever: a case report. Int J Infect Dis 2020;92:49-52. PMID 31866549
110: Ehelepola NDB, Basnayake BMLS, Sathkumara SMBY, Kaluphana KLR. Two atypical cases of Hantavirus infections from Sri Lanka. Case Reports Infect Dis 2018;2018:4069862. PMID 29850303
111: Ellwanger JH, Kulmann-Leal B, Kaminski VDL, et al. Beyond HIV infection: neglected and varied impacts of CCR5 and CCR5delta32 on viral diseases. Virus Res 2020;286:198040. PMID 32479976
112: Enria DA, Briggiler AM, Fernandez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralizing antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet 1984;2(8397):255-6. PMID 6146809
113: Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31. PMID 8141590
114: Farez MF, Correale J. Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 2011;68(10):1267-71. PMID 21670384
115: Farias LABG, Ferragut JM, Pires Neto RDJ. Encephalitis and transverse myelitis in dengue and chikungunya coinfection. Rev Soc Bras Med Trop 2018;51(3):403. PMID 29972580
116: Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat Rev Immunol 2003;3(8):677-85. PMID 12974482
117: Fernandez E, Diamond MS. Vaccination strategies against Zika virus. Curr Opin Virol 2017;23:59-67. PMID 28432975
118: Fischer SA, Graham MB, Kuehnert MJ, et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006;354(21):2235-49. PMID 16723615
119: Fong CY, Khine MM, Peter AB, Lim WK, Rozalli FI, Rahmat K. Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) due to dengue virus. J Clin Neurosci 2017;36:73-5. PMID 27887978
120: Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 2013;100(2):446-54. PMID 24084488
121: Gajdusek DC. Virus hemorrhagic fevers. Special reference to hemorrhagic fever with renal syndrome (epidemic hemorrhagic fever). J Pediatr 1962;60:841-57. PMID 13896278
122: Ganaraja VH, Kamble N, Netravathi M, et al. Stereotypy with Parkinsonism as a rare sequelae of dengue encephalitis: A case report and literature review. Tremor Other Hyperkinet Mov (NY) 2021;11(1):22:1-7. PMID 34221697
123: Ganesan K, Diwan A, Shankar SK, Desai SB, Sainani GS, Katrak SM. Chikungunya encephalomyeloradiculitis: report of 2 cases with neuroimaging and 1 case with autopsy findings. Am J Neuroradiol 2008;29(9):1636-7. PMID 18566010
124: Garcia G, Gonzalez N, Perez AB, et al. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. Int J Infect Dis 2011;15(1):e38-e43. PMID 21112804
125: Garg RK, Rizvi I, Ingole R, et al. Cortical laminar necrosis in dengue encephalitis- a case report. BMC Neurol 2017;17(1):79. PMID 28427358
126: Garnett LE, Strong JE. Lassa fever: with 50 years of study, hundreds of thousands of patients and an extremely high disease burden, what have we learned? Curr Opin Virol 2019;37:123-31. PMID 31479990
127: Gauri LA, Ranwa BL, Nagar K, Vyas A, Fatima Q. Post chikungunya brain stem encephalitis. J Assoc Physicians India 2012; 60:68-9. PMID 23029750
128: Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol 1999;73(5):3951-9. PMID 10196290
129: Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J 1975;4:489-93. PMID 811315
130: Geisbert TW, Jahrling PB. Exotic emerging viral diseases: progress and challenges. Nat Med 2004;10:S110-21. PMID 15577929
131: Gerardin P, Couderc T, Bintner M, et al. Chikungunya virus-associated encephalitis: a cohort study on La Réunion Island, 2005-2009. Neurology 2016;86(1):94-102. PMID 26609145
132: Gibbs WN, Kreidie MA, Kim RC, Hasso AN. Acute hemorrhagic leukoencephalitis. Neuroimaging features and neuropathologic diagnosis. J Comput Assist Tomogr 2005;29:689-93. PMID 16163044
133: Gilchuk P, Kuzima N, Ilinykh PA, et al. Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the Ebolavirus glycoprotein. Immunity 2018;49(2):363-74.e10. PMID 30029854
134: Gooskens J, Kuiken T, Claas EC, et al. Severe influenza resembling hemorrhagic shock and encephalopathy syndrome. J Clin Virol 2007;39(2):136-40. PMID 17499546
135: Goswami RP, Mukherjee A, Biswas T, Karmakar PS, Ghosh A. Two cases of dengue meningitis: a rare first presentation. J Infect Dev Ctries 2012;6(2):208-11. PMID 22337854
136: Graham AS, Pruszynski CA, Hribar LJ, et al. Mosquito-associated dengue virus, Key West, Florida, USA, 2010. Emerg Infect Dis 2011;17(11):2074-5. PMID 22099104
137: Grahn A, Brave A, Lagging M, et al. Imported case of Lassa Fever in Sweden with encephalopathy and sensorineural hearing deficit. Open Forum Infect Dis 2016;3(4):ofw198. PMID 27975074
138: Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:917-62.
139: Gubler DJ. Dengue and dengue hemorrhagic fever: Its history and resurgence as a global public health problem. In: Gubler DJ and Kuno G, editors. Dengue and dengue hemorrhagic fever. New York: CABI, 1997:1-22.
140: Gulia M, Dalal P, Gupta M, Kaur D. Concurrent Guillain-Barre syndrome and myositis complicating dengue fever. BMJ Case Rep 2020;13(2):e232940. PMID 32047085
141: Gulland A. First Ebola treatment is approved by WHO. BMJ 2014;349:g5539. PMID 25200068
142: Gunther S, Hoofd G, Charrel R, et al. Mopeia virus-related arenavirus in natal multimammate mice, Morogoro, Tanzania. Emerging Infect Dis 2009;15:2008-12. PMID 19961688
143: Gunther S, Weisner B, Roth A, et al. Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid by not serum. J Infect Dis 2001;184:345-9. PMID 11443561
144: Guo WP, Lin X-D, Wang W et al. Phylogeny and origins of hantaviruses harbored by bats, insectivores, and rodents. PLOS Pathogens 2013;9:e10033159. PMID 23408889
145: Gutch M, Agarwal A, Amar A. Hypokalemic quadriparesis: an unusual manifestation of dengue fever. J Nat Sci Biol Med 2012;3(1):81-3. PMID 22690057
146: Guzman MG, Kouri G. Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007. Trans R Soc Trop Med Hyg 2008;102(6):522-3. PMID 18420239
147: Halstead SB. Neuralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-67. PMID 14689700
148: Halstead SB. Dengue. Lancet 2007;370(9599):1644-52. PMID 17993365
149: Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr 2014;2(6). PMID 26104444
150: Halstead SB. Dengue virus-mosquito interactions. Ann Rev Entomology 2008;53:273-91. PMID 17803458
151: Happi AN, Happi CT, Schoepp RJ. Lassa fever diagnostics: past, present and future. Curr Opin Virol 2019;37:132-8. PMID 31518896
152: Hart CA, Bennett M. Hantaviruses: an increasing problem. Ann Trop Med Parasitol 1994;88:347-58. PMID 7979621
153: Hartman A. Rift Valley Fever. Clin Lab Med 2017;37(2):285-301. PMID 28457351
154: Hautala T, Mahonen SM, Sironen T, et al. Central nervous system-related symptoms and findings are common in acute Puumala hantavirus infection. Ann Int Med 2010;42(5):344-51. PMID 20545485
155: Hautala N, Partanen T, Kubin AM, et al. Central nervous system and ocular manifestations in Puumala hatavirus infection. Viruses 2021;13(6):1040. PMID 34072819
156: Hautala N, Partanen T, Sironin T, et al. Elevated cerebrospinal fluid neopterin concentration is associated with disease severity in acute Puumala hantavirus infection. Clin Dev Immunol 2013;2013:634642. PMID 23983770
157: Hautala T, Sironen T, Vapalahti O, et al. Hypohyseal hemorrhage and panhypopituitarism during Puumala virus infection: magnetic resonance imaging and detection of viral antigen in the hypophysis. Clin Infect Dis 2002;35:96-101. PMID 12060884
158: Hawman DW, Feldmann H. Crimean-Congo haemorrhagic fever virus. Nat Rev Microbiol 2023;21(7):463-77. PMID 36918725
159: Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012;30(29):4301-6. PMID 22682286
160: Henao-Restrepo AM, Camacho A, Longini IM, et al. Ebola virus disease: final results from the Guinea ring vaccination, open label, cluster-randomized trial (Ebola Ca Suffit!) Lancet 2017;389(10068):505-18. PMID 28017403
161: Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015;386(9996):857-66. PMID 26248676
162: Honda S, Saito M, Dimaano EM, et al. Increased phagocytosis of platelets from patients with secondary Dengue virus infection by human macrophages. Am J Trop Med Hyg 2009;80:841-5. PMID 19407135
163: Hopkins HK, Traverse EM, Barr KL. Chikungunya encephalitis: an inconsistently reported headache and cause of death in patients with pre-existing conditions. Curr Trop Med Rep 2022;9:73-91.
164: Howlett P, Brown C, Helderman T, et al. Ebola virus disease complicated by late-onset encephalitis and polyarthritis, Sierra Leone. Emerg Infect Dis 2016;22(1):150-2. PMID 26690042
165: Howlett P, Walder AR, Lisk DR, et al. Case series of severe neurologic sequelae of Ebola virus disease during epidemic, Sierra Leone. Emerg Infect Dis 2018;24(8):1412-21. PMID 30014839
166: Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27. PMID 1683355
167: Huisa BN, Chapin JE, Adair JC. Central nervous system complications following Hanta virus cardiopulmonary syndrome. J Neurovirol 2009;15(2):202-5. PMID 19089788
168: Hullinghorst RL, Steer A. Pathology of epidemic hemorrhagic fever. Ann Intern Med 1953;38:77-101. PMID 13008317
169: Hung NT. Fluid management for dengue in children. Paediatr Int Child Health 2012;32 Suppl 1:39-42. PMID 22668449
170: Ikegami T. Candidate vaccines for human Rift Valley fever. Expert Opin Biol Therapy 2019;19(12):1333-42. PMID 31478397
171: Imai N, Ferguson NM. Targeting vaccinations for the licensed dengue vaccine: considerations for serosurvey design. PLoS One 2018;13(6):e0199450. PMID 29944696
172: Ishii A, Thomas Y, Moonga L, et al. Novel arenavirus, Zambia. Emerg Infect Dis 2011;17(10):1921-4. PMID 22000372
173: Jacob H. The neuropathology of the Marburg disease in man. In: Martini GA, Siegert R, editors. Marburg virus disease. Berlin: Springer-Verlag, 1971:54-61.
174: Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016;388(10043):498-503. PMID 27209148
175: Javelle E, Lesueur A, de Santi VP, et al. The challenging management of Rift Valley fever in humans: literature review of the clinical disease and algorithm proposal. Ann Clin Microbiol Antimicrob 2020;19(1):4. PMID 31969141
176: Jha S, Ansari MK. Dengue infection causing acute hypokalemic quadriparesis. Neurol India 2010;58(4):592-4. PMID 20739798
177: Jiao J, Wu L, Yin J, Quan X, Chen W, Hu J. Guillain-Barre syndrome associated with hemorrhagic fever with renal syndrome in China: a case report. BMC Infectious Dis 2018;18(1):143. PMID 29587642
178: Johnson BW, Kosoy O, Hunsberger E, et al. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immune 2009;16(7):1052-9. PMID 19458204
179: Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, King IJ. Clinical virology of Lassa Fever in hospitalized patients. J Infect Dis 1987;155:456-64. PMID 3805773
180: Johnson TP, Larman HB, Lee MH, et al. Chronic dengue virus pan encephalitis in a patient with progressive dementia with extrapyramidal features. Ann Neurol 2019;86(5):695-703. PMID 31461177
181: Jois D, Moorchung N, Gupta S, Mutreja D, Patil S. Autopsy in dengue encephalitis: an analysis of three cases. Neurol India 2018;66(6):1721-5. PMID 30504573
182: Jolany Vangah S, Katalani C, Booneh HA, Hajizade A, Sijercic A, Ahmadian G. CRISPR-based diagnosis of infectious and noninfectious diseases. Biological Proc Online 2020;22:22. PMID 32939188
183: Kalane SU, Gokhale AN, Kalane UD. Dengue encephalitis in a newborn. Indian J Pediatr 2021;88(7):716. PMID 34018130
184: Kalenga OI, Moeti M, Sparrow A, et al. The ongoing Ebola epidemic in the Democratic Republic of Congo, 2018-2019. N Engl J Med 2019;381(4):373-83. PMID 31141654
185: Kalimuddin S, Teh YE, Wee LE, et al. Chronic sequelae complicate convalescence from both dengue and acute viral respiratory illness. PLOS Neglected Trop Dis 2022;16(8):e0010724. PMID 35981059
186: Kalita J, Kumar P, Misra UK. Stimulus-sensitive myoclonus and cerebellar ataxia following chikungunya meningoencephalitis. Infection 2013;41(3):727-9. PMID 23355353
187: Kalita J, Misra UK. EEG in dengue virus infection with neurological manifestations: a clinical and CT/MRI correlation. Clin Neurophysiol 2006;117(10):2252-6. PMID 16931144
188: Kallas EG, Precioso AR, Palacios R, et al. Safety and immunogenicity of the tetravalent, live attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. Lancet Infect Dis 2020;20(7):839-850. PMID 32220283
189: Kaneko M, Maruta M, Shikata H, et al. Unusual presentation of a severely ill patient having severe fever with thrombocytopenia syndrome: a case report. J Med Case Rep 2017;11(1):27. PMID 28153057
190: Kankirawatana P, Chokephaibulkit K, Puthavathana P, Yoksan S, Apintanapong S, Pongthapisit V. Dengue infection presenting with central nervous system manifestation. J Child Neurol 2000;15(8):544-7. PMID 10961794
191: Kaputu-Kalala-Malu C, Musalu EM, Walker T, Ntumba-Tshitenge O, Ahuka-Mundeke S. PTSD, depression and anxiety in Ebola virus disease survivors in Beni town, Democratic Republic of the Congo. BMC Psychiatry 2021;21(1):342. PMID 34238249
192: Kasereka MC, Ericson AD, Conroy AL, et al. Prior vaccination with recombinant vesicular stomatitis virus -- Zaire Ebolavirus vaccine is associated with improved survival among patients with Ebolavirus infection. Vaccine 2020;38(14):3003-7. PMID 32093984
193: Katzelnick LC, Bos S, Harris E. Protective and enhancing interations among dengue viruses 1-4 and Zika virus. Curr Opin Virol 2020;43:59-70. PMID 32979816
194: Kaur J, Virk JS, Paul BS, Saggar K. Dengue fever presenting as cauda equina syndrome. BMJ Case Rep 2017;2017. PMID 28739570
195: Kaveri M. WHO aims to accelerate trials of vaccine candidates for Marburg disease as Equatorial Guinea reports nine deaths. Health Policy Watch. Accessed on February 14, 2023.
196: Keita AK, Koundouno FR, Faye M, et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature 2021;597(7877):539-43. PMID 34526718
197: Kerber R, Reindl S, Romanowski V, et al. Research efforts to control highly pathogenic arenaviruses: a summary of the progress and gaps. J Clin Virol 2015;64:120-7. PMID 25549822
198: Kho LK, Sumarmo, Wulur H, Jahja EC, Gubler DJ. Dengue hemorrhagic fever accompanied by encephalopathy in Jakarta. Southeast Asian J Trop Med Public Health 1981;12(1):83-6. PMID 7256360
199: Kilgore PE, Grabenstein JD, Salim AM, Rybak M. Treatment of ebola virus disease. Pharmacotherapy 2015;35(1):43-53. PMID 25630412
200: Kilpatrick ME, Girgis NI, Farid Z, Sippel JE. Epidemiology, prevalence and clinical diagnosis of meningitis at Abbassia Fever Hospital, Cairo, 1966-1989. Trans R Soc Trop Med Hyg 1991;85(Suppl 1):4-5. PMID 1803696
201: Kim D. Clinical analysis of 11 fatal cases of epidemic hemorrhagic fever. Ann J Med 1965;39:218-20. PMID 14320687
202: Kitching A, Addiman S, Cathcart S, et al. A fatal case of Lassa fever in London, January 2009. Eurosurveillance 2009;14:1-3. PMID 19215723
203: Kleib AS, Salihy SM, Ghaber SM, Sidiel BW, Sidiya KC, Bettar ES. Crimean-Congo hemorrhagic fever with acute subdural hematoma. Emergence Infect Dis 2016;22(7):1305-6. PMID 27315138
204: Koczula KM, Gallotta A. Lateral flow assays. Essays Biochem 2016;60(1):111-20. PMID 27365041
205: Koga S, Takazono T, Ando T, et al. Severe fever with thrombocytopenia syndrome virus RNA in semen, Japan. Emerg Infect Dis Nov 2019;25(11):2127-8. PMID 31625854
206: Kreuels B, Wichmann D, Emmeriich P, et al. A case of severe Ebola Virus infection complicated by gram-negative septicemia. N Engl J Med 2014;371(25):2394-401. PMID 25337633
207: Ku MC, Sun SI, Lee HJ, et al. Hemorrhagic fever with renal syndrome-related encephalopathy: magnetic resonance imaging findings. Clin Imaging 2015;39(6):975-8. PMID 26362353
208: Kuhn JH, Becker S, Ebihara H, et al. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol 2010;155:2083-103. PMID 21046175
209: Kumar AS, Mehta S, Singh P, Lal V. Dengue encephalitis: “Double doughnut” sign. Neurol India 2017;65(3):670-1. PMID 28488653
210: Kumar R, Prakash O, Sharma BS. Intracranial hemorrhage in dengue fever: management and outcome A series of 5 cases and review of literature. Surg Neurol 2009;PMID19328535. PMID 19328535
211: Kumar R, Tripathi S, Tambe JJ, Arora V, Srivastava A, Nag VL. Dengue encephalopathy in children in Northern India: clinical features and comparison with non dengue. J Neurol Sci 2008;269(1-2):41-8. PMID 18222482
212: Kupferschmidt K. Ebola virus may lurk in survivors for many years. Science 2021;371(6535):1188. PMID 33737465
213: Kuvula K, Kibadi K, Massamba M, Ndaberey D, Colebunders R, Muyembe-Tamfum JJ. Ebola hemorrhagic fever and pregnancy. J Infect Dis 1999;179(Suppl 1):S11-12. PMID 9988157
214: Lahdevirta J. Nephropathia epidemica in Finland. A clinical, histological and epidemiological study. Ann Clin Res 1971;3(Suppl 8):1-154. PMID 5149038
215: Lai KK. Treating Ebola: The Hunt for a Drug. Available at: nytimes.com. NY Times; Oct 23 2014.
216: Larsen T, Stevens EL, Davis KJ, et al. Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis 2007;196 Suppl 2:S323-8. PMID 17940967
217: Leblebicioglu H, Sunbul M, Memish A et al. Consensus report: preventive measure for Crimean-Congo hemorrhagic fever during Eid-al-Adha festival. Int J Infect Dis 2015;38:9-15. PMID 26183413
218: Lecuit M, Eloit M. The diagnosis of infectious diseases by whole genome next generation sequencing: a new era is opening. Front Cell Infect Microbiol 2014;4:25. PMID 24639952
219: Lederberg J, Shope RE, Oaks SC. Emerging infections: microbial threats to health in the United States. Washington, DC: National Academy Press, 1992.
220: Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine- preliminary report. N Engl J Med 2017;376(10):928-38. PMID 25426834
221: LeDuc JW, Smith GA, Childs JE, et al. Global survey of antibody to Hantaan-related viruses among peridomestic rodents. Bull World Health Organ 1986;64:139-44. PMID 2425998
222: LeDuc JW, Smith GA, Johnson KM. Hantaan-like viruses from domestic rats captured in the United States. Am J Trop Med Hyg 1984;33:992-8. PMID 6435464
223: Lee HW. Hemorrhagic fever with renal syndrome in Korea. Rev Infect Dis 1989;11(Suppl 4):S864-76. PMID 2568676
224: Lee HW, Dalrymple JM. Manual of hemorrhagic fever with renal syndrome. Seoul, Republic of Korea: WHO collaborating center for virus reference and research (Hemorrhagic fever with renal syndrome). Institute for Virus Diseases, Korea University, 1989;1-134.
225: Leroy EM, Kumulungi B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005;438:575-6. PMID 16319873
226: Liou LM, Lan SH, Lai CL. Dengue fever with ischemic stroke: a case report. Neurologist 2008a;14(1):40-2. PMID 18195656
227: Liou LM, Lan SH, Lai CL. Electroencephalography burst suppression in a patient with dengue encephalopathy: A case report. Clin Neurophysiol 2008b;119(10):2205-8. PMID 18448389
228: Liu J, Trefry JC, Babka AM, et al. Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Science Transl Med 2022;14(631):eabi5229. PMID 35138912
229: Liu Z, Gao M, Han Z, Lou S, Fang J. Platelet glycoprotein IIb/IIIa (HPA-1 and HPA-3) polymorphisms in patients with hemorrhagic fever with renal syndrome. Hum Immunol 2009;70(6):452-6. PMID 19286442
230: Lnu P, Sehgal V, Sehgal LB, Gulati N, Kapila S. The spectrum of MRI findings in dengue encephalitis. Cureus 2022;14(9):e29048. PMID 36237802
231: Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK. Vaccination against infection in patients with multiple sclerosis. Nat Rev Neurol 2012;8(3):143-51. PMID 22270022
232: Longet S, Leggio C, Bore JA, et al. Influence of landscape patterns on exposure to Lassa fever virus, Guinea. Emerg Infect Dis 2023;29(2):304-13. PMID 36692336
233: Lukes RJ. The pathology of thirty-nine fatal cases of epidemic hemorrhagic fever. Am J Med 1954;16:639-50. PMID 13148206
234: Lum LC, Lam SK, Choy YS, George R, Harun F. Denge encephalitis: a true entity. Am J Trop Med Hyg 1996;54:256-9. PMID 8600761
235: Luplertlop N, Misse D, Bray D, et al. Dengue-virus-infected dendritic cells trigger vascular leakage through metalloproteinase overproduction. EMBO Rep 2006;7(11):1176-81. PMID 17028575
236: Lustig Y, Keler S, Kolodny R, et al. Potential antigenic cross-reactivity between SARS-CoV-2 and dengue viruses. Clin Infect Dis 2021;73(7):e2444-9. PMID 32797228
237: Maar SA, Swanepoel R, Gelfand M. Rift Valley fever encephalitis. A description of a case. Cent Afr J Med 1979;25:8-11. PMID 421266
238: Madani TA. Alkumra virus infection, a new viral hemorrhagic fever in Saudi Arabia. J Infection 2005;51(2):91-7. PMID 16038757
239: Madani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003;36(12):1613-8. PMID 12802764
240: Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine hemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979;2(8154):1216-7. PMID 92624
241: Malavige GN, Ranatunga PK, Jayaratne SD, Wijesiriwardana B, Seneviratne SL, Karunatilaka DH. Dengue viral infections as a cause of encephalopathy. Indian J Med Microbiol 2007;25(2):143-5. PMID 17582186
242: Malchair P, Giol J, Garcia V, et al. Three-day icatibant on top of standard care in patients with coronavirus disease 2019 pneumonia: a randomized, open-label, phase 2, proof-of-concept trial. Clin Infect Dis 2023;76(10):1784-92. PMID 36610464
243: Mallick AK, Purkait R, Sinhamahapatra TK. Dengue fever with unusual thalamic involvement. J Indian Med Assoc 2012;110:48-9. PMID 23029832
244: Marcondes MC, Borelli P, Yoshida N, Russo M. Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leucopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment. Microbes Infect 2000;2:347-52. PMID 10817635
245: Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003;36(12):1613-8. PMID 12802764
246: Mari Saez A, Weiss S, Nowak K, et al. Investigating the zoonotic origin of the West African Ebola epidemic. EMBO Molecular Medicine 2015;7:17-23. PMID 25550396
247: Marra AR, de Matos GF, Janeri RD, et al. Managing patients with dengue fever during an epidemic: the importance of a hydration tent and of a multidisciplinary approach. BMC Res Notes 2011;4:335. PMID 21902823
248: Martini GA. Marburg agent disease: in man. Trans R Soc Trop Med Hyg 1969;63:295-302. PMID 5815873
249: Martini GA. Marburg virus disease. Clinical syndrome. In: Martini GA, Siegert R, editors. Marburg virus disease. Berlin: Springer-Verlag, 1971:1-9.
250: Mathur G, Yadav K, Ford B, et al. High clinical suspicion of donor-derived disease leads to timely recognition and early intervention to treat solid organ transplant-transmitted lymphocytic choriomeningitis virus. Transplant Infect Dis 2017;19(4):e12707. PMID 28423464
251: Matlani M, Chakravarti A, Rawal A, Kashyap B, Gurtoo A. Dengue encephalitis: an entity now common in dengue-prone regions. Trop Doct 2009;39(2):115-6. PMID 19299303
252: Mayor J, Engler O, Rothenberger S. Antiviral efficacy of ribavirin and favipiravir against Hantaan virus. Microorganisms 2021;9(6):1306. PMID 34203936
253: Mbala-Kingebeni P, Pratt C, Mutafali-Ruffin M, et al. Ebola virus transmission initiated by relapse of systemic Ebola virus disease. NEJM 2021;384(13):1240-47. PMID 33789012
254: Mbaya OT, Mukumbay P, Mulangu S. Review: insights on current FDA-approved monoclonal antibodies against Ebola virus infection. Front Immunol 2021;12:721328. PMID 34526994
255: McCarthy M. US signs contract with ZPapp makker to accelerate development of the Ebola drug. BMJ 2014;349:g5488. PMID 25189475
256: McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-6. PMID 3940312
257: McElroy AK, Harmon JR, Flietstra T, Nichol ST, Spiropoulou CF. Human biomarkers of outcome following Rift Valley fever virus infection. J Infect Dis 2018;218(11):1847-51. PMID 29955891
258: McEntire CRS, Song KW, McInnis RP, et al. Neurologic manifestations of the World Health Organization’s list of pandemic and epidemic diseases. Front Neurol 2021;12:634827. PMID 33692745
259: McIntosh BM, Russell D, dos Santos I, Gear JH. Rift Valley fever in humans in South Africa. S Afr Med J 1980;58:803-6. PMID 7192434
260: McJunkin JE, Nahata MC, De Los Reyes EC, et al. Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Pediatr Infect Dis J 2011;30(10):860-5. PMID 21544005
261: McLay L, Liang Y, Ly H. Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections. J Gen Virol 2014;95(Pt 1):1-15. PMID 24068704
262: McMahon AW, Eidex RB, Marfin AA, et al, and Yellow fever working group. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007;25:1727-34. PMID 17240001
263: McMillen CM, Hartman AL. Rift Valley fever in animals and humans: current perspectives. Antiviral Res 2018;156:29-37. PMID 29857007
264: McMullan LK, Folk SM, Kelly AJ, et al. A new Phlebovirus associated with severe febrile illness in Missouri. N Engl J Med 2012a;367(9): 834-41. PMID 22931317
265: McMullan LK, Frace M, Sammons SA, et al. Using next generation sequencing to identify yellow fever virus in Uganda. Virology 2012b;422(1):1-5. PMID 21962764
266: Mehla R, Kumar SR, Yadav P, et al. Recent ancestry of Kyasanur Forest disease virus. Emerg Infect Dis 2009;15(9):1431-7. PMID 19788811
267: Meltzer E, Heyman Z, Bin H, Schwartz E. Capillary leakage in travelers with dengue infection: implication for pathogenesis. Am J Trop Med Hyg 2012;86(3):536-9. PMID 22403332
268: Meltzer E, Schwartz E. A travel medicine view of dengue and dengue hemorrhagic fever. Travel Med Infect Dis 2009;7:278-83. PMID 19747662
269: Miagostovich MP, Ramos RG, Nicol AF, et al. Retrospective study on dengue fatal cases. Clin Neuropath 1997;16:204-8. PMID 9266146
270: Milligan ID, Gibani MM, Sewell R, et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial. JAMA 2016;315(15):1610-23. PMID 27092831
271: Misra A, Pandey S. Generalized dystonia/Parkinsonism and double-doughnut sign in dengue encephalitis. Movement Dis Clin Pract 2020;7(5):585-6. PMID 32626815
272: Misra UK, Kalita J, Syam UK, Dhole TN. Neurological manifestations of dengue virus infection. J Neurol Sci 2006;244:117-22. PMID 16524594
273: Mohammed AP, Koraddi A, Prabhu A, Kotian C, Umakanth S. Rapidly progressive dementia with seizures: a post-dengue complication. Trop Doct 2020;50(1):81-3. PMID 31694475
274: Monath TP. A short history of Lassa fever: the first 10-15 years after discovery. Curr Opin Virol 2019;37:77-83. PMID 31323506
275: Monson MH, Cole AK, Frame JD, Serwint JR, Alexander S, Jahrling PB. Pediatric Lassa fever: a review of 33 Liberian cases. Am J Prop Med Hyg 1987;36:408-15. PMID 3826501
276: Morais BA, Pereira NM, Franco CL, Ribeiro PRJ. Hydrocephalus secondary to dengue encephalitis in an infant: case report. Childs Nervs Syst 2021;37(7):2357-61. PMID 32895752
277: Morse SS. The evolutionary biology of viruses. New York: Raven Press, 1994.
278: Morvan JM, Digoutte JP, Marsan P, Roux JF. Ilesha virus: a new aetiological agent of haemorrhagic fever in Madagascar. Trans R Soc Trop Med Hyg 1994;88(2):205. PMID 8036675
279: Moulton SL, Mulligan J, Srikiatkhachorn A, et al. State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 2016;10(1):233. PMID 27553703
280: Mrzljak A, Novak R, Pandak N, et al. Emerging and neglected zoonoses in transplant population. World J Transplant 2020;10(3):47-63. PMID 32257849
281: Mukadi-Bamuleka D, Bulabula-Penge J, De Weggheleire A, et al. Field performance of three Ebola rapid diagnostic tests used during the 2018-20 outbreak in the eastern Democratic Republic of the Congo: a retrospective, multicentre observational study. Lancet Infect Dis 2022;22(6):891-900. PMID 35298901
282: Mulangu S, Dodd LE, Davey Jr RT, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381(24):2293-303. PMID 31774950
283: Munoz LS, Garcia MA, Gordon-Lipkin E, Parra B, Pardo CA. Emerging viral infections and their impact on the global burden of neurological disease. Semin Neurol 2018;38(2):163-75. PMID 29791942
284: Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. J Infect Dis 1999;179 Suppl 1:S18-23. PMID 9988160
285: Murphy BR, Whitehead SS. Immune response to Dengue Virus and prospects for a vaccine. Ann Rev Immunol 2011;29:587-619. PMID 21219187
286: Musso D, Gubler DJ. Zika virus. Clin Micro Rev 2016;29(3):487-524. PMID 27029595
287: Mustonen J, Makela S, Outinen T, et al. The pathogenesis of nephropathia epidemica: new knowledge and unanswered questions. Antiviral Res 2013;100(3):589-604. PMID 24126075
288: Mustonen J, Partanen J, Kanerva M, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998;47(3):277-9. PMID 9519867
289: Muzaffar J, Venkata Krisnan P, Gupta N, Kar P. Dengue encephalitis: why we need to identify this entity in a dengue-prone region. Singapore Med J 2006;47:975-7. PMID 17075667
290: Nadarajah J, Madhusudhan KS, Yadav AK, Gupta AK, Vikram NK. Acute hemorrhagic encephalitis: an unusual presentation of dengue virua infection. Indian J Radiol Imaging 2015;25(1):52-5. PMID 25709166
291: Nair AG, Biswas J, Bhende MP. A case of bilateral Chikungunya neuroretinitis. J Ophthalmic Inflamm Infect 2012;2(1):39-40. PMID 21881835
292: Nakamura S, Azuma M, Maruhashi T, et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. J Infect Chemother 2018;24(5):389-92. PMID 29428565
293: N’Dilimabaka N, Berthet N, Rougeron V, et al. Evidence of lymphocytic choriomeningitis virus (LCMV) in domestic mice in Gabon: risk of emergence of LCMV encephalitis in Central Africa. J Virol 2015;89(2):1456-60. PMID 25378495
294: Nelson J, Waggoner JJ, Sahoo MK, Grant PM, Pinsky BA. Encephalitis caused by Chikungunya virus in a traveler from the Kingdom of Tonga. J Clin Microbiol 2014;52(9):3459-61. PMID 24958800
295: Newman-Gerhardt S, Muiruri S, Muchiri E, et al. Potential for autoimmune pathogenesis of Rift Valley Fever virus retinitis. Am J Trop Med Hyg 2013;89(3):495-7. PMID 23918215
296: Ng DH, Sadarangani SP. “Locked in a cage”-A case of dengue virus 4 encephalitis. PLoS Negl Trop Dis 2017;11(5):e0005369. PMID 28472166
297: Ng WW, Cheong BMK. Dengue encephalitis associated with symptomatic hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion. Med J Malaysia 2021;76(2):261-3. PMID 33742642
298: Nichol ST. Bunyaviruses. In: Knipe DM, Howley PM editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:1603-34.
299: Nogueira RM, Filippis AM, Coelho JM, et al. Dengue virus infection of the central nervous system (CNS): a case report from Brazil. Southeast Asian J Trop Med Public Health 2002;33(1):68-71. PMID 12118463
300: Noisakran S, Gibbons RV, Songprakhon P, et al. Detection of dengue virus in platelets isolated from dengue patients. Southeast Asian J Trop Med Public Health 2009;40:253-62. PMID 19323010
301: Noisakran S, Onlamoon N, Hsiao HM, et al. Infection of bone marrow cells by dengue virus in vivo. Exp Hematol 2012.40(3):250-9. PMID 22193689
302: Noisakran S, Perng GC. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in Dengue virus infection. Exp Biol Med (Maywood) 2008;233(4):401-8. PMID 18367628
303: Oestereich L, Ludtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014;105:17-21. PMID 24583123
304: O’Hearn AE, Voorhees MA, Fetterer DP, et al. Serosurveillance of viral pathogens circulating in West Africa. Virol J 2016;13(1):163. PMID 27716429
305: Okokhere PO, Bankole IA, Iruolagbe CO, et al. Aseptic meningitis caused by Lassa virus: case series report. Case Rep Neurol Med 2016;2016:1978461. PMID 27957363
306: Okokhere PO, Colubri A, Azubike C, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. Lancet Infect Dis 2018;18(6):684-95. PMID 29523497
307: Okuno T. Immunological studies relating two recently isolated viruses, Germiston virus from South Africa and Ilesha virus from West Africa, to the Bunyamwera group. Am J Trop Med Hyg 1961;10:223-6. PMID 13730655
308: Olival KJ, Daszak P. The ecology of emerging neurotropic viruses. J Neurovirol 2005;11:441-6. PMID 16287685
309: Olival KJ, Hayman DT. Filoviruses in bats: current knowledge and future directions. Viruses 2014;6(4):1759-1788. PMID 24747773
310: Olival KJ, Islam A, Yu M, et al. Ebola virus antibodies in fruit bats, bangladesh. Emerg Infect Dis 2013;19(2):270-3. PMID 23343532
311: Olivero J, Fa JE, Real R, et al. Recent loss of closed forests is associated with Ebola virus disease outbreaks. Sci Rep 2017;7(1):14291. PMID 29085050
312: Osnaya-Romero N, Perez-Guille MG, Andrade-Garcia S, et al. Neurological complications and death in children with dengue virus infection: report of two cases. J Venom Anim Toxins Incl Trop Dis 2017;23:25. PMID 28465676
313: Osterholm MT, Moore KA, Kelley NS, et al. Transmission of Ebola viruses: what we know and what we do not know. MBio 2015;6(2):e00137. PMID 25698835
314: Ostronoff M, Ostronoff F, Florencio R, et al. Serious thrombocytopenia due to dengue hemorrhagic fever treated with high dosages of immunoglobulin. Clin Infect Dis 2003;36:1623-4. PMID 12802766
315: Ozkurt Z, Kiki I, Erol S, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006;52(3):207-15. PMID 15953646
316: Outbreak News Today. Pakistan: Dengue cases near 10K in Sindh province, Most recorded in September. Available at: https://outbreaknewstoday.com/pakistan-dengue-cases-near-10k-in-sindh-province-most-recorded-in-september-52908/. Published Oct 1, 2022.
317: Oygar PD, Gurlevik SL, Sag E, et al. Changing disease course of Crimean-Congo Hemorrhagic Fever in children, Turkey. Emerg Infect Dis 2023;29(2):268-77. PMID 36692327
318: Pachler K, Ruzek D, Nowotny N. Molecular characterization of the African orthobunyavirus Ilesha virus. Infect Genet Evol 2013;20:124-30. PMID 23988729
319: Palacios G, Druce J, Du L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008;358(10):991-8. PMID 18256387
320: Palacios G, Savji N, Hui J, et al. Genomic and phylogenetic characterization of Merino Walk virus, a novel arenavirus isolated in South Africa. J Gen Virol 2010;91(Pt 5):1315-24. PMID 20071489
321: Pang YH, Divakar TG, De Silva DA. Fatal cerebral haemorrhage in a thrombolysed patient with ischemic stroke who developed interval thrombocytopenia from acute dengue infection. Ann Acad Med Singapore 2020;49(2):98-102. PMID 32246712
322: Park I, Kim HI, Kwon KT. Two treatment cases of severe fever and thrombocytopenia syndrome with oral ribavirin and plasma exchange. Infect Chemotherapy 2017;49(1):72-7. PMID 28271646
323: Park SY, Choi WY, Chong YP, et al. Use of plasma therapy for severe fever with thrombocytopenia syndrome encephalopathy. Emerg Infect Dis 2016;22(7):1306-8. PMID 27315224
324: Park SY, Kwon JS, Kim JY, et al. Severe fever with thrombocytopenia syndrome-associated encephalopathy/encephalitis. Clin Microbiol Infection 2018;24(4):432e1-4. PMID 28899841
325: Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med 2016;375(16):1513-23. PMID 27705091
326: Partanen T, Chen J, Lehtonen J, et al. Heterozygous TLR3 mutation in patients with Hantavirus encephalitis. J Clin Immunol 2020;40(8):1156-62. PMID 32936395
327: Paweska JT, Sewlall NH, Ksiazek TG, et al. Nosocomial outbreak of novel arenavirus infection, southern Africa. Emerg Infect Dis 2009;15:1598-602. PMID 19861052
328: Pea L, Roda L, Moll F. Desmopressin treatment for a case of dengue hemorrhagic fever/dengue shock syndrome. Clin Infect Dis 2001;33:1611-12. PMID 11588706
329: Pekic S, Cvijovic G, Stojanovic M, Kendereski A, Micic D, Popovic V. Hypopituitarism as a late complication of hemorrhagic fever. Endocrine 2005;26:79-82. PMID 15888918
330: Pellor AS, Alessandri JL, Robin S, et al. [Severe forms of chikungunya virus infection in a pediatric intensive care unit on Reunion Island.] [French] Med Trop (Mars) 2012;72 Spec No:88-93. PMID 22693937
331: Peng SH, Yang SL, Tang SE, et al. Human case of severe fever with thrombocytopenia syndrome virus infection, Taiwan, 2019. Emerg Infect Dis 2020;26(7):1612-4. PMID 32568054
332: Perng GC, Solbrig MV. Viral hemorrhagic fevers. In: Jackson AC, ed. Viral Infections of the Human Nervous System. Basel: Springer, 2013:339-41.
333: Peters CJ, Anderson GW Jr. Pathogenesis of Rift Valley fever. Contr Epidemiol Biostatist 1981;3:21-41.
334: Petersen LR, Stramer SL, Powers AM. Chikungunya virus: possible impact on transfusion medicine. Transfus Med Rev 2010;24(1):15-21. PMID 19962571
335: Plyusnina A, Ferenczi E, Racz GR, et al. Co-circulation of three pathogenic hantaviruses: Puumala, Dobrava, and Saaremaa in Hungary. J Med Virol 2009;81(12):2045-52. PMID 19856478
336: Powell GM. Hemorrhagic fever: study of 300 cases. Medicine 1954;33:97-153. PMID 13153699
337: PREVAIL Study Group. A longitudinal study of Ebola sequelae in Liberia. N Engl J Med 2019;380(10):924-34. PMID 30855742
338: Price ME, Fisher-Hoch SP, Craven RB, McCormick JB. A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ 1988;297:584-7. PMID 3139220
339: Priyamvada L, Quicke KM, Hudson WH, et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A 2016;113(28):7852-7. PMID 27354515
340: ProMED. Crimean-Congo hem, fever- Eurasia:future risk. Archive Number 20150930.3679955. Available at: http://www.promedmail.org Published Sept 30, 2015.
341: ProMED. COVID-19 update (14): immune response, serology, dengue confection, WHO, global. Available at:https://promedmail.org/promed-post/?id=20210112.8094266 Published Jan 12, 2021a.
342: ProMED. Ebola update (11): Congo DR (NK, IT) cases, summary, vaccine. Available at: http://www.promedmail.org Published February 26, 2020a.
343: ProMED. Ebola update (14): Congo DR (NK, IT) cases, WHO, summaries. Available at: http://www.promedmail.org Published March 22, 2020b.
344: ProMED. Ebola update (18): Congo DR (North Kivu, Ituri) WHO, cases, summaries, vaccine research, request for information. http://www.promedmail.org Published April 17, 2020c.
345: ProMED. Ebola update (32): post-Ebola syndrome. Archive Number 20150207.3149458. Available at: http://www.promedmail.org Published February 7, 2015.
346: ProMED. Ebola update (55): Sierra Leone, Ebola virus variant, Democratic Republic of Congo cases, WHO. Available at: http://www.promedmail.org Published July 27, 2018.
347: ProMED. Ebola update (50): Democratic Republic of Congo (North Kivu, Ituri) cases, preparedness, response, vaccine. Available at: http://www.promedmail.org Published June 3, 2019a.
348: ProMED. Ebola update (68): Democratic Republic of Congo (North Kivu, Ituri) cases, WHO, Uganda. Available at: http://www.promedmail.org Published July 18, 2019b.
349: ProMED. Ebola update (26): Congo DR (NK) Guinea. Available at: http://www.promedmail.org Published March 18, 2021b.
350: ProMED. Ebola update (04): Congo DR (EQ) 2nd case. Available at: http://www.promedmail.org Published April 26, 2022a.
351: ProMED. Dengue/DHF update (08): Americas, Asia, Europe, Middle East. Available at: http://www.promedmail.org Published Nov 13, 2022b.
352: ProMED. Ebola update (11): Congo DR (NK) conference. Available at: http://www.promedmail.org Published Aug 8, 2022c.
353: ProMED. Ebola update (24): Uganda, polymerase/suramin complex research. Available at: http://www.promedmail.org Published Oct 5, 2022d.
354: ProMED. Ebola update (40): Uganda, WHO, Sudan ebolavirus vaccine trials. Available at: http://www.promedmail.org Published Nov 26, 2022e.
355: ProMED. Marburg virus disease- Guinea (04): resolved, WHO. Available at: http://www.promedmail.org Published Sept 20, 2021c.
356: ProMED. Marburg virus disease- Ghana (06). Available at: http://www.promedmail.org Published Sept 18, 2022f.
357: ProMED. Marburg virus disease- Equatorial Guinea (01) (KN) WHO Conference. Available at: http://www.promedmail.org Published Feb 13, 2023a.
358: ProMED. Marburg virus disease- Tanzania: (KG). Available at: http://www.promedmail.org Published March 3, 2023b.
359: Puccioni-Sohler M, Ornelas AMM, de Souza AS, et al. First report of persistent dengue-1-associated autoimmune neurological disturbance: neuromyelitis optic spectrum disorder. J Neurovirol 2017a;23(5):678-771. PMID 28748449
360: Puccioni-Sohler M, Rosadas C, Cabral-Castro MJ. Neurological complications in dengue infection: a review for clinical practice. Arq Neuropsiquiatr 2013;71(9B):667-71. PMID 24141501
361: Puccioni-Sohler M, Roveroni N, Rosadas C, Ferry F, Peralta JM, Tanuri A. Dengue infection in the nervous system: lessons learned from Zika and Chikungunya. Arq Neuropsiquiatr 2017b;75(2):123-6. PMID 28226083
362: Puccioni-Sohler M, Soares CN, Papaiz-Alvarenga R, Castro MJ, Faria LC, Peralta JM. Neurologic dengue manifestations associated with intrathecal specific immune response. Neurology 2009;73(17):1413-7. PMID 19858464
363: Purushotham J, Lambe T, Gilbert SC. Vaccine platforms for the prevention of Lassa fever. Immunol Letters 2019;215:1-11. PMID 31026485
364: Putkuri N, Kantele A, Levanov L, et al. Acute human Inkoo and Chatanga virus infections, Finland. Emerg Infect Dis 2016;22(5):810-7. PMID 27088268
365: Qiu X, Wong G, Fernando L, et al. mAbs and Ad-Vectored IFN-alpha therapy rescue ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med 2013;5(207):207ra143. PMID 24132638
366: Raabe V, Kann G, Ribner BS, et al. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis 2017;65(5):855-9. PMID 29017278
367: Radke EG, Gregory CJ, Kintziger KW, et al. Dengue outbreak in Key West, Florida, USA, 2009. Emerg Infect Dis 2012;18(1):135-7. PMID 22257471
368: Ramos C, Sanchez G, Pando RH, et al. Dengue virus in the brain of a fatal case of hemorrhagic dengue fever. J Neurovirol 1998;4(4):465-8. PMID 9718141
369: Ranjan R, Ranjan S. Ocular pathology: role of emerging viruses in the Asia-Pacific Region-a review. Asia-Pacific J Ophthalmol (Phila) 2014;3(5):299-307. PMID 26107917
370: Ratnayake EC, Shivanthan C, Wijesiriwardena BC. Diaphragmatic paralysis: a rare consequence of dengue fever. BMC Infect Dis 2012;12:46. PMID 22356701
371: Ravanini P, Hasu E, Huhtamo E, et al. Rhabdomyolysis and severe muscular weakness in a traveler diagnosed with Alkhurma hemorrhagic fever virus infection. J Clin Virol 2011;52(3):254-6. PMID 21889906
372: Reusken C, Heyman P. Factors driving hantavirus emergence in Europe. Curr Opin Virology 2013;3:92-9. PMID 23384818
373: Riou O, Philippe B, Jouan A, Coulibaly I, Mondo M, Digoutte JP. Neurologic and neurosensory forms of Rift Valley fever in Mauritania. Bull Soc Pathol Exot Filiales 1989;82:605-10. PMID 2633869
374: Robbiani DF, Bozzacco L, Keeffe JR, et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 2017;169(4):597-609. PMID 28475892
375: Robin S, Ramful D, Le Seach F, Jaffar-Bandjee MC, Rigou G, Alessandri JL. Neurologic manifestations of pediatric chikungunya infection. J. Child Neurol 2008;23(9):1028-35. PMID 18287573
376: Rivera L, Biswal S, Saez-Llorens X, et al. Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis 2022;75(1):107-17. PMID 34606595
377: Rodriguez-Barraquer I, Costa F, Nascimento EJM, et al. Impact of preexisting dengue immunity on Zika virus emergence in a dengue endemic region. Science 2019;3634(6427):607-10. PMID 30733412
378: Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis 2007;196(Supp 2):S364-71. PMID 17940972
379: Rottingen JA, Gouglas D, Feinberg M, et al. New vaccines against epidemic infectious diseases. New Engl J Med 2017;376(7):610-3. PMID 28099066
380: Rustemoglu A, Ekinci D, Nursal AF, et al. The possibile role of CCR5Δ32 mutation in Crimean-Congo hemorrhagic fever infection. J Med Virol 2017;89(10):1714-9. PMID 28547880
381: Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559-67. PMID 22975340
382: Sagui E, Janvier F, Baize S, et al. Severe Ebola virus infection with encephalopathy: evidence for direct virus involvement. Clin Infect DIs 2015;61(10):1627-8. PMID 26197842
383: Salzberg SL, Breitwieser FP, Kumar A, et al. Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. Neurol Neuroimmunol Neuroinflammation 2016;3(4):e251. PMID 27340685
384: Sanchez A, Khan AS, Zaki SR, Nabel GJ, Ksiazek TG, Peters CJ. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001:1279-1304.
385: Scharton D, Bailey KW, Vest Z, et al. Favipiravir (T-705) protects against parachute Rift Valley fever virus and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res 2014;104:84-92. PMID 24486952
386: Schuffenecker I, Iterman I, Michault A, et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 2006;3(7):e263. PMID 16700631
387: Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. Post-Ebola syndrome, Sierra Leone. Emerg Infect Dis 2016;22(4):641-6. PMID 26983037
388: Sebba D, Lastovich AG, Kuroda M, et al. A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases. Sci Transl Med 2018;10(471):eaat0944. PMID 30541788
389: Seligsohn U, Hoots WK. Disseminated intravascular coagulation. In: Lichtman MA, Beutler E, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J, editors. Williams Hematology. 7th ed. New York: McGraw-Hill, 2005.
390: Shantha JG, Crozier I, Hayek BR, et al. Ophthalmic manifestations and causes of vision impairment in Ebola virus disease survivors in Monrovia, Liberia. Ophthalmology 2017a;124(2):170-7. PMID 27914832
391: Shantha JG, Crozier I, Yeh S. An update on ocular complications of Ebola virus disease. Curr Opin Ophthalmol 2017b;28(6):600-6. PMID 28872492
392: Shantha JG, Mattia JG, Goba A, et al. Ebola Virus Persistence in Ocular Tissues and Fluids (EVICT) II study: reverse transcription-polymerase chain reaction and cataract surgery outcomes of Ebola survivors in Sierra Leone. EBioMedicine 2018;30:217-24. PMID 29622497
393: Sharifi-Mood B, Alavi-Naini R, Metanat M, Mohammadi M, Shakeri A, Amjadi A. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. Trop Doc 2013;43(2):49-53. PMID 23796671
394: Sharma CM, Kumawat BL, Ralot T, Tripathi G, Dixit S. Guillain-Barre syndrome occurring during dengue fever. J Indian Med Assoc 2011;109(9):675, 682. PMID 22480104
395: Shorten RJ, Brown CS, Jacobs M, Rattenbury S, Simpson AJ, Mepham S. Diagnostics in Ebola virus disease in resource-rich and resource-limited settings. PLOS Negl Trop DIs 2016;10(10):e0004948. PMID 27788135
396: Shurrab FM, Al-Sadeq DW, Amanullah FH, et al. Low risk of serological cross-reactivity between the dengue virus and SARS-CoV-2-IgG antibodies using advanced detection assays. Intervirology 2022;1-6. PMID 35134813
397: Simon F, Javelle E, Oliver M, Leparc-Goffart I, Marimoutou C. Chikungunya viral infection. Curr Infect Dis Rep 2011;13(3):218-28. PMID 21465340
398: Singh AS. Jack-o’-lantern sign in dengue encephalitis. Neurol: Clin Pract 2018;8(3):e9-11. PMID 30105171
399: Singh KP, Mishra G, Jain P, et al. Co-positivity of anti-dengue virus and anti-Japanese encephalitis virus IgM in endemic area: co-infection or cross reactivity. Asian Pac J Trop Med 2014;7(2):124-9. PMID 24461525
400: Singh SS, Manimunda SP, Sugunan AP, Sahina, Vijayachari P. Four cases of acute flaccid paralysis associated with chikungunya virus infection. Epidemiol Infect 2008;136(9):1277-80. PMID 18634716
401: Sinha G. Sanofi’s dengue vaccine first to complete phase 3. Nature Biotech 2014;32:605-6. PMID 25004214
402: Sirinavin S, Nuntnarumit P, Supapannachart S, Boonkasidecha S, Techasaensiri C, Yoksarn S. Vertical dengue infection: case reports and review. Pediatr Infect Dis J 2004;23(10):1042-7. PMID 15545860
403: Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S. Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J 2014;11:48. PMID 24620925
404: Sironen T, Sane J, Lokki ML, et al. Fatal Puumala hantavirus disease: involvement of complement activation and vascular leakage in the pathobiology. Open Forum Infect Dis 2017;4(4):ofx229. PMID 29255728
405: Smalley HK, Anand N, Buczek D, et al. Assessment of risk for transplant-transmissible infectious encephalitis among deceased organ donors. Transpl Infect Dis 2018;20(5):e12933. PMID 29809311
406: Smith JR, Todd S, Ashander LM, et al. Retinal pigment epithelial cells are a potential reservoir for Ebola virus in the human eye. Transl Vis Sci Techno 2017;6(4):12. PMID 28721309
407: Snape M. Persistence of immune responses induced by Ebola virus vaccines. Lancet Glob Health 2017;5(3):e238-9. PMID 28193382
408: Soares C, Puccioni-Sohler M. Diagnosis criteria of dengue encephalitis. Arq Neuro-Psyquiatr 2014;72(3):263.
409: Solbrig MV. The history and neurology of hantaviral infections. Neurol Infect Epidemiol 1997;2:129-34.
410: Solbrig MV, McCormick JB. Lassa fever: central nervous system manifestations. J Trop Geogr Neurol 1991;1:23-30.
411: Solbrig MV, Naviaux RK. Review of the neurology and biology of Ebola and Marburg virus infections. Neurol Infect Epidemiol 1997;2:5-12.
412: Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000;355:1053-9. PMID 10744091
413: Song G. Epidemiological progresses of hemorrhagic fever with renal syndrome in China. Chin Med J (Engl) 1999;112:472-7. PMID 11593522
414: Spengler JR, Keating MK, McElroy AK, et al. Crimean-Congo hemorrhagic fever in humanized mice reveals glial cells as primary targets of neurological infection. J Infect Dis 2017;216(11):1386-97. PMID 28482001
415: Srichaikul T, Nimmannitya S. Haematology in dengue and dengue haemorrhagic fever. Baillieres Best Pract Res Clin Haematol 2000;13(2):261-76. PMID 10942625
416: Stefani A, Dusfour I, Correa APSA, et al. Land cover, land use and malaria in the Amazon: a systematic literature review of studies using remotely sensed data. Malar J 2013;12:192. PMID 23758827
417: Stenglein MD, Sanders C, Kistler AL, et al. Identification, characterization and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: candidate etiologic agents for snake inclusion body disease. MBio 2012;3:e00180-12. PMID 22893382
418: Steptoe PJ, Scott JT, Baxter JM, et al. Novel retinal lesion in Ebola survivors, Sierra Leone, 2016. Emerg Infect Dis 2017;23(7):1102-9. PMID 28628441
419: Srivastava S, Bhatia MS, Jhanjee A. Organic mania in dengue. J Clin Diagn Res 2013;7:566-7. PMID 23634425
420: Stille W, Bohle E. Clinical course and prognosis of Marburg virus (“green monkey”) disease. In: Martini GA, Siegert R, editors. Marburg virus disease. Berlin: Springer-Verlag, 1971:10-8.
421: Subissi L, Keita M, Mesfin S, et al. Ebola virus transmission caused by persistently infected survivors of the 2014-2016 outbreak in West Africa. J Infect Dis 2018;218(suppl_5):S287-91. PMID 29920602
422: Suh DC, Park JS, Park SK, Lee HK, Chang KH. Pituitary hemorrhage as a complication of hataviral disease. Am J Neuroradiol 1994;16:175-8. PMID 7900589
423: Swanpoel R, Erasmus BJ, Williams R, Taylor MB. Encephalitis and chorioretinitis associated with neurotropic African horsesickness virus infection in laboratory workers. Part III. Virological and serological investigations. S Afr Med J 1992;81(9):458-61. PMID 1574748
424: Tabbara K. Dengue retinochoroiditis. Ann Saudi Med 2012;32(5):530-3. PMID 22871625
425: Tahir M, Gupta E, Salmani S, et al. Dengue fever with papilledema: a case of dengue-3 virus infection in central nervous system. J Clin Virol 2006;37:65-7. PMID 16797229
426: Takahashi M, Yamada T, Nakashita Y, et al. Influenza virus-induced encephalopathy: clinicopathologic study of an autopsied case. Pediatr Int 2000;42(2):204-14. PMID 10804743
427: Talamonti L, Padula PJ, Caqnteli MS, et al. Hantavirus pulmonary syndrome: encephalitis caused by virus Andes. J Neurovirol 2011;17(2):189-92. PMID 21240581
428: Tantawichien T. Dengue fever and dengue hemorrhagic fever in adolescents and adults. Paediatr Int Child Health 2012;32 Suppl 1:22-7. PMID 22668446
429: Tanveer F, Younas M, Fisbain J. Lymphocytic choriomeningitis virus meningoencephalitis in a renal transplant recipient following exposure to mice. Transpl Infect Dis 2018;20(6):e13013. PMID 30325104
430: Tasdelen Fisgin N, Ergonul O, Dognanci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009;28(8):929-33. PMID 19301047
431: Ternovoi VA, Kurzhukov P, Sokolov YV, et al. Tick-borne encephalitis with hemorrhagic syndrome, Novosibirsk region, Russia, 1999. Emerg Infect Dis 2003;9:743-6. PMID 12781020
432: Thakare J, Walhekar B, Banerjee K. Hemorrhagic manifestations and encephalopathy in cases of dengue in India. Southeast Asian J Trop Med Public Health 1996;27:471-5. PMID 9185255
433: Thiruvengadam KV, Kalyanasundaram V, Rajgopal J. Clinical and pathological studies on chikungunya fever in Madras city. Indian J Med Res 1965;53(8):729-44. PMID 5830407
434: Towner JS, Sealy TK, Khristova ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 2008;4(11):e1000212. PMID 19023410
435: Tozay S, Fischer WA II, Wohl DA, et al. Long-term complications of Ebola virus disease: prevalence and predictors of major symptoms and the role of inflammation. Clin Infect Dis 2020;71(7):1749-55. PMID 31693114
436: Treib J, Dobler G, Haass A, et al. Thunderclap headache caused by Erve virus? Neurology 1998;50(2):509-11. PMID 9484383
437: Trivedi S, Chakravarty A. Neurological complications of dengue fever. Curr Neurol Neurosci Rep 2022;22(8):515-29. PMID 35727463
438: Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007;3(12):e201 PMID 18069894
439: Usawattanakul W, Nimmannitya S, Sarabenjawong K, Tharavanij S. Endotoxin and dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1986;17(1):8-12. PMID 3738611
440: Vaheri A, Strandin T, Jaaskelainen A, et al. Pathophysiology of a severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant. Antiviral Res 2014;111:23-5. PMID 25194993
441: Vaheri A, Smura T, Vauhkonen H, et al. Puumala Hantavirus infections show extensive variation in clinical outcome. Viruses 2023;15(3):805. PMID 36992513
442: van de Weg CA, Koraka P, van Gorp ECM, et al. Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J Clin Virol 2012;53(1):38-42. PMID 22014848
443: Varatharaj A. Encephalitis in the clinical spectrum of dengue infection. Neurology India 2010;58(4):585-91. PMID 20739797
444: Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. NEJM 2015;372(25):2423-7. PMID 25950269
445: Veliziotis I, Roman A, Martiny D, et al. Clinical management of Argentine hemorrhagic fever using ribavirin and favipiravir, Belgium, 2020. Emerg Infect Dis 2020;26(7). PMID 32271701
446: Verma R, Bharti K, Mehta M, Bansod A. Rhombencephalitis associated with Dengue fever. J Clin Virol 2016;78:99-101. PMID 27015434
447: Verma R, Sharma P, Garg RK, Atam V, Singh MK, Mehrotra HS. Neurological complications of dengue fever: Experience from a tertiary center of north India. Ann Indian Acad Neurol 2011a;14(4):272-8. PMID 22346016
448: Verma R, Sharma P, Khurana N, Sharma LN. Neuralgic amyotrophy associated with dengue fever: case series of three patients. J Postgrad Med 2011b;57(4):329-31. PMID 22120863
449: Villar L, Dayan GH, Arredondo-Garcia J, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. New Engl J Med 2015;372(2):113-23. PMID 25365753
450: Volchkov VE, Blinov MV, Netesov SV. The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses. FEBS Lett 1992;305(3):181-4. PMID 1299611
451: Waggoner JJ, Pinsky BA. How great is the threat of Chikungunya virus? Expert Rev Anti Infect Ther 2015;13(3):291-3. PMID 25537007
452: Wang C, Gong L, Zeng Z, et al. Genome-based analysis of SFTSV causing severe encephalitis with brain lesions. J Neurovirol 2020;26(2):181-7. PMID 31872389
453: Wang J, Zhang H, Fu S, et al. Isolation of Kyasanur forest disease virus from febrile patient, Yunnan, China. Emerg Infect Dis 2009;15(2):326-8. PMID 19193286
454: Wasay M, Channa R, Jumani M, et al. Encephalitis and myelitis associated with dengue viral infection clinical and neuroimaging features. Clin Neurol Neurosurg 2008;110:635-40. PMID 18467022
455: Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G. Transmission of Ebola virus from pigs to non-human primates. Sci Rep 2012;2:811-4. PMID 23155478
456: Weiss S, Witkowski PT, Auste B, et al. Hantavirus in bat, Sierra Leone. Emerg Infect Dis 2012;18:159-61. PMID 22261176
457: West BR, Hastie KM, Saphire EO. Structure of the LCMV nucleoprotein provides a template for understanding arenavirus replication and immunosuppression. Acta Crystallogr D Biol Crystallogr 2014;70(Pt6):1764-9. PMID 24914986
458: Whitehead SS, Pierson TC. Effects of Dengue immunity on Zika virus infection. Nature 2019;567(7749):467-8. PMID 30911157
459: Whitmer SLM, Ladner JT, Wiley MR, et al. Active Ebola virus replication and heterogeneous evolutionary rates in EVD survivors. Cell Rep 2018;22(5):1159-68. PMID 29386105
460: Wilder-Smith A. Moving forward with Takeda’s live chimeric tetravalent dengue vaccine. Lancet Infect Dis 2017;17(6):566-8. PMID 28365227
461: Wilder-Smith A. The first licensed dengue vaccine: can it be used in travelers. Curr Opin infect Dis 2019;32(5):394-400. PMID 31305495
462: Wilder-Smith A. Dengue vaccine development by the year 2020: challenges and prospects. Curr Opin Virol 2020;43:71-8. PMID 33086187
463: Wilder-Smith A, Gubler DJ. Public Health. Dengue vaccines at a crossroad. Science 2015;350(6261):626-7. PMID 26542552
464: Wilder-Smith A, Ooi EE, Horstick O, WIlls B. Dengue. Lancet 2019;393(10169):350-63. PMID 30696575
465: Withana M, Rodrigo C, Chang T, Karunanayake P, Rajapakse S. Dengue fever presenting with acute cerebellitis: a case report. BMC Res Notes 2014;7:125. PMID 24598036
466: World Health Organization. Technical guide for diagnosis, treatment, surveillance, prevention, and control of dengue hemorrhagic fever. Geneva: WHO, 1982.
467: World Health Organization. Dengue haemorrhagic fever; diagnosis, treatment, prevention, and control. Geneva: WHO, 1997.
468: World Health Organization. Crimean-Congo hemorrhagic fever. World Health Organization fact sheet no. 208. Geneva: WHO, 2001.
469: World Health Organization. Dengue guidelines for diagnosis, treatment, prevention and control: new edition. WHO, 2009.
470: World Health Organization. Four countries in the African region license vaccine in milestone for Ebola prevention. WHO news release, February 11, 2020.
471: World Health Organization. Revised SAGE recommendation on use of dengue vaccine in immunization, vaccines and biologicals. WHO, 2018.
472: World Health Organization. Democratic Republic of Congo declares Ebola outbreak over. WHO, 2021.
473: WHO Ebola Response Team. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371(16);1481-95. PMID 25244186
474: Xu GJ, Kula T, Xu Q, et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science 2015;348(6239):aaa0698. PMID 26045439
475: Xu Y, Shao M, Liu N, Dong D, Tang J, Gu Q. Clinical features of severe fever with thrombocytopenia syndrome (SFTS)-associated encephalitis/encephalopathy: a retrospective study. BMC Infect Dis 2021;21(1):904. PMID 34479504
476: Yaddanapudi K, Palacios G, Towner JS, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 2006;20(14):2519-30. PMID 17023517
477: Yanagisawa N, Wada K, Spengler JD, Sanchez-Pina R. Health preparedness plan for dengue detection during the 2020 summer Olympic and Paralympic games in Tokyo. PLoS Negl Trop Dis 2018;12(9):e0006755. PMID 30235211
478: Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, Nabel GJ. Identification of the Ebola virus glycoprotein as the main determinant of vascular cell cytotoxicity and injury. Nat Med 2000;6:886-9. PMID 10932225
479: Yeo PS, Pinheiro L, Tong P, Lim PL, Sitoh YY. Hippocampal involvement in dengue fever. Singapore Med J 2005;46:647-50. PMID 16228099
480: Young NS. Faviviruses and bone marrow failure. JAMA 1990;263(22):3065-8. PMID 2160551
481: Yu XJ, Liang M-F, Zhang S-Y, et al. Fever with thrombocytopenia associated with a novel Bunyavirus in China. N Engl J Med 2011;364:1523-32. PMID 21410387
482: Yun ZY, Dong LJ, Peng YQ, Wang YH, Yu YP, Shen BY. An analysis of various diseases and hearing screening in NICU infants. .Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016;30(14):1134-6. PMID 29798439
483: Zaki AM. Isolation of a flavivirus related to the tick-borne encephalitis complex from human cases in Saudi Arabia. Trans R Soc Trop Med Hyg 1997;91(2):179-81. PMID 9196762
484: Zaki SR, Peters CJ. Viral hemorrhagic fevers In: Connor DH, Chandler FW, editors. Pathology of infectious diseases. Vol 1. Stamford, Connecticut: Appleton & Lange, 1997:347-64.
485: Zeitlin L, Geisbert JB, Deer DJ, et al. Monoclonal antibody therapy for Junin virus infection. Proc Natl Acad Sci USA 2016;113(16):4458-63. PMID 27044104
486: Zhang Y, Zhu J, Tao K, et al. Proliferation and location of Hantaan virus in gamasid mites and chigger mites, a molecular biological study. Zhonghua Yi Xue Za Zhi 2002;82:1415-9. PMID 12509926

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Marylou V Solbrig MD

Dr. Solbrig of the University of Manitoba has no relevant financial relationships to disclose.
See Profile

Editor

John E Greenlee MD

Dr. Greenlee of the University of Utah School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Yu-Chih Lo PhD and Guey Chuen Perng PhD

Patient Profile

Age range of presentation: 0 month to 65+ years

Dengue hemorrhagic fever: 0 month to 5 years
Sex preponderance: male=female
Heredity: None
Population groups selectively affected: None selectively affected
Occupation groups selectively affected: Health care workers

Laboratory workers

Primate workers

Farmers

Slaughterhouse workers

Veterinarians

People living in rural areas handling livestock

Military troops

Forest workers

Agriculture workers

Diamond miners

Gold miners

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Viral hemorrhagic fevers: neurologic complications

Associated Disorders

Alkhurma virus
Argentine hemorrhagic fever
Bolivian hemorrhagic fever
Congo-Crimean hemorrhagic fever
Dengue hemorrhagic fever
- Dengue virus
- Ebola virus
- Guanarito virus
- Hantaan virus
- Hemorrhagic fever with renal syndrome
- Junin virus
- Kyasanur Forest disease
- Lassa fever virus
- Lymphocytic choriomeningitis virus
- “Lymphocytic choriomeningitis virus like” arenavirus infections
- Machupo virus
- Marburg virus
- Omsk hemorrhagic fever virus
- Puumala (nephropathia epidemica)
- Rift Valley fever virus
- Sabia virus
- Seoul virus
- South American hemorrhagic fever
- Venezuelan hemorrhagic fever
- White Water Arroyo virus
- Yellow fever

Differential Diagnosis

malaria
rickettsial diseases
leptospirosis
shigellosis
typhoid
- N meningitidis meningitis
- N meningitides meningococcemia
- measles
- hepatitis
- systemic lupus erythematosus
- hemolytic-uremic syndrome
- trypanosomiasis
- Japanese encephalitis
- Nipah encephalitis
- hematologic disorders associated with fever, infectious, and parainfectious syndromes
- thrombotic thrombocytopenic purpura
- immunologic thrombocytopenia
- idiopathic thrombocytopenia purpura
- infectious mononucleosis
- acute toxoplasmosis
- cytomegalovirus
- viral hepatitis
- viral exanthems
- initial infection with HIV
- streptococcus A toxic shock syndrome
- meningococcemia
- Staphylococcus aureus infection
- Streptococcus pneumoniae infection
- Waterhouse-Friderichsen syndrome (adrenal apoplexy and hemorrhage)
- acute hemorrhagic leukoencephalitis
- hemorrhagic smallpox (purpura variolosa)
- hemorrhagic chickenpox
- snake bite
- tick-borne encephalitis
- Inkoo and Chatanga viruses
- mosquito-borne California serogroup viruses
- congenital lymphocytic choriomeningitis virus

Viral hemorrhagic fevers: neurologic complications

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Viral Hemorrhagic Fevers and CNS Disease

Epidemiology

Prevention

Differential diagnosis

Associated or underlying disorders

Diagnostic workup

Table 2. ICD Codes for Viral Hemorrhagic Fevers

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Prion diseases

Rabies

Malaria

Neuropathies associated with cytomegalovirus infection

Genital herpes: neurologic complications

Neurocysticercosis

Trichinosis

Zika virus: neurologic complications

This is an article preview.
Start a Free Account
to access the full version.